Polθ inhibitor, and preparation method therefor and use thereof

By developing Polθ inhibitors, the problem of limited therapeutic effect on HR-deficient tumor cells in the prior art is solved, especially in HR-deficient ovarian and breast cancers, which enhance the therapeutic efficacy and reduce the risk of drug resistance.

WO2024245415A1PCT designated stage expired Publication Date: 2024-12-05CHENGDU CHIPSCREEN PHARM LTD
View PDF 7 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2024/096761
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-12-08
Filing Date
2024-05-31
Publication Date
2024-12-05

AI Technical Summary

Technical Problem

The existing tumor treatment methods have limited effect on HR-deficient tumor cells, especially HR-deficient ovarian and breast cancers, and have high resistance to PARP inhibitors and lack effective treatment strategies.

Method used

A class of Polθ inhibitors were developed, designed through specific compound structures to inhibit the activity of Polθ, thereby enhancing the killing effects of PARP inhibitors and DNA damage agents on HR-deficient tumor cells.

Benefits of technology

It effectively improves the killing efficacy of HR-deficient tumor cells, especially in HR-deficient ovarian and breast cancers, providing new therapeutic strategies and reducing the risk of drug resistance of treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2024096761_05122024_PF_FP_ABST
    Figure CN2024096761_05122024_PF_FP_ABST
Patent Text Reader

Abstract

A compound as shown in formula (I), or a pharmaceutically acceptable salt, stereoisomer, tautomer, polymorph, eutectic, hydrate, solvate, metabolite, prodrug, or a deuterated compound thereof. A pharmaceutical composition comprising the compound as an active ingredient and the use of the compound or pharmaceutical composition in treating and / or preventing related diseases mediated by Polθ.
Need to check novelty before this filing date? Find Prior Art

Description

Polθ inhibitors and their preparation methods and uses Technical Field

[0001] The present invention relates to the field of medicinal chemistry, and in particular to Polθ inhibitors and preparation methods and uses thereof. Background Art

[0002] DNA double-strand breaks (DSBs) can be caused by a variety of factors, including exogenous damage such as ionizing radiation and chemotherapy drugs, or the accumulation of intrinsic damage during DNA replication and meiosis. Improper repair can lead to genomic instability and even cell death. In humans, DSBs are primarily repaired through three pathways: homologous recombination (HR), nonhomologous end joining (NHEJ), and microhomology-mediated end joining (MMEJ) [Curr Opin Genet Dev. 2020. 60: 119–126; J Mol Biol. 2015. 427(3): 652-658].

[0003] In tumor cells, the HR pathway and the MMEJ pathway have a mutually inhibitory or compensatory relationship. When HR is deficient, DSBs are repaired by enhancing MMEJ [Cell Mol Life Sci. 2020.77(4):677-703; Nucleic Acids Research, 2016.44(12):5743–5757]. Polθ is a key factor in the MMEJ pathway and belongs to the A family of polymerases. It contains a helicase domain that can compete with HR to remove DNA ends and a polymerase domain for chain annealing and extension, connected by a central region. It is the only known DNA polymerase to contain both a polymerization domain and a helicase domain. [Trends Cancer. 2021Feb;7(2):98-111.]. Polθ is upregulated in human tumors (including lung cancer, gastric cancer, and colorectal cancer), especially in breast cancer and ovarian cancer with HR function loss, and is associated with poor clinical outcomes in breast cancer and ovarian cancer [Nature.2015.518(7538):254–257; Curr Opin Genet Dev.2020.60:119–126].

[0004] Studies have confirmed that there is a synthetic lethal relationship between the HR pathway and the Polθ-mediated MMEJ pathway. In HR-deficient tumor cells, knocking down the POLQ gene can induce tumor cell death, indicating that HR-deficient tumors are abnormally sensitive to Polθ-mediated repair inhibition [Nature.2015.518(7538):258–262]. Inhibiting Polθ can also increase the killing effect of PARP inhibitors and DNA-damaging agents on HR-deficient tumor cells or have a synergistic effect [Genes.2021;12(8):1-16].

[0005] HR pathway dysfunction is most common in endometrial cancer (34.4%), biliary tract cancer (28.9%), bladder cancer (23.9%), hepatocellular carcinoma (20.9%), gastroesophageal cancer (20.8%), ovarian cancer (20.0%), and breast cancer (15.6%) [JCO Precis Oncol. 2018(2):PO.17.00286]. Among ovarian and breast cancers, the proportion of HR defects in high-grade serous ovarian cancer (HGSOC) and triple-negative breast cancer (TNBC) is as high as over 50% [Ann Oncol. 2021.32(2):240-249; Curr Opin Obstet Gynecol. 2017.29(1):26-34]. Currently, the treatment options for HGSOC are relatively limited, mainly surgery and chemotherapy, as well as PARP inhibitors. The recurrence rate of chemotherapy is high, with 25% of patients developing platinum resistance after 6 months of treatment, and the 5-year survival rate is low, at approximately 31% [Nature. 2011, 474(7353):609-615]. More than 40% of patients with BRCA1 / 2 deficiency are ineffective against PARP inhibitors, and long-term oral PARP inhibitor resistance develops [Mol Cancer. 2020, 19(1):1-16]. Polθ inhibitors can enhance the killing effect of PARP inhibitors and DNA damaging agents on HR-deficient tumor cells or have a synergistic effect.

[0006] Therefore, developing small molecule inhibitors of Polθ for the treatment of HR-deficient tumors can provide new therapeutic strategies for tumor treatment.

[0007] Summary of the Invention

[0008] The object of the present invention is to provide a class of compounds that can be used to treat HR-deficient tumors.

[0009] In order to achieve the above-mentioned object of the invention, the present invention provides a compound described in general formula (I), or a pharmaceutically acceptable salt, stereoisomer, tautomer, polymorph, cocrystal, hydrate, solvate, metabolite, prodrug, or deuterated compound thereof:

[0010] Wherein, X is selected from -C(O)- or -C(S)-, and Y is selected from -NR 1 -; or X is selected from -NR 1 -, Y is selected from -C(O)- or -C(S)-;

[0011] Ring A is selected from phenyl, 5-10 membered heteroaryl; wherein the 5-10 membered heteroaryl contains 1 to 3 heteroatoms selected from N, O and S; the phenyl and 5-10 membered heteroaryl are each independently unsubstituted or substituted by one or more identical or different R a replace;

[0012] R 1 Selected from C 1-8 Alkyl, C 3-8 Cycloalkyl, C 1-8 Halogenated alkyl, C 1-8 Hydroxyalkyl; wherein the C 1-8 Alkyl, C 3-8 Cycloalkyl, C 1-8 Halogenated alkyl, C 1-8 Each hydroxyalkyl group is independently unsubstituted or substituted with one or more identical or different R b replace;

[0013] R 2 Selected from C 1-8 Alkyl, 5-10 membered heteroaryl, C 6-10 Aryl, C 3-10 Cycloalkyl, 4-10 membered heterocycloalkyl, unsaturated 4-10 membered heterocyclic group; wherein, the C 3-10 -CH2- on the cycloalkyl ring is optionally replaced by -C(=O)-, -C(=S)- and -S(=O)2-; the 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl and unsaturated 4-10 membered heterocyclic group each independently contain 1 to 3 heteroatoms selected from N, O and S; wherein the C 1-8 Alkyl, 5-10 membered heteroaryl, C 6-10 Aryl, C 3-10 Cycloalkyl, 4-10 membered heterocycloalkyl, unsaturated 4-10 membered heterocyclic group are each independently unsubstituted or substituted by one or more identical or different R c replace;

[0014] L does not exist or C 1-3 alkylene;

[0015] Each R a 、R b 、R c Each independently selected from halogen, -CN, -OH, -SR i 、-SF5、-SCF3、-S(O)2Ri 、-S(O)(=NR i )R j 、-N=S(O)R i R j 、C 1-8 Alkyl, C 1-8 Alkoxy, C 1-8 Halogenated alkyl, C 1-8 Halogenated alkoxy, C 1-8 Hydroxyalkyl, C 3-8 Cycloalkyl, unsubstituted or substituted by one or more identical or different R aa Substituted 5-6 membered heteroaryl, -NR i R j 、-C(O)NR i R j ; or two adjacent R a Combined with the atoms on ring A to form an unsubstituted or substituted R bb Substituted 4-7 membered heterocycloalkyl; wherein the 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl each independently contain 1 to 3 heteroatoms selected from N, O and S; each R aa 、R bb are each independently selected from halogen, C 1-4 alkyl;

[0016] Each R i 、R j Each independently selected from the same or different -H, C 1-4 Alkyl; or R i 、R j The connected N forms an unsubstituted or substituted group with one or more identical or different R cc Substituted 4-7 membered heterocycloalkyl; wherein the 4-7 membered heterocycloalkyl contains 1 to 3 heteroatoms selected from N, O and S, and the -CH2- on the 4-7 membered heterocycloalkyl ring is optionally replaced by -C(=O)-, -C(=S)- and -S(=O)2-; each R cc Each independently selected from C 1-4 Alkyl, halogen.

[0017] The present invention provides a compound of formula (I), or a pharmaceutically acceptable salt, stereoisomer, tautomer, polymorph, cocrystal, hydrate, solvate, metabolite, prodrug, or deuterated compound thereof:

[0018] Wherein, X and Y are each independently selected from -C(O)- or -NR 1 -, and X and Y are different;

[0019] Ring A is selected from phenyl, 5-10 membered heteroaryl; wherein the 5-10 membered heteroaryl contains 1 to 3 heteroatoms selected from N, O and S; the phenyl and 5-10 membered heteroaryl are each independently unsubstituted or substituted by one or more identical or different R a replace;

[0020] R 1 Selected from C 1-8 Alkyl, C 3-8 Cycloalkyl, C 1-8 Halogenated alkyl, C 1-8 Hydroxyalkyl; wherein the C 1-8 Alkyl, C 3-8 Cycloalkyl, C 1-8 Halogenated alkyl, C 1-8 Each hydroxyalkyl group is independently unsubstituted or substituted with one or more identical or different R b replace;

[0021] R 2 Selected from C 1-8 Alkyl, 5-10 membered heteroaryl, C 6-10 Aryl, C 3-10 Cycloalkyl, 4-10 membered heterocycloalkyl, unsaturated 4-10 membered heterocyclic group; wherein, the C 3-10 -CH2- on the cycloalkyl ring is optionally replaced by -C(=O)-, -C(=S)- and -S(=O)2-; the 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl and unsaturated 4-10 membered heterocyclic group each independently contain 1 to 3 heteroatoms selected from N, O and S; wherein the C 1-8 Alkyl, 5-10 membered heteroaryl, C 6-10 Aryl, C 3-10 Cycloalkyl, 4-10 membered heterocycloalkyl, unsaturated 4-10 membered heterocyclic group are each independently unsubstituted or substituted by one or more identical or different R c replace;

[0022] L does not exist or C 1-3 alkylene;

[0023] Each R a 、R b 、R c Each independently selected from halogen, -CN, -OH, C 1-8 Alkyl, C 1-8 Alkoxy, C 1-8 Halogenated alkyl, C 1-8 Halogenated alkoxy, C 1-8 Hydroxyalkyl, C 3-8 Cycloalkyl, unsubstituted or substituted by one or more identical or different R aa Substituted 5-6 membered heteroaryl, -NRi R j 、-C(O)NR i R j ; or two adjacent R a Combined with the atoms on ring A to form an unsubstituted or substituted R bb Substituted 4-7 membered heterocycloalkyl; wherein the 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl each independently contain 1 to 3 heteroatoms selected from N, O and S; each R aa 、R bb are each independently selected from halogen, C 1-4 alkyl;

[0024] Each R i 、R j Each independently selected from -H, C 1-4 Alkyl; or R i 、R j The connected N forms an unsubstituted or substituted group with one or more identical or different R cc Substituted 4-7 membered heterocycloalkyl; wherein the 4-7 membered heterocycloalkyl contains 1 to 3 heteroatoms selected from N, O and S, and the -CH2- on the 4-7 membered heterocycloalkyl ring is optionally replaced by -C(=O)-, -C(=S)- and -S(=O)2-; each R cc Each independently selected from C 1-4 Alkyl, halogen.

[0025] The present invention provides a compound of formula (I), or a pharmaceutically acceptable salt, stereoisomer, tautomer, polymorph, cocrystal, hydrate, solvate, metabolite, prodrug, or deuterated compound thereof:

[0026] Wherein, X and Y are each independently selected from -C(O)- or -NR 1 -, and X and Y are different;

[0027] Ring A is selected from phenyl, 5-10 membered heteroaryl; wherein the 5-10 membered heteroaryl contains 1 to 3 heteroatoms selected from N, O and S; the phenyl and 5-10 membered heteroaryl are each independently unsubstituted or substituted by one or more identical or different R a replace;

[0028] R 1 Selected from C 1-8 Alkyl, C 3-8 Cycloalkyl, C 1-8 Halogenated alkyl, C 1-8 Hydroxyalkyl; wherein the C 1-8 Alkyl, C 3-8 Cycloalkyl, C1-8 Halogenated alkyl, C 1-8 Each hydroxyalkyl group is independently unsubstituted or substituted with one or more identical or different R b replace;

[0029] R 2 Selected from C 1-8 Alkyl, 5-10 membered heteroaryl, C 6-10 Aryl, C 3-10 Cycloalkyl, 4-10 membered heterocycloalkyl, unsaturated 4-10 membered heterocyclic group; wherein, the C 3-10 -CH2- on the cycloalkyl ring is optionally replaced by -C(=O)-, -C(=S)- and -S(=O)2-; the 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl and unsaturated 4-10 membered heterocyclic group each independently contain 1 to 3 heteroatoms selected from N, O and S; wherein the 5-10 membered heteroaryl, C 6-10 Aryl, C 3-10 Cycloalkyl, 4-10 membered heterocycloalkyl, unsaturated 4-10 membered heterocyclic group are each independently unsubstituted or substituted by one or more identical or different R c replace;

[0030] L does not exist or C 1-3 alkylene;

[0031] Each R a 、R b 、R c Each independently selected from halogen, -CN, -OH, C 1-8 Alkyl, C 1-8 Alkoxy, C 1-8 Halogenated alkyl, C 1-8 Halogenated alkoxy, C 1-8 Hydroxyalkyl, C 3-8 Cycloalkyl, unsubstituted or substituted by one or more identical or different R aa Substituted 5-6 membered heteroaryl, -NR i R j 、-C(O)NR i R j ; or two adjacent R a Combined with the atoms on ring A to form an unsubstituted or substituted R bb Substituted 4-7 membered heterocycloalkyl; wherein the 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl each independently contain 1 to 3 heteroatoms selected from N, O and S; each R aa 、R bb are each independently selected from halogen, C 1-4 alkyl;

[0032] Each R i、R j Each independently selected from -H, C 1-4 Alkyl; or R i 、R j The connected N forms an unsubstituted or substituted group with one or more identical or different R cc Substituted 4-7 membered heterocycloalkyl; wherein the 4-7 membered heterocycloalkyl contains 1 to 3 heteroatoms selected from N, O and S, and the -CH2- on the 4-7 membered heterocycloalkyl ring is optionally replaced by -C(=O)-, -C(=S)- and -S(=O)2-; each R cc Each independently selected from C 1-4 alkyl.

[0033] In some specific embodiments, the above compounds, or pharmaceutically acceptable salts, stereoisomers, tautomers, polymorphs, cocrystals, hydrates, solvates, metabolites, prodrugs, deuterated compounds thereof, Ring A is selected from phenyl, 5-6 membered heteroaryl; wherein the 5-6 membered heteroaryl contains 1 to 3 heteroatoms selected from N, O and S; the phenyl and 5-6 membered heteroaryl are each independently unsubstituted or substituted by one or more identical or different R a replace.

[0034] In some specific embodiments, ring A is selected from phenyl, 6-membered heteroaryl; wherein the 6-membered heteroaryl contains 1 to 2 heteroatoms selected from N; the phenyl and 6-membered heteroaryl are each independently unsubstituted or substituted by one or more identical or different R a replace.

[0035] In some embodiments, ring A is selected from phenyl and pyridyl; wherein the phenyl and pyridyl are each independently unsubstituted or substituted by one or more identical or different R a replace.

[0036] In some embodiments, ring A is selected from phenyl and pyridyl; wherein the phenyl and pyridyl are each independently unsubstituted or substituted by 1, 2 or 3 identical or different R a replace.

[0037] In some embodiments, Ring A is selected from

[0038] In some embodiments, each R a Each independently selected from halogen, -CN, -OH, -SR i 、-SF5、-SCF3、-S(O)2R i 、-S(O)(=NR i )R j 、-N=S(O)Ri R j 、C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl, C 1-6 Halogenated alkoxy, C 1-6 Hydroxyalkyl, C 3-6 Cycloalkyl, unsubstituted or substituted by one or more identical or different R aa Substituted 5-6 membered heteroaryl, -NR i R j 、-C(O)NR i R j ; or two adjacent R a Combined with the atoms on ring A to form an unsubstituted or substituted R bb Substituted 4-7 membered heterocycloalkyl; wherein the 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl each independently contain 1 to 3 heteroatoms selected from N, O and S; each R aa 、R bb are each independently selected from halogen, C 1-4 alkyl;

[0039] Each R i 、R j Each independently selected from the same or different -H, C 1-4 Alkyl; or R i 、R j The connected N forms an unsubstituted or substituted group with one or more identical or different R cc Substituted 4-7 membered heterocycloalkyl; wherein the 4-7 membered heterocycloalkyl contains 1 to 3 heteroatoms selected from N, O and S, and the -CH2- on the 4-7 membered heterocycloalkyl ring is optionally replaced by -C(=O)-, -C(=S)- and -S(=O)2-; each R cc Each independently selected from C 1-4 alkyl.

[0040] In some embodiments, each R a Each independently selected from halogen, -CN, -SR i 、-SF5、-SCF3、-S(O)2R i 、-S(O)(=NR i )R j 、-N=S(O)R i R j 、C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl, C 1-6 Haloalkoxy; or two adjacent R aCombined with the atoms on ring A to form an unsubstituted or substituted R bb Substituted 4-7 membered heterocycloalkyl; wherein the 4-7 membered heterocycloalkyl contains 1 to 3 heteroatoms selected from N, O and S; each R bb are each independently selected from halogen, C 1-4 Alkyl; each R i 、R j Each independently selected from the same or different -H, C 1-4 alkyl.

[0041] In some embodiments, each R a Each independently selected from halogen, -CN, -SR i 、-SF5、-SCF3、-S(O)2R i 、-S(O)(=NR i )R j 、-N=S(O)R i R j 、C 1-4 Alkyl, C 1-4 Alkoxy, C 1-4 Halogenated alkyl, C 1-4 Haloalkoxy; or two adjacent R a Combined with the atoms on ring A to form an unsubstituted or substituted R bb Substituted 5-6 membered heterocycloalkyl; wherein the 5-6 membered heterocycloalkyl contains 1 to 2 heteroatoms selected from N and O; each R bb are each independently selected from halogen, C 1-4 Alkyl; each R i 、R j Each independently selected from the same or different -H, C 1-4 alkyl.

[0042] In some embodiments, each R a Each independently selected from -F, -Cl, -Br, -CN, -SR i 、-SF5、-SCF3、-S(O)2R i 、-S(O)(=NR i )R j 、-N=S(O)R i R j, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, sec-butoxy, isobutoxy, tert-butoxy, fluoromethyl, fluoroethyl, fluoro-n-propyl, fluoroisopropyl, fluoro-n-butyl, fluoro-sec-butyl, fluoroisobutyl, fluoro-tert-butyl, fluoromethoxy, fluoroethoxy, fluoro-n-propoxy, fluoroisopropoxy, fluoro-n-butoxy, fluoro-sec-butoxy, fluoroisobutoxy, fluoro-tert-butoxy; or two adjacent R a Combined with the atoms on ring A to form an unsubstituted or substituted R bb Substituted 1,3-dioxolane or morpholinyl; each R bb Each R is independently selected from -F, -Cl, -Br, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl; i 、R j Each is independently selected from the same or different -H, methyl, ethyl.

[0043] In some embodiments, each R a Each independently selected from -F, -Cl, -Br, -CN, methyl, ethyl, methoxy, ethoxy, fluoromethyl, fluoroethyl, fluoromethoxy, fluoroethoxy, -SR i 、-SF5、-SCF3、-S(O)2R i 、-S(O)(=NR i )R j 、-N=S(O)R i R j ; or two adjacent R a Combined with the atoms on ring A to form an unsubstituted or substituted R bb Substituted 1,3-dioxolane or morpholinyl; each R bb Each R is independently selected from -F, methyl; i 、R j Each is independently selected from the same or different -H, methyl.

[0044] In some embodiments, each R a Each independently selected from -F, -Cl, -Br, -CN, methyl, methoxy, -CF3, -OCF3, -CHF2, -OCHF2, -CH2CHF2, -SF5, -SCF3, -SCH3, Or two adjacent R a Combined with the atoms on ring A to form an unsubstituted or substituted R bb Substituted 1,3-dioxolane or morpholinyl; each R bbEach is independently selected from -F, methyl.

[0045] In some specific embodiments, the above-mentioned compound, or a pharmaceutically acceptable salt, stereoisomer, tautomer, polymorph, cocrystal, hydrate, solvate, metabolite, prodrug, or deuterated compound thereof, each R a Each independently selected from halogen, -CN, -OH, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl, C 1-6 Halogenated alkoxy, C 1-6 Hydroxyalkyl, C 3-6 Cycloalkyl, unsubstituted or substituted by one or more identical or different R aa Substituted 5-6 membered heteroaryl, -NR i R j 、-C(O)NR i R j ; or two adjacent R a Combined with the atoms on ring A to form an unsubstituted or substituted R bb Substituted 4-7 membered heterocycloalkyl; wherein the 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl each independently contain 1 to 3 heteroatoms selected from N, O and S; each R aa 、R bb are each independently selected from halogen, C 1-4 alkyl;

[0046] R i 、R j Each independently selected from -H, C 1-4 Alkyl; or R i 、R j The connected N forms an unsubstituted or substituted group with one or more identical or different R cc Substituted 4-7 membered heterocycloalkyl; wherein the 4-7 membered heterocycloalkyl contains 1 to 3 heteroatoms selected from N, O and S, and the -CH2- on the 4-7 membered heterocycloalkyl ring is optionally replaced by -C(=O)-, -C(=S)- and -S(=O)2-; each R cc Each independently selected from C 1-4 alkyl.

[0047] In some embodiments, each R a are independently selected from halogen, -CN, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl, C 1-6 Haloalkoxy; or two adjacent R aCombined with the atoms on ring A to form an unsubstituted or substituted R bb Substituted 4-7 membered heterocycloalkyl; wherein each of the 4-7 membered heterocycloalkyl groups independently contains 1 to 3 heteroatoms selected from N, O and S; each R bb are each independently selected from halogen, C 1-4 alkyl.

[0048] In some embodiments, each R a are independently selected from halogen, -CN, C 1-4 Alkyl, C 1-4 Alkoxy, C 1-4 Halogenated alkyl, C 1-4 Haloalkoxy; or two adjacent R a Combined with the atoms on ring A to form an unsubstituted or substituted R bb Substituted 5-6 membered heterocycloalkyl; wherein the 5-6 membered heterocycloalkyl contains 1 to 2 heteroatoms selected from N and O; each R bb are each independently selected from halogen, C 1-4 alkyl.

[0049] In some embodiments, each R a R is each independently selected from -F, -Cl, -Br, -CN, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, sec-butoxy, isobutoxy, tert-butoxy, fluoromethyl, fluoroethyl, fluoro-n-propyl, fluoroisopropyl, fluoro-n-butyl, fluoro-sec-butyl, fluoroisobutyl, fluoro-tert-butyl, fluoromethoxy, fluoroethoxy, fluoro-n-propoxy, fluoroisopropoxy, fluoro-n-butoxy, fluoro-sec-butoxy, fluoroisobutoxy, fluoro-tert-butoxy; or two adjacent R a Combined with the atoms on ring A to form an unsubstituted or substituted R bb Substituted 1,3-dioxolane or morpholinyl; each R bb Each is independently selected from -F, -Cl, -Br, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, and tert-butyl.

[0050] In some embodiments, each R a Each independently selected from -F, -Cl, -Br, -CN, methyl, methoxy, fluoromethyl, fluoroethyl, fluoromethoxy; or two adjacent R a Combined with the atoms on ring A to form an unsubstituted or substituted R bb Substituted 1,3-dioxolane or morpholinyl; each R bbEach is independently selected from -F, methyl.

[0051] In some embodiments, each R a Each independently selected from -F, -Cl, -Br, -CN, methyl, methoxy, -CF3, -OCF3, -CHF2, -OCHF2, -CH2CHF2; or two adjacent R a Combined with the atoms on ring A to form an unsubstituted or substituted R bb Substituted 1,3-dioxolane or morpholinyl; each R bb Each is independently selected from -F, methyl.

[0052] In some embodiments, each R a Each independently selected from -F, -Cl, -Br, -CN, methyl, methoxy, fluoromethyl, fluoromethoxy; or two adjacent R a Combined with the atoms on ring A to form an unsubstituted or substituted R bb Substituted 1,3-dioxolane or morpholinyl; each R bb Each is independently selected from -F, methyl.

[0053] In some embodiments, each R a Each independently selected from -F, -Cl, -Br, -CN, methyl, methoxy, -CF3, -OCF3, -CHF2, -OCHF2; or two adjacent R a Combined with the atoms on ring A to form an unsubstituted or substituted R bb Substituted 1,3-dioxolane or morpholinyl; each R bb Each is independently selected from -F, methyl.

[0054] In some specific embodiments, the above compound, or a pharmaceutically acceptable salt, stereoisomer, tautomer, polymorph, cocrystal, hydrate, solvate, metabolite, prodrug, or deuterated compound thereof, Ring A is selected from

[0055] In some specific embodiments, the above compound, or a pharmaceutically acceptable salt, stereoisomer, tautomer, polymorph, cocrystal, hydrate, solvate, metabolite, prodrug, or deuterated compound thereof, Ring A is selected from

[0056] In some specific embodiments, the above compound, or a pharmaceutically acceptable salt, stereoisomer, tautomer, polymorph, cocrystal, hydrate, solvate, metabolite, prodrug, or deuterated compound thereof, Ring A is selected from

[0057] In some specific embodiments, the above-mentioned compound, or a pharmaceutically acceptable salt, stereoisomer, tautomer, polymorph, cocrystal, hydrate, solvate, metabolite, prodrug, deuterated compound thereof, R 1 Selected from C 1-6 Alkyl, C 3-6 Cycloalkyl, C 1-6 Halogenated alkyl, C 1-6 Hydroxyalkyl; wherein the C 1-6 Alkyl, C 3-6 Cycloalkyl, C 1-6 Halogenated alkyl, C 1-6 Each hydroxyalkyl group is independently unsubstituted or substituted with one or more identical or different R b replace.

[0058] In some specific embodiments, R 1 Selected from C 1-6 Alkyl; wherein the C 1-6 The alkyl group is unsubstituted or substituted with one or more identical or different R b replace.

[0059] In some specific embodiments, R 1 Selected from C 1-4 Alkyl; wherein the C 1-4 The alkyl group is unsubstituted or substituted with one or more identical or different R b replace.

[0060] In some specific embodiments, R 1 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl; wherein the methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl and tert-butyl are each independently unsubstituted or substituted by one or more R b replace.

[0061] In some specific embodiments, R 1 is selected from methyl, ethyl, isopropyl; wherein the methyl, ethyl, isopropyl are each independently unsubstituted or substituted by one or more R b replace.

[0062] In some specific embodiments, R 1is selected from methyl, ethyl, isopropyl; wherein the methyl and ethyl groups are each independently unsubstituted or substituted by one or more R b replace.

[0063] In some specific embodiments, R 1 is selected from methyl, ethyl, isopropyl; wherein the methyl and ethyl groups are each independently unsubstituted or replaced by one R b replace.

[0064] In some specific embodiments, R 1 Selected from C 1-2 Alkyl; wherein the C 1-2 The alkyl group is unsubstituted or substituted with one or more identical or different R b replace.

[0065] In some specific embodiments, R 1 is selected from methyl and ethyl; wherein the methyl and ethyl groups are each independently unsubstituted or substituted by one or more identical or different R b replace.

[0066] In some specific embodiments, R 1 is selected from methyl and ethyl; wherein the methyl and ethyl groups are each independently unsubstituted or substituted by one R b replace.

[0067] In some specific embodiments, the above-mentioned compound, or a pharmaceutically acceptable salt, stereoisomer, tautomer, polymorph, cocrystal, hydrate, solvate, metabolite, prodrug, or deuterated compound thereof, each R b Each independently selected from halogen, -CN, -OH, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl, C 1-6 Halogenated alkoxy, C 1-6 Hydroxyalkyl, C 3-6 Cycloalkyl, unsubstituted or substituted by one or more identical or different R aa Substituted 5-6 membered heteroaryl, -NR i R j 、-C(O)NR i R j ; wherein the 5-6 membered heteroaryl group contains 1 to 3 heteroatoms selected from N, O and S.

[0068] In some embodiments, each R b Each independently selected from C 1-6 Alkoxy, C 3-6 Cycloalkyl, unsubstituted or substituted by one or more identical or different R aaSubstituted 5-6 membered heteroaryl, -NR i R j 、-C(O)NR i R j ; wherein the 5-6 membered heteroaryl group contains 1 to 3 heteroatoms selected from N, O and S.

[0069] In some embodiments, each R b Each independently selected from C 1-4 Alkoxy, C 3-6 Cycloalkyl, unsubstituted or substituted by one or more identical or different R aa Substituted 5-membered heteroaryl, -NR i R j 、-C(O)NR i R j ; wherein the 5-membered heteroaryl group contains 2 to 3 heteroatoms selected from N, O and S.

[0070] In some embodiments, each R b Each is independently selected from methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, sec-butoxy, isobutoxy, tert-butoxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, -NR i R j 、-C(O)NR i R j , unsubstituted or replaced by one or more identical or different R aa Substituted 5-membered heteroaryl; the 5-membered heteroaryl is selected from pyrazolyl, thiazolyl, oxazolyl, and oxadiazolyl.

[0071] In some embodiments, each R b Each independently selected from methoxy, cyclopropyl, -NR i R j 、-C(O)NR i R j , 1 or more identical or different R aa Substituted 5-membered heteroaryl; the 5-membered heteroaryl is selected from pyrazolyl, thiazolyl, oxazolyl, and oxadiazolyl.

[0072] In some embodiments, each R b Each independently selected from methoxy, cyclopropyl, -NR i R j 、-C(O)NR i R j , 1 R aa Substituted 5-membered heteroaryl; the 5-membered heteroaryl is selected from pyrazolyl, thiazolyl, oxazolyl, and oxadiazolyl.

[0073] In some specific embodiments, the above-mentioned compound, or a pharmaceutically acceptable salt, stereoisomer, tautomer, polymorph, cocrystal, hydrate, solvate, metabolite, prodrug, or deuterated compound thereof, each R aa are each independently selected from halogen, C 1-4 alkyl.

[0074] In some embodiments, each R aa Each independently selected from C 1-4 alkyl.

[0075] In some embodiments, each R aa Each is independently selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, and tert-butyl.

[0076] In some embodiments, each R aa are each independently selected from methyl.

[0077] In some specific embodiments, the above-mentioned compound, or a pharmaceutically acceptable salt, stereoisomer, tautomer, polymorph, cocrystal, hydrate, solvate, metabolite, prodrug, or deuterated compound thereof, each R i 、R j Each independently selected from -H, C 1-4 Alkyl; or R i 、R j The connected N forms an unsubstituted or substituted group with one or more identical or different R cc Substituted 4-6 membered heterocycloalkyl; wherein the 4-6 membered heterocycloalkyl contains 1 to 3 heteroatoms selected from N, O and S, and the -CH2- on the 4-6 membered heterocycloalkyl ring is optionally replaced by -C(=O)-, -C(=S)- and -S(=O)2-; each R cc Each independently selected from C 1-4 Alkyl, halogen.

[0078] In some embodiments, each R i 、R j Each independently selected from -H, C 1-4 Alkyl; or R i 、R j The connected N forms an unsubstituted or substituted group with one or more identical or different R cc Substituted 4-6 membered heterocycloalkyl; wherein the 4-6 membered heterocycloalkyl contains 1 to 2 heteroatoms selected from N and O, and the -CH2- on the 4-6 membered heterocycloalkyl ring is optionally replaced by -C(=O)-; each R cc Each independently selected from C 1-4 Alkyl, halogen.

[0079] In some embodiments, each R i 、R j Each is independently selected from -H, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl; or R i 、R j The connected N forms an unsubstituted or substituted group with one or more identical or different R cc substituted azetidinyl, piperidinyl, piperazinyl, morpholinyl or piperazinonyl; wherein each R cc Each is independently selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, F, Cl, and Br.

[0080] In some embodiments, each R i 、R j are each independently selected from -H, methyl; or R i 、R j The connected N forms an unsubstituted or substituted group with one or more identical or different R cc substituted azetidinyl, piperidinyl, piperazinyl, morpholinyl or piperazinonyl; wherein each R cc Each is independently selected from methyl, F.

[0081] In some embodiments, each R i 、R j are each independently selected from -H, methyl; or R i 、R j Together with the attached N, it forms a fluoroazetidinyl, morpholinyl, piperidinyl, N-methylpiperazinyl or N-methylpiperazinone group.

[0082] In some specific embodiments, the above-mentioned compound, or a pharmaceutically acceptable salt, stereoisomer, tautomer, polymorph, cocrystal, hydrate, solvate, metabolite, prodrug, or deuterated compound thereof, each R i 、R j Each independently selected from -H, C 1-4 Alkyl; or R i 、R j The connected N forms an unsubstituted or substituted group with one or more identical or different R cc Substituted 5-6 membered heterocycloalkyl; wherein the 5-6 membered heterocycloalkyl contains 1 to 3 heteroatoms selected from N, O and S, and the -CH2- on the 5-6 membered heterocycloalkyl ring is optionally replaced by -C(=O)-, -C(=S)- and -S(=O)2-; each R cc Each independently selected from C 1-4 alkyl.

[0083] In some embodiments, each R i 、R j Each independently selected from -H, C 1-4 Alkyl; or R i 、R j The connected N forms an unsubstituted or substituted group with one or more identical or different R cc Substituted 5-6 membered heterocycloalkyl; wherein the 5-6 membered heterocycloalkyl contains 1 to 2 heteroatoms selected from N and O, and the -CH2- on the 5-6 membered heterocycloalkyl ring is optionally replaced by -C(=O)-; each R cc Each independently selected from C 1-4 alkyl.

[0084] In some embodiments, each R i 、R j Each is independently selected from -H, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl; or R i 、R j The connected N forms an unsubstituted or substituted group with one or more identical or different R cc substituted piperidinyl, piperazinyl, morpholinyl or piperazinonyl; wherein each R cc Each is independently selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, and tert-butyl.

[0085] In some embodiments, each R i 、R j are each independently selected from -H, methyl; or R i 、R j The connected N forms an unsubstituted or substituted group with one or more identical or different R cc substituted piperidinyl, piperazinyl, morpholinyl or piperazinonyl; wherein each R cc are each independently selected from methyl.

[0086] In some embodiments, each R i 、R j are each independently selected from -H, methyl; or R i 、R j Together with the attached N, it forms a morpholinyl, piperidinyl, N-methylpiperazinyl or N-methylpiperazinone group.

[0087] In some specific embodiments, the above-mentioned compound, or a pharmaceutically acceptable salt, stereoisomer, tautomer, polymorph, cocrystal, hydrate, solvate, metabolite, prodrug, deuterated compound thereof, R 1 Selected from methyl, ethyl, isopropyl,

[0088] In some specific embodiments, the above-mentioned compound, or a pharmaceutically acceptable salt, stereoisomer, tautomer, polymorph, cocrystal, hydrate, solvate, metabolite, prodrug, deuterated compound thereof, R 1 Selected from methyl,

[0089] In some specific embodiments, the above-mentioned compound, or a pharmaceutically acceptable salt, stereoisomer, tautomer, polymorph, cocrystal, hydrate, solvate, metabolite, prodrug, deuterated compound thereof, R 2 Selected from C 1-6 Alkyl, 5-6 membered heteroaryl, phenyl, C 3-8 Cycloalkyl, 4-7 membered heterocycloalkyl, unsaturated 4-7 membered heterocyclic group; wherein, the C 3-8 -CH2- on the cycloalkyl ring is optionally replaced by -C(=O)-, -C(=S)- and -S(=O)2-; the 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl and unsaturated 4-7 membered heterocyclic group each independently contain 1 to 3 heteroatoms selected from N, O and S; the C 1-6 Alkyl, 5-6 membered heteroaryl, phenyl, C 3-8 Cycloalkyl, 4-7 membered heterocycloalkyl, unsaturated 4-7 membered heterocyclic group are each independently unsubstituted or substituted by one or more identical or different R c replace.

[0090] In some specific embodiments, R 2 Selected from C 1-6 Alkyl, 5-6 membered heteroaryl, phenyl, C 3-8 Cycloalkyl, 4-7 membered heterocycloalkyl; wherein the C 3-8 -CH2- on the cycloalkyl ring is optionally replaced by -C(=O)-, -C(=S)- and -S(=O)2-; the 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl each independently contain 1 to 3 heteroatoms selected from N, O and S; the C 1-6 Alkyl, 5-6 membered heteroaryl, phenyl, C 3-8 Cycloalkyl and 4-7 membered heterocycloalkyl are each independently unsubstituted or substituted by one or more identical or different R c replace.

[0091] In some specific embodiments, R 2 Selected from C 1-4 Alkyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, furyl, thienyl, pyrrolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, pyrazolyl, imidazolyl, phenyl, C3-7 Cycloalkyl, 4-6 membered heterocycloalkyl; wherein the C 3-7 -CH2- on the cycloalkyl ring is optionally replaced by -S(=O)2-; the 4-6 membered heterocycloalkyl contains 1 to 2 heteroatoms selected from N and O; the C 1-4 Alkyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, furyl, thienyl, pyrrolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, pyrazolyl, imidazolyl, phenyl, C 3-7 Cycloalkyl and 4-6 membered heterocycloalkyl are each independently unsubstituted or substituted by one or more identical or different R c replace.

[0092] In some specific embodiments, R 2 Selected from Methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, furyl, thienyl, pyrrolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, pyrazolyl, imidazolyl, phenyl, C 3-7 Cycloalkyl, 4-6 membered heterocycloalkyl; wherein the 4-6 membered heterocycloalkyl contains 1 to 2 heteroatoms selected from N and O; the methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, furyl, thienyl, pyrrolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, pyrazolyl, imidazolyl, phenyl, C 3-7 Cycloalkyl and 4-6 membered heterocycloalkyl are each independently unsubstituted or substituted by one or more identical or different R c replace.

[0093] In some specific embodiments, R 2 Selected from Methyl, ethyl, pyridyl, pyrimidinyl, pyrazinyl, phenyl, C 3-7 Cycloalkyl, 4-6 membered heterocycloalkyl; wherein the C 3-7 The cycloalkyl group is selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, C5 bridged cycloalkyl, C7 spirocycloalkyl, the 4-6 membered heterocycloalkyl group is selected from tetrahydrofuranyl, oxetane, piperidinyl, 1,4-dioxetane; the methyl, ethyl, pyridinyl, pyrimidinyl, pyrazinyl, phenyl, C 3-7 Cycloalkyl and 4-6 membered heterocycloalkyl are each independently unsubstituted or substituted by one or more identical or different R c replace.

[0094] In some specific embodiments, R 2 Selected from Methyl, ethyl, pyridyl, pyrimidinyl, pyrazinyl, phenyl, C 3-7Cycloalkyl, 4-6 membered heterocycloalkyl; wherein the C 3-7 The cycloalkyl group is selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, C5 bridged cycloalkyl, C7 spirocycloalkyl, the 4-6 membered heterocycloalkyl group is selected from tetrahydrofuranyl, oxetane, piperidinyl, 1,4-dioxetane; the methyl, ethyl, pyridinyl, pyrimidinyl, pyrazinyl, phenyl, C 3-7 The cycloalkyl and 4-6 membered heterocycloalkyl groups are each independently unsubstituted or substituted by 1, 2 or 3 R c replace.

[0095] In some specific embodiments, R 2 Selected from C 1-4 Alkyl, pyridyl, phenyl, C 3-7 Cycloalkyl, 4-6 membered heterocycloalkyl; wherein the C 3-7 -CH2- on the cycloalkyl ring is optionally replaced by -S(=O)2-; the 4-6 membered heterocycloalkyl contains 1 to 2 heteroatoms selected from N and O; the C 1-4 Alkyl, pyridyl, phenyl, C 3-7 Cycloalkyl and 4-6 membered heterocycloalkyl are each independently unsubstituted or substituted by one or more identical or different R c replace.

[0096] In some specific embodiments, R 2 Selected from Methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, pyridyl, phenyl, C 3-7 Cycloalkyl, 4-6 membered heterocycloalkyl; wherein the 4-6 membered heterocycloalkyl contains 1 to 2 heteroatoms selected from N and O; the methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, pyridyl, phenyl, C 3-7 Cycloalkyl and 4-6 membered heterocycloalkyl are each independently unsubstituted or substituted by one or more identical or different R c replace.

[0097] In some specific embodiments, R 2 Selected from Methyl, ethyl, pyridyl, phenyl, C 3- 7-membered cycloalkyl, 4-6-membered heterocycloalkyl; wherein the C 3-7 The cycloalkyl group is selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, C5 bridged cycloalkyl, C7 spirocycloalkyl, the 4-6 membered heterocycloalkyl group is selected from tetrahydrofuranyl, oxetane, piperidinyl, 1,4-dioxetane; the methyl, ethyl, pyridinyl, phenyl, C 3-7 Cycloalkyl and 4-6 membered heterocycloalkyl are each independently unsubstituted or substituted by one or more identical or different R creplace.

[0098] In some specific embodiments, R 2 Selected from Methyl, ethyl, pyridyl, phenyl, C 3- 7-membered cycloalkyl, 4-6-membered heterocycloalkyl; wherein the C 3-7 The cycloalkyl group is selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, C5 bridged cycloalkyl, C7 spirocycloalkyl, the 4-6 membered heterocycloalkyl group is selected from tetrahydrofuranyl, oxetane, piperidinyl, 1,4-dioxetane; the methyl, ethyl, pyridinyl, phenyl, C 3-7 The cycloalkyl and 4-6 membered heterocycloalkyl groups are each independently unsubstituted or substituted by 1, 2 or 3 R c replace.

[0099] In some specific embodiments, the above-mentioned compound, or a pharmaceutically acceptable salt, stereoisomer, tautomer, polymorph, cocrystal, hydrate, solvate, metabolite, prodrug, deuterated compound thereof, R 2 Selected from C 1-6 Alkyl, 5-6 membered heteroaryl, phenyl, C 3-8 Cycloalkyl, 4-7 membered heterocycloalkyl, unsaturated 4-7 membered heterocyclic group; wherein, the C 3-8 -CH2- on the cycloalkyl ring is optionally replaced by -C(=O)-, -C(=S)- and -S(=O)2-; the 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, unsaturated 4-7 membered heterocyclic group each independently contains 1 to 3 heteroatoms selected from N, O and S; the 5-6 membered heteroaryl, phenyl, C 3-8 Cycloalkyl, 4-7 membered heterocycloalkyl, unsaturated 4-7 membered heterocyclic group are each independently unsubstituted or substituted by one or more identical or different R c replace.

[0100] In some specific embodiments, R 2 Selected from C 1-6 Alkyl, 5-6 membered heteroaryl, phenyl, C 3-8 Cycloalkyl, 4-7 membered heterocycloalkyl; wherein the C 3-8 -CH2- on the cycloalkyl ring is optionally replaced by -C(=O)-, -C(=S)- and -S(=O)2-; the 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl each independently contain 1 to 3 heteroatoms selected from N, O and S; the 5-6 membered heteroaryl, phenyl, C 3-8 Cycloalkyl and 4-7 membered heterocycloalkyl are each independently unsubstituted or substituted by one or more identical or different R c replace.

[0101] In some specific embodiments, R2 Selected from C 1-4 Alkyl, pyridyl, phenyl, C 3-7 Cycloalkyl, 4-6 membered heterocycloalkyl; wherein the C 3-7 -CH2- on the cycloalkyl ring is optionally replaced by -S(=O)2-; the 4-6 membered heterocycloalkyl contains 1 to 2 heteroatoms selected from N and O; the pyridyl, phenyl, C 3-7 Cycloalkyl and 4-6 membered heterocycloalkyl are each independently unsubstituted or substituted by one or more identical or different R c replace.

[0102] In some specific embodiments, R 2 Selected from Methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, pyridyl, phenyl, C 3-7 Cycloalkyl, 4-6 membered heterocycloalkyl; wherein the 4-6 membered heterocycloalkyl contains 1 to 2 heteroatoms selected from N and O; the pyridyl, phenyl, C 3-7 Cycloalkyl and 4-6 membered heterocycloalkyl are each independently unsubstituted or substituted by one or more identical or different R c replace.

[0103] In some specific embodiments, R 2 Selected from Methyl, ethyl, pyridyl, phenyl, C 3- 7-membered cycloalkyl, 4-6-membered heterocycloalkyl; wherein the C 3-7 The cycloalkyl group is selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, C5 bridged cycloalkyl, C7 spirocycloalkyl, the 4-6 membered heterocycloalkyl group is selected from tetrahydrofuranyl, oxetane, piperidinyl, 1,4-dioxetane; the pyridinyl, phenyl, C 3-7 Cycloalkyl and 4-6 membered heterocycloalkyl are each independently unsubstituted or substituted by one or more identical or different R c replace.

[0104] In some specific embodiments, R 2 Selected from Methyl, ethyl, pyridyl, phenyl, C 3- 7-membered cycloalkyl, 4-6-membered heterocycloalkyl; wherein the C 3-7 The cycloalkyl group is selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, C5 bridged cycloalkyl, C7 spirocycloalkyl, the 4-6 membered heterocycloalkyl group is selected from tetrahydrofuranyl, oxetane, piperidinyl, 1,4-dioxetane; the pyridinyl, phenyl, C 3-7 The cycloalkyl and 4-6 membered heterocycloalkyl groups are each independently unsubstituted or substituted by 1, 2 or 3 R c replace.

[0105] In some specific embodiments, the above-mentioned compound, or a pharmaceutically acceptable salt, stereoisomer, tautomer, polymorph, cocrystal, hydrate, solvate, metabolite, prodrug, or deuterated compound thereof, each R c Each independently selected from halogen, -CN, -OH, -SR i 、-SF5、-SCF3、-S(O)2R i 、-S(O)(=NR i )R j 、-N=S(O)R i R j 、C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl, C 1-6 Halogenated alkoxy, C 1-6 Hydroxyalkyl, C 3-6 Cycloalkyl, unsubstituted or substituted by one or more identical or different R aa Substituted 5-6 membered heteroaryl, -NR i R j 、-C(O)NR i R j ; wherein the 5-6 membered heteroaryl group contains 1 to 3 heteroatoms selected from N, O and S; each R aa are each independently selected from halogen, C 1-4 Alkyl; each R i 、R j Each independently selected from -H, C 1-4 Alkyl; or R i 、R j The connected N forms an unsubstituted or substituted group with one or more identical or different R cc Substituted 4-7 membered heterocycloalkyl; wherein the 4-7 membered heterocycloalkyl contains 1 to 3 heteroatoms selected from N, O and S, and the -CH2- on the 4-7 membered heterocycloalkyl ring is optionally replaced by -C(=O)-, -C(=S)- and -S(=O)2-; each R cc Each independently selected from C 1-4 alkyl.

[0106] In some embodiments, each R c Each independently selected from halogen, -CN, -OH, -SF5, -SCF3, -S(O)2R i 、C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl, C 1-6 Hydroxyalkyl, C 3-6 Cycloalkyl; Ri Selected from -H, C 1-4 alkyl.

[0107] In some embodiments, each R c Each independently selected from halogen, -CN, -OH, -SF5, -SCF3, -S(O)2R i 、C 1-4 Alkyl, C 1-4 Alkoxy, C 1-4 Halogenated alkyl, C 1-4 Hydroxyalkyl, C 3-6 Cycloalkyl; R i Selected from -H, C 1-4 alkyl.

[0108] In some embodiments, each R c Each independently selected from -F, -Cl, -Br, -CN, -OH, -SF5, -SCF3, -S(O)2R i , methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, sec-butoxy, isobutoxy, tert-butoxy, fluoromethyl, fluoroethyl, fluoro-n-propyl, fluoroisopropyl, fluoro-n-butyl, fluoro-sec-butyl, fluoroisobutyl, fluoro-tert-butyl, hydroxymethyl, hydroxyethyl, hydroxy-n-propyl, hydroxyisopropyl, hydroxy-n-butyl, hydroxy-sec-butyl, hydroxyisobutyl, hydroxy-tert-butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl; R i Selected from -H, methyl, ethyl.

[0109] In some embodiments, each R c Each independently selected from -F, -Cl, -Br, -CN, -OH, -SF5, -SCF3, methyl, ethyl, methoxy, ethoxy, fluoromethyl, fluoroethyl, hydroxymethyl, hydroxyethyl, hydroxyisopropyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl.

[0110] In some embodiments, each R c Each independently selected from -F, -Cl, -CN, -OH, -SF5, -SCF3, Methyl, methoxy, -CF3, -CHF2, -CH2F, hydroxymethyl, hydroxyisopropyl, cyclopropyl.

[0111] In some specific embodiments, the above-mentioned compound, or a pharmaceutically acceptable salt, stereoisomer, tautomer, polymorph, cocrystal, hydrate, solvate, metabolite, prodrug, or deuterated compound thereof, each R cEach independently selected from halogen, -CN, -OH, C 1-6 Alkoxy, C 1-6 Halogenated alkyl, C 1-6 Hydroxyalkyl, C 3-6 Cycloalkyl.

[0112] In some embodiments, each R c Each independently selected from halogen, -CN, -OH, C 1-4 Alkoxy, C 1-4 Halogenated alkyl, C 1-4 Hydroxyalkyl, C 3-6 Cycloalkyl.

[0113] In some embodiments, each R c Each is independently selected from -F, -Cl, -Br, -CN, -OH, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, sec-butoxy, isobutoxy, tert-butoxy, fluoromethyl, fluoroethyl, fluoro-n-propyl, fluoroisopropyl, fluoro-n-butyl, fluoro-sec-butyl, fluoroisobutyl, fluoro-tert-butyl, hydroxymethyl, hydroxyethyl, hydroxy-n-propyl, hydroxyisopropyl, hydroxy-n-butyl, hydroxy-sec-butyl, hydroxyisobutyl, hydroxy-tert-butyl, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.

[0114] In some embodiments, each R c Each is independently selected from -F, -Cl, -Br, -CN, -OH, methoxy, ethoxy, fluoromethyl, fluoroethyl, hydroxymethyl, hydroxyethyl, hydroxyisopropyl, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.

[0115] In some embodiments, each R c Each is independently selected from -F, -Cl, -CN, -OH, methoxy, -CF3, -CHF2, -CH2F, hydroxyisopropyl, and cyclopropyl.

[0116] In some specific embodiments, the above-mentioned compound, or a pharmaceutically acceptable salt, stereoisomer, tautomer, polymorph, cocrystal, hydrate, solvate, metabolite, prodrug, or deuterated compound thereof, each R c Each independently selected from halogen, -CN, -OH, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl, C 1-6 Halogenated alkoxy, C 1-6 Hydroxyalkyl, C 3-6 Cycloalkyl, unsubstituted or substituted by one or more identical or different R aa Substituted 5-6 membered heteroaryl, -NR i Rj 、-C(O)NR i R j ; wherein the 5-6 membered heteroaryl group contains 1 to 3 heteroatoms selected from N, O and S; each R aa are each independently selected from halogen, C 1-4 Alkyl; each R i 、R j Each independently selected from -H, C 1-4 Alkyl; or R i 、R j The connected N forms an unsubstituted or substituted group with one or more identical or different R cc Substituted 4-7 membered heterocycloalkyl; wherein the 4-7 membered heterocycloalkyl contains 1 to 3 heteroatoms selected from N, O and S, and the -CH2- on the 4-7 membered heterocycloalkyl ring is optionally replaced by -C(=O)-, -C(=S)- and -S(=O)2-; each R cc Each independently selected from C 1-4 alkyl.

[0117] In some embodiments, each R c Each independently selected from halogen, -OH, C 1-6 Alkoxy, C 1-6 Halogenated alkyl, C 1-6 Hydroxyalkyl.

[0118] In some embodiments, each R c Each independently selected from halogen, -OH, C 1-4 Alkoxy, C 1-4 Halogenated alkyl, C 1-4 Hydroxyalkyl.

[0119] In some embodiments, each R c Each is independently selected from -F, -Cl, -Br, -OH, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, sec-butoxy, isobutoxy, tert-butoxy, fluoromethyl, fluoroethyl, fluoro-n-propyl, fluoroisopropyl, fluoro-n-butyl, fluoro-sec-butyl, fluoroisobutyl, fluoro-tert-butyl, hydroxymethyl, hydroxyethyl, hydroxy-n-propyl, hydroxyisopropyl, hydroxy-n-butyl, hydroxy-sec-butyl, hydroxyisobutyl, and hydroxy-tert-butyl.

[0120] In some embodiments, each R c Each is independently selected from -F, -Cl, -OH, methoxy, -CF3, -CH2CF3, and hydroxyisopropyl.

[0121] In some specific embodiments, the above-mentioned compound, or a pharmaceutically acceptable salt, stereoisomer, tautomer, polymorph, cocrystal, hydrate, solvate, metabolite, prodrug, deuterated compound thereof, R 2 Selected from Fluoromethyl, fluoroethyl, pyridyl, phenyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, C5 bridged cycloalkyl, C7 spirocycloalkyl, tetrahydrofuranyl, oxetanyl, piperidinyl, 1,4-dioxetanyl; wherein the cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, C5 bridged cycloalkyl, C7 spirocycloalkyl are each independently unsubstituted or substituted by hydroxy, hydroxyisopropyl or methoxy; the pyridyl and phenyl are each independently unsubstituted or substituted by F, Cl, -CN, -CF3 or cyclopropyl.

[0122] In some specific embodiments, R 2 Selected from Fluoromethyl, fluoroethyl, pyridyl, pyrimidinyl, pyrazinyl, phenyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, C5 bridged cycloalkyl, C7 spirocycloalkyl, tetrahydrofuranyl, oxetanyl, piperidinyl, 1,4-dioxocyclohexyl; wherein the cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, C5 bridged cycloalkyl, C7 spirocycloalkyl are each independently unsubstituted or substituted by hydroxy, hydroxyisopropyl or methoxy; the pyridyl, pyrimidinyl, pyrazinyl, phenyl are each independently unsubstituted or substituted by -SF5, -SCF3, Substituted with hydroxymethyl, methoxy, methyl, F, Cl, -CN, -CHF2, -CH2F, -CF3 or cyclopropyl.

[0123] In some specific embodiments, R 2 Selected from Cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, -CF3, -CH2CF3,

[0124] In some specific embodiments, R 2 Selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, -CF3, -CH2CF3,

[0125] In some specific embodiments, the above-mentioned compound, or a pharmaceutically acceptable salt, stereoisomer, tautomer, polymorph, cocrystal, hydrate, solvate, metabolite, prodrug, deuterated compound thereof, R 2 Selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, -CF3, -CH2CF3,

[0126] In some specific embodiments, the above compound, or a pharmaceutically acceptable salt, stereoisomer, tautomer, polymorph, cocrystal, hydrate, solvate, metabolite, prodrug, or deuterated compound thereof, L is absent or C 1-2 Alkylene.

[0127] In some embodiments, L is absent or -CH2-.

[0128] In some embodiments, L is -CH2-.

[0129] In a preferred technical solution of the present invention, the above-mentioned compound, or a pharmaceutically acceptable salt, stereoisomer, tautomer, polymorph, cocrystal, hydrate, solvate, metabolite, prodrug, or deuterated compound thereof, has the structure shown in Formula III:

[0130] Wherein, m is 1 or 2; R b is hydrogen or as defined above; L is as defined above; R 2 As defined above; Ring A is as defined above.

[0131] The preferred technical solution of the present invention, the above-mentioned compound, or its pharmaceutically acceptable salt, stereoisomer, tautomer, polymorph, cocrystal, hydrate, solvate, metabolite, prodrug, deuterated compound, has the structure shown in Formula III-1:

[0132] Wherein, L is as defined above; R 2 As defined above; Ring A is as defined above.

[0133] The preferred technical solution of the present invention, the above-mentioned compound, or its pharmaceutically acceptable salt, stereoisomer, tautomer, polymorph, cocrystal, hydrate, solvate, metabolite, prodrug, deuterated compound, has the structure shown in Formula III-2:

[0134] Among them, R 2 As defined above; R a As defined above; n is 0, 1, 2 or 3.

[0135] The preferred technical solution of the present invention, the above-mentioned compound, or its pharmaceutically acceptable salt, stereoisomer, tautomer, polymorph, cocrystal, hydrate, solvate, metabolite, prodrug, deuterated compound, has the structure shown in Formula III-3:

[0136] Among them, R 2 As defined above; R a As defined above.

[0137] The preferred technical solution of the present invention, the above-mentioned compound, or its pharmaceutically acceptable salt, stereoisomer, tautomer, polymorph, cocrystal, hydrate, solvate, metabolite, prodrug, deuterated compound, has the structure shown in Formula III-4:

[0138] wherein Z1 is selected from N or CH; Z2 is selected from N or CH; R a Selected from halogen, -CN, C 1-8 Alkyl, C 1-8 Haloalkyl; R c Selected from halogen, -CN, C 1-8 Alkyl, C 1-8 Halogenated alkyl.

[0139] The preferred technical solution of the present invention, the above-mentioned compound, or its pharmaceutically acceptable salt, stereoisomer, tautomer, polymorph, cocrystal, hydrate, solvate, metabolite, prodrug, deuterated compound, has the structure shown in Formula III-5:

[0140] Among them, R a Selected from halogen, -CN, C 1-8 Alkyl, C 1-8 Haloalkyl; R c Selected from halogen, -CN, C 1-8 Alkyl, C 1-8 Halogenated alkyl.

[0141] In some specific embodiments, the compound of formula III-4 or III-5, or a pharmaceutically acceptable salt, stereoisomer, tautomer, polymorph, cocrystal, hydrate, solvate, metabolite, prodrug, deuterated compound thereof, R a Selected from halogen, -CN, C 1-6 Alkyl, C 1-6 Halogenated alkyl.

[0142] In some specific embodiments, R a Selected from halogen, -CN, C 1-4 Alkyl, C 1-4 Halogenated alkyl.

[0143] In some specific embodiments, R a Selected from halogen, -CN, C 1-2 Alkyl, C 3-4 Alkyl, C 1-2 Fluorinated alkyl, C3-4 Fluoroalkyl.

[0144] In some specific embodiments, R a Selected from halogen, C 1-2 Alkyl, C 3-4 Alkyl, C 1-2 Fluorinated alkyl, C 3-4 Fluoroalkyl.

[0145] In some specific embodiments, R a Selected from F, Cl, Br, -CN, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, fluoromethyl, fluoroethyl.

[0146] In some specific embodiments, R a Selected from F, Cl, Br, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, fluoromethyl, fluoroethyl.

[0147] In some specific embodiments, R a Selected from F, Cl, -CN, methyl, -CF3, -CHF2.

[0148] In some specific embodiments, R a Selected from Cl, methyl, -CF3, -CHF2.

[0149] In some specific embodiments, the compound of formula III-4 or III-5, or a pharmaceutically acceptable salt, stereoisomer, tautomer, polymorph, cocrystal, hydrate, solvate, metabolite, prodrug, deuterated compound thereof, R c Selected from halogen, -CN, C 1-6 Alkyl, C 1-6 Halogenated alkyl.

[0150] In some specific embodiments, R c Selected from halogen, -CN, C 1-4 Alkyl, C 1-4 Halogenated alkyl.

[0151] In some specific embodiments, R c Selected from halogen, -CN, C 1-2 Fluorinated alkyl, C 3-4 Fluoroalkyl.

[0152] In some specific embodiments, R c Selected from -CN, C 1-2 Fluorinated alkyl, C 3-4 Fluoroalkyl.

[0153] In some specific embodiments, Rc Selected from F, Cl, Br, -CN, fluoromethyl, fluoroethyl.

[0154] In some specific embodiments, R c Selected from -CN, fluoromethyl, fluoroethyl.

[0155] In some specific embodiments, R c Selected from Cl, -CN, -CHF2, -CF3.

[0156] In some specific embodiments, R c Selected from -CN, -CHF2, -CF3.

[0157] The preferred technical solution of the present invention is the above-mentioned compound, or its pharmaceutically acceptable salt, stereoisomer, tautomer, polymorph, cocrystal, hydrate, solvate, metabolite, prodrug, deuterated compound, wherein the compound is selected from the following structures:

[0158] As used herein, the term "pharmaceutically acceptable salt of a compound of formula (I)" is exemplified by organic acid addition salts formed from organic acids that form pharmaceutically acceptable anions / cations, and suitable inorganic salts may also be formed. Pharmaceutically acceptable salts can be obtained using standard procedures well known in the art, for example, by reacting a sufficient amount of a basic compound with a suitable acid that provides a pharmaceutically acceptable anion.

[0159] As used herein, the term "prodrug of a compound represented by formula (I)" is a derivative of a compound represented by general formula (I), which may have weak activity or even no activity itself, but after administration, is converted into the corresponding biologically active form under physiological conditions (for example, by metabolism, solvent decomposition or other means).

[0160] As used herein, the term "metabolite of a compound of formula (I)" refers to a product obtained by the metabolism of a compound of formula (I) or a salt thereof in vivo. Metabolites of a compound can be identified by techniques known in the art, and their activity can be characterized by assays as described herein. Such products can be obtained by administering the compound through oxidation, reduction, hydrolysis, amidation, deamidation, esterification, defatting, enzymatic cleavage, and the like. Accordingly, the present invention includes metabolites of the compound, including metabolites produced by contacting a compound of the present invention with a mammal for a sufficient period of time.

[0161] Preparation method:

[0162] The present invention also provides a method for preparing the compound. The preparation of the compound described in the general formula (I) of the present invention can be completed by the following illustrative methods and examples, but these methods and examples should not be considered in any way to limit the scope of the present invention. The compound described in the present invention can also be synthesized by synthetic techniques known to those skilled in the art, or a combination of synthetic methods known in the art and the method described in the present invention. The product obtained by each step of the reaction is obtained using separation techniques known in the art, including but not limited to extraction, filtration, distillation, crystallization, chromatographic separation, etc. The starting materials and chemical reagents required for the synthesis can be conventionally synthesized according to the literature (such as provided by Scifinder) or purchased.

[0163] Method 1:

[0164] The preparation method of the compound represented by formula (I) comprises the following steps:

[0165] 1) The compound represented by Ia undergoes a coupling reaction with the compound represented by Ib to generate the compound represented by Ic;

[0166] 2) The compound shown in Ic is subjected to a dehydrolysis reaction to generate the compound shown in Id;

[0167] 3) The compound represented by Id and the compound represented by Ie are condensed to form the compound represented by I;

[0168] Wherein: B is selected from halogen (Cl, Br, I), trifluoromethanesulfonyloxy (OTf) or p-toluenesulfonyloxy (OTs); Ring A, X, Y, L, R 2 As defined in formula I; R a’ Selected from B(OH)2 or BPin; R b’ Selected from C 1-4 Alkyl, C 3-6 Cycloalkyl;

[0169] Preferably, B is selected from Cl, Br, and trifluoromethanesulfonyloxy (OTf).

[0170] Method 2:

[0171] The preparation method of the compound represented by formula (I) comprises the following steps:

[0172] 1) The compound represented by If undergoes a coupling reaction with the compound represented by Ig to generate the compound represented by Ic;

[0173] 2) The compound shown in Ic is subjected to a dehydrolysis reaction to generate the compound shown in Id;

[0174] 3) The compound represented by Id and the compound represented by Ie are condensed to form the compound represented by I;

[0175] Wherein: B is selected from halogen (Cl, Br, I), trifluoromethanesulfonyloxy (OTf) or p-toluenesulfonyloxy (OTs); Ring A, X, Y, L, R 2 As defined in formula I; R a’ Selected from B(OH)2 or BPin; R b’ Selected from C 1-4 Alkyl, C 3-6 Cycloalkyl;

[0176] Preferably, B is selected from Cl, Br, and trifluoromethanesulfonyloxy (OTf).

[0177] Pharmaceutical composition

[0178] The present invention also provides a pharmaceutical composition comprising a compound of the aforementioned formula (I), (III), (III-1), (III-2), (III-3), (III-4) or (III-5) or a pharmaceutically acceptable salt, stereoisomer, tautomer, polymorph, cocrystal, hydrate, solvate, metabolite, prodrug, deuterated compound thereof, and optionally a pharmaceutically acceptable carrier and / or adjuvant and / or diluent.

[0179] In some embodiments, the pharmaceutical composition may further comprise other drugs for treating and / or preventing diseases mediated by Polθ.

[0180] Methods for preparing various pharmaceutical compositions containing a certain amount of active ingredient are known or will be apparent to those skilled in the art based on the disclosure of the present invention. As described in REMINGTON'S PHARMACEUTICAL SCIENCES, Martin, EW, ed., Mack Publishing Company, 19th ed. (1995), the method for preparing the pharmaceutical composition includes incorporating appropriate pharmaceutical excipients, carriers, diluents, etc.

[0181] Medical uses

[0182] On the other hand, the present invention also provides the use of the compounds of the aforementioned formula (I), (III), (III-1), (III-2), (III-3), (III-4) or (III-5) or their pharmaceutically acceptable salts, stereoisomers, tautomers, polymorphs, cocrystals, hydrates, solvates, metabolites, prodrugs, deuterated compounds, or the pharmaceutical compositions thereof in the preparation of Polθ inhibitors or in the preparation of drugs for the treatment and / or prevention of related diseases mediated by Polθ.

[0183] In another aspect, the present invention further provides the use of a compound of the aforementioned formula (I), (III), (III-1), (III-2), (III-3), (III-4), or (III-5), or a pharmaceutically acceptable salt, stereoisomer, tautomer, polymorph, cocrystal, hydrate, solvate, metabolite, prodrug, deuterated compound thereof, or a pharmaceutical composition thereof, in the preparation of a medicament for treating and / or preventing cancer or tumors. The cancer or tumor is a HR-deficient cancer or tumor.

[0184] On the other hand, the present invention also provides a compound of the aforementioned formula (I), (III), (III-1), (III-2), (III-3), (III-4) or (III-5) or a pharmaceutically acceptable salt, stereoisomer, tautomer, polymorph, cocrystal, hydrate, solvate, metabolite, prodrug, deuterated compound, or the pharmaceutical composition, which is used to treat and / or prevent related diseases mediated by Polθ.

[0185] In another aspect, the present invention further provides a compound of the aforementioned formula (I), (III), (III-1), (III-2), (III-3), (III-4), or (III-5), or a pharmaceutically acceptable salt, stereoisomer, tautomer, polymorph, cocrystal, hydrate, solvate, metabolite, prodrug, deuterated compound, or pharmaceutical composition thereof, for use in treating and / or preventing cancer or tumors. The cancer or tumor is a HR-deficient cancer or tumor.

[0186] On the other hand, the present invention also provides a method for treating and / or preventing related diseases mediated by Polθ, which comprises: administering to a subject / individual in need thereof an effective amount of the compound of the aforementioned formula (I), (III), (III-1), (III-2), (III-3), (III-4) or (III-5) or its pharmaceutically acceptable salt, stereoisomer, tautomer, polymorph, cocrystal, hydrate, solvate, metabolite, prodrug, deuterated compound, or the pharmaceutical composition.

[0187] In another aspect, the present invention also provides a method for treating and / or preventing cancer or tumors, comprising administering to a subject / individual in need thereof a therapeutically and / or preventatively effective amount of a compound of Formula (I), (III), (III-1), (III-2), (III-3), (III-4), or (III-5), or a pharmaceutically acceptable salt, stereoisomer, tautomer, polymorph, cocrystal, hydrate, solvate, metabolite, prodrug, deuterated compound, or pharmaceutical composition thereof. The cancer or tumor is a HR-deficient cancer or tumor.

[0188] In some embodiments, the aforementioned Polθ-mediated disease refers to cancer or tumor.

[0189] In some embodiments, the aforementioned Polθ-mediated related diseases refer to Polθ-mediated related diseases with HR deficiency.

[0190] In some embodiments, the aforementioned Polθ-mediated related diseases refer to cancers or tumors with HR deficiency.

[0191] As used herein, "treat" generally refers to obtaining a desired pharmacological and / or physiological effect. This effect can be prophylactic, in terms of completely or partially preventing a disease or its symptoms; and / or therapeutic, in terms of partially or completely stabilizing or curing a disease and / or causing side effects due to the disease. As used herein, "treat" encompasses any treatment of a disease in a patient, including: (a) preventing the onset of a disease or symptom in a patient who is susceptible to the disease or symptom but has not yet been diagnosed with the disease; (b) suppressing the symptoms of a disease, i.e., arresting its development; or (c) alleviating the symptoms of a disease, i.e., causing the disease or symptom to regress.

[0192] In the present invention, "subject / individual" refers to a vertebrate. In certain embodiments, a vertebrate refers to a mammal. Mammals include, but are not limited to, livestock (such as cattle), pets (such as cats, dogs, and horses), primates, mice, and rats. In certain embodiments, a mammal refers to a human.

[0193] In the present invention, an "effective amount" refers to an amount that is effective at the necessary dosage and time to achieve the desired therapeutic or preventive effect. The "therapeutically effective amount" of the substance / molecule of the present invention may vary according to factors such as the disease state, age, sex and weight of the individual and the ability of the substance / molecule to elicit the desired response in the individual. A therapeutically effective amount also encompasses an amount in which the therapeutically beneficial effects of the substance / molecule outweigh any toxic or deleterious consequences. A "prophylactically effective amount" refers to an amount that is effective at the necessary dosage and time to achieve the desired preventive effect. Typically, but not necessarily, a prophylactic dose is used in subjects before the onset of disease or in the early stages of the disease, so the prophylactic effective amount will be lower than the therapeutically effective amount. In the case of cancer, a therapeutically effective amount of a drug can reduce the number of cancer cells; reduce tumor size; inhibit (i.e., slow down to a certain extent, preferably stop) cancer cell infiltration into surrounding organs; inhibit (i.e., slow down to a certain extent, preferably stop) tumor metastasis; inhibit tumor growth to a certain extent; and / or alleviate one or more symptoms associated with cancer to a certain extent.

[0194] Definition of terms:

[0195] According to the common practice in this field, The bonds used in the formulae herein to describe the points of attachment of the moiety or substituent to the parent core or structure.

[0196] A dash "-" that does not appear between two letters or symbols is used to indicate the point of attachment of a substituent. For example, -CONH2 is attached through a carbon atom.

[0197] In the present invention, the term "optional" means that it can be selected or not. For example, "the C 3-10 The "-CH2- on the cycloalkyl ring is optionally replaced by -C(=O)-, -C(=S)- and -S(=O)2-" can be understood as "C 3- 10 The -CH2- on the cycloalkyl ring may be replaced by -C(=O)-, -C(=S)- and / or -S(=O)2-", which can also be understood as "C 3-10 The -CH2- on the cycloalkyl ring may not be replaced by -C(=O)-, -C(=S)- and / or -S(=O)2-.

[0198] In the present invention, the term "substituted" means that an atom or a group of atoms formally replaces hydrogen and is connected to another group as a "substituent". Unless otherwise noted, the term "substituted" refers to any degree of substitution in the case where such substitution is allowed, such as mono-, di-, tri-, tetra- or penta-substitution. Substituents are selected independently, and substitution can be at any chemically accessible position. It should be understood that the substitution on the specified atom is subject to atomic valence restrictions. It should be understood that the substitution on the specified atom produces a chemically stable molecule.

[0199] In the present invention, the term "alkyl" used alone or in combination with other terms refers to a saturated hydrocarbon group that can be a straight chain or a branched chain. 1-10 "Alkyl" refers to an alkyl group having 1 to 10 carbon atoms. Alkyl formally corresponds to an alkane with one C-H bond replaced as the point of attachment of the alkyl group to the rest of the compound. In some embodiments, the alkyl group contains 1-10 carbon atoms, 1-8 carbon atoms, 1 to 6 carbon atoms, 1 to 4 carbon atoms, 1 to 3 carbon atoms, or 1 to 2 carbon atoms. Examples of alkyl moieties include, but are not limited to, chemical groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, isobutyl, sec-butyl; higher homologs such as 2-methyl-1-butyl, n-pentyl, 3-pentyl, n-hexyl, 1,2,2-trimethylpropyl, and the like.

[0200] In the present invention, the term "alkoxy" used alone or in combination with other terms refers to a group having the formula -O-alkyl, wherein the term "alkyl" is as defined above. 1-8"Alkoxy" refers to an alkoxy group whose alkyl group has 1 to 8 carbon atoms. Example alkoxy groups include methoxy, ethoxy, propoxy (e.g., n-propoxy and isopropoxy), tert-butoxy, and the like. In some embodiments, the alkyl group has 1 to 8 carbon atoms, 1 to 6 carbon atoms, 1 to 4 carbon atoms, or 1 to 3 carbon atoms.

[0201] In the present invention, the term "halo" or "halogen" used alone or in combination with other terms refers to F, Cl, Br and I. In some embodiments, the term "halo" refers to a halogen atom selected from F, Cl or Br.

[0202] In the present invention, the term "haloalkyl" or "haloalkoxy" used alone or in combination with other terms refers to an alkyl or alkoxy group substituted with one or more halogens, wherein the terms "halogen", "alkyl" and "alkoxy" are as defined above. In some embodiments, the term "C 1-6 "Haloalkyl" is preferably fluorinated, for example, -CF3, -CHF2, -CH2F, -CH2CH2F, -CH2CHF2, -CH2CF3, etc. In some embodiments, the term "C 1-6 The "haloalkoxy" is preferably fluorinated, for example, -OCF3, -OCHF2, -OCH2F, -OCH2CH2F, -OCH2CHF2, -OCH2CF3, etc.

[0203] In the present invention, the term "deuterated alkyl" used alone or in combination with other terms refers to an alkyl group substituted with one or more deuterium atoms, wherein the term "alkyl" is as defined above.

[0204] In the present invention, the term "hydroxyalkyl" used alone or in combination with other terms refers to an alkyl group substituted with one or more hydroxy groups, wherein the term "alkyl" is as defined above.

[0205] In the present invention, the term "heteroatom" used alone or in combination with other terms includes B, P, S, O and N.

[0206] In the present invention, the term "aryl" used alone or in combination with other terms refers to an aromatic hydrocarbon group, which may be monocyclic or polycyclic (for example, having two fused rings). 6-10 "Aryl" refers to an aromatic radical having 6 to 10 ring carbon atoms. Aryl radicals include, for example, phenyl, naphthyl, indanyl, indenyl, and the like. In some embodiments, an aryl radical has 6 carbon atoms. In some embodiments, an aryl radical has 10 carbon atoms. In some embodiments, an aryl radical is phenyl. In some embodiments, an aryl radical is naphthyl.

[0207] In the present invention, the term "heteroaryl" used alone or in combination with other terms refers to a monocyclic or polycyclic aromatic heterocycle having at least one heteroatom ring member selected from B, P, S, O, and N. In some embodiments, the heteroaryl ring has 1, 2, 3, or 4 heteroatom ring members independently selected from S, O, and N. In some embodiments, any ring-forming N in the heteroaryl moiety can be an N-oxide. In some embodiments, the heteroaryl group has 5 to 14 ring atoms, including carbon atoms and 1, 2, 3, or 4 heteroatom ring members independently selected from S, O, and N. In some embodiments, the heteroaryl group has 5 to 10 ring atoms, including carbon atoms and 1, 2, 3, or 4 heteroatom ring members independently selected from S, O, and N. In some embodiments, the heteroaryl group has 5 to 6 ring atoms and 1 or 2 heteroatom ring members independently selected from S, O, and N. In some embodiments, the heteroaryl group is a five-membered or six-membered heteroaryl ring. In other embodiments, the heteroaryl group is an eight-membered, nine-membered, or ten-membered fused bicyclic heteroaryl ring. Example heteroaryl groups include, but are not limited to, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, pyrrolyl, pyrazolyl, oxazolyl, oxazolyl, thiazolyl, imidazolyl, furyl, thienyl, quinolyl, isoquinolyl, naphthyridinyl (including 1,2-naphthyridine, 1,3-naphthyridine, 1,4-naphthyridine, 1,5-naphthyridine, 1,6-naphthyridine, 1,7-naphthyridine, 1,8-naphthyridine, 2,3-naphthyridine, and 2,6-naphthyridine), indolyl, benzothienyl, benzofuranyl, benzisoxazolyl, imidazo[1,2-b]thiazolyl, purinyl, and the like.

[0208] In the present invention, the term "cycloalkyl" used alone or in combination with other terms refers to a saturated ring system (monocyclic, bicyclic or polycyclic), including cyclized alkyl. 3-8 Cycloalkyl" or "C 3-14 "Cycloalkyl" refers to a cycloalkyl group having 3 to 8 or 3 to 14 ring member carbon atoms, respectively. Cycloalkyl groups can include monocyclic or polycyclic (e.g., having 2, 3, or 4 fused rings) groups and spirocyclic and bridged rings. Cycloalkyl groups can have 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14 ring member carbon atoms (C 3-14 In some embodiments, the cycloalkyl group has 3 to 12 ring members, 3 to 10 ring members, 3 to 8 ring members, 3 to 6 ring members, 3 to 5 ring members, or 3 to 4 ring members. In some embodiments, the cycloalkyl group is monocyclic. In some embodiments, the cycloalkyl group is monocyclic or bicyclic. In some embodiments, the cycloalkyl group is C 3-8Monocyclic cycloalkyl. Cycloalkyl also includes cycloalkylene. In some embodiments, cycloalkyl is cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl. Examples of cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, norbornyl, norpinyl, norcaryl, bicyclo[1.1.1]pentanyl, bicyclo[2.1.1]hexanyl, and the like. In some embodiments, cycloalkyl is cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.

[0209] In the present invention, the term "heterocycloalkyl" used alone or in combination with other terms refers to a saturated ring system having at least one heteroatom ring member independently selected from B, P, N, S and O, and having 4 to 10 ring members, 4 to 7 ring members or 4 to 6 ring members. The term "heterocycloalkyl" includes monocyclic 4-, 5-, 6- and 7-membered heterocycloalkyls. Heterocycloalkyl can include monocyclic or bicyclic (e.g., having two fused or bridged rings, spiro rings) ring systems. In some embodiments, heterocycloalkyl is a monocyclic group having 1, 2 or 3 heteroatoms independently selected from N, S and O. Heterocycloalkyl can be connected via annular carbon atoms or annular heteroatoms. Examples of heterocycloalkyl groups include azetidinyl, azepanyl, N-morpholinyl, 3-oxa-9-azaspiro[5.5]undecyl, 1-oxa-8-azaspiro[4.5]decyl, piperidinyl, piperazinyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydropyranyl, tropanediyl.

[0210] In the present invention, the "unsaturated 4- to 10-membered heterocyclic group" does not include a heteroaryl group, and refers to an unsaturated heterocyclic group other than a heteroaryl group that is not capable of forming aromaticity.

[0211] It will be understood by those skilled in the art that when "-C(O)-" is used herein, this refers to the group When "-S(O)2-" is used, this refers to the group

[0212] Herein, unless otherwise expressly stated, the description “…are independently selected from” used throughout this document may mean that in different groups, the specific options expressed by the same or different symbols do not affect each other, or that in the same group, the specific options expressed by the same or different symbols do not affect each other.

[0213] The term "XXX is substituted with one or more substituents selected from YYY" means that XXX can be substituted with one or more substituents at any substitutable position, and the substituents are selected from YYY. When XXX is substituted with multiple substituents selected from YYY at any substitutable position, the multiple substituents can be the same or different. The multiple substituents are 2 or more, preferably 2, 3 or 4, and more preferably 2 or 3. For example, C 1-6The alkyl group is substituted by one or more substituents selected from cyano and hydroxy groups, which means that C 1-6 The alkyl group may be substituted by one or more cyano groups at any substitutable position, may be substituted by one or more hydroxyl groups at any substitutable position, or may be substituted by one or more cyano groups and hydroxyl groups (e.g., one cyano group and one hydroxyl group, or two cyano groups and one hydroxyl group, or two cyano groups and two hydroxyl groups, etc.) at any substitutable position.

[0214] Beneficial effects of the present invention:

[0215] The compounds of the present invention have excellent Pol θ inhibitory activity and can be used as drugs for preventing and / or improving and / or treating diseases associated with this activity. BRIEF DESCRIPTION OF THE DRAWINGS

[0216] Figure 1 DLD1 BRCA2 - / - Tumor growth curve of mouse CDX model

[0217] Note: ##, compared with the olaparib alone group, P < 0.01

[0218] ****, P < 0.001 compared with vehicle

[0219] Figure 2 DLD1 BRCA2 - / - Body weight change curve of CDX model mice

[0220] Note: ####, compared with the olaparib alone group, P < 0.001

[0221] *, P < 0.05 compared with vehicle DETAILED DESCRIPTION

[0222] The present invention is further described below with reference to specific examples, but the scope of protection of the present invention is not limited to these examples. Unless otherwise specified, the percentages described in the present invention are all weight percentages. The numerical ranges described in the specification, such as units of measurement, reaction conditions, physical states of compounds, or percentages, are all intended to provide clear written references. When practicing the present invention, those skilled in the art may still obtain the desired results using temperatures, concentrations, amounts, carbon number, etc. outside of these ranges or different from the individual numerical values.

[0223] The structures of the compounds were determined by nuclear magnetic resonance (NMR) or mass spectrometry (MS). NMR measurements were performed using a Bruker Avance II-400 MHz NMR spectrometer (BBFO probe) or a Bruker Avance II-600 MHz NMR spectrometer (BBO probe). The measurement solvents were deuterated solvents such as deuterated dimethyl sulfoxide (DMSO-d6), deuterated chloroform (CDCl3), deuterated methanol (CD3OD), and heavy water (D2O). The internal standard was tetramethylsilane (TMS). Chemical shifts were expressed in 10 -6 The units are given in ppm.

[0224] Reaction monitoring and MS determination were performed using a Thermo Scientific ISQ EC single quadrupole mass spectrometer (Phenomenon Titank C18 3 μm 4.6*50 mm).

[0225] HPLC determination was performed using a Thermo Ultimate 3000 high performance liquid chromatograph (GL Sciences ODS-HL HP 3um 3.0*100mm).

[0226] Qingdao Ocean GF254 silica gel plates were used for thin-layer chromatography (TLC). The silica gel plates used for thin-layer chromatography (TLC) were 0.15-0.2 mm in size, and 0.9-1.0 mm in size for high-performance thin-layer chromatography (HPLC) preparative plates were used for TLC separation and purification. Qingdao Ocean 200-300 mesh silica gel was used as the carrier for column chromatography. The developing solvents used included dichloromethane and methanol, petroleum ether and ethyl acetate, and the solvent volume ratio was adjusted according to the polarity of the compound. A Biotage Isera One preparative liquid phase was used for MPLC medium-pressure preparative liquid phase purification.

[0227] In the following examples, unless otherwise specified, all reaction raw materials can be purchased from suppliers in the scifinder database. For example, some reagents in the examples of the present invention were purchased from manufacturers such as San Chemical Technology (Shanghai) Co., Ltd., Shanghai Shaoyuan Reagent Co., Ltd., Nanjing Yaoshi Technology Co., Ltd., Jiangsu Aikang Biopharmaceutical Research and Development Co., Ltd., and Shanghai Bid Pharmaceutical Technology Co., Ltd. Further, unless otherwise specified, the raw materials used in the examples of the present invention were all analytically pure.

[0228] Intermediate 1:

[0229] Step 1: Intermediate 1a (1.4 g, 10 mmol) and THF (25 mL) were placed in a 100 mL eggplant flask. Sodium hydride (60%, dispersed in mineral oil) (0.5 g, 12.5 mmol) was added under ice-cooling and stirred for 1 hour. Intermediate 1b (1.5 g, 8.33 mmol) was then added and stirred for 3 hours. TLC confirmed the completion of the reaction. Water (40 mL) was added to quench the mixture and the mixture was extracted with EA (30 mL). The organic phase was washed twice with saturated brine (30 mL x 2), dried over anhydrous sodium sulfate, and the residue was purified by column chromatography to obtain the target compound, Intermediate 1 (800 mg, 3.3 mmol, 39.6% yield). MS Calcd: 242.00; MS Found: 243.02 ([M+H] + ).

[0230] Intermediate 5:

[0231] Step 1: Intermediate 3a (220 mg, 0.80 mmol), (2-chloro-5-methoxypyridin-4-yl)boronic acid (150 mg, 0.80 mmol), Pd(dppf)Cl2 (58 mg, 0.08 mmol), and potassium carbonate (333 mg, 0.24 mmol) were weighed into a 50 mL single-necked flask. 1,4-dioxane (5 mL) and water (2 mL) were added. The atmosphere was replaced with nitrogen three times and the reaction was allowed to proceed at 90°C overnight. The reaction was complete as monitored by LCMS. The reaction solution was concentrated and the residue was purified by column chromatography to obtain the target compound, Intermediate 5a (190 mg, 0.58 mmol, 73% yield). MS Calcd: 308.06; MS Found: 309.06 ([M+H] + ).

[0232] Step 2: Intermediate 5a (190 mg, 0.58 mmol) was weighed into a 50 mL single-necked flask and THF (4 mL) was added. Lithium hydroxide monohydrate (122 mg, 2.92 mmol) was then weighed, dissolved in water (2 mL), and added to the system. After addition, the mixture was allowed to react at room temperature for 2 hours. LCMS monitored the reaction for completion. 1N dilute hydrochloric acid was then added to the system to adjust the pH to approximately 5. The reaction solution was concentrated, the residue was slurried with methanol, and the filtrate was concentrated to obtain the target compound, Intermediate 5 (144 mg, 0.44 mmol, 75.2% yield). MS Calcd: 294.04; MS Found: 295.03 ([M+H] + ).

[0233] Intermediate 6:

[0234] Step 1: Intermediate 3a (500 mg, 2.03 mmol), 5-fluoro-2-methoxyphenylboronic acid (518 mg, 3.05 mmol), Pd(dppf)Cl2 (148 mg, 0.20 mmol), and potassium carbonate (842 mg, 6.10 mmol) were weighed into a 50 mL single-necked flask. 1,4-dioxane (10 mL) and water (2 mL) were added. The atmosphere was replaced with nitrogen three times and the reaction was allowed to proceed at 90°C overnight. The reaction was monitored for completion by LCMS. The reaction solution was concentrated and the residue was purified by column chromatography to obtain the target compound, Intermediate 6a (280 mg, 0.96 mmol, 47.3% yield). MS Calcd: 291.09; MS Found: 292.10 ([M+H] + ).

[0235] Step 2: Intermediate 6a (280 mg, 0.96 mmol) was weighed into a 25 mL single-necked flask and THF (5 mL) was added. Lithium hydroxide monohydrate (62 mg, 1.06 mmol) was then dissolved in water (2 mL) and added to the system. The reaction was allowed to react at room temperature for 2 hours. LCMS monitored the reaction to completion. The reaction solution was directly dried under reduced pressure to obtain the target compound, Intermediate 6 (200 mg, 0.72 mmol, 75.0% yield). MS Calcd: 277.08; MS Found: 278.10 ([M+H] + ).

[0236] Intermediate 8:

[0237] Step 1: Intermediate 3a (671 mg, 2.73 mmol), 5-trifluoromethyl-2-methoxyphenylboronic acid (500 mg, 2.27 mmol), Pd(dppf)Cl2 (166 mg, 0.23 mmol), and potassium carbonate (942 mg, 6.82 mmol) were weighed into a 50 mL single-necked flask. 1,4-dioxane (10 mL) and water (2 mL) were added. The atmosphere was replaced with nitrogen three times and the reaction was allowed to proceed at 90°C overnight. The reaction was monitored for completion by LCMS. The reaction solution was concentrated and the residue was purified by column chromatography to obtain the target compound, Intermediate 8a (280 mg, 0.82 mmol, 36.1% yield). MS Calcd: 341.09; MS Found: 342.15 ([M+H] + ).

[0238] Step 2: Intermediate 8a (180 mg, 0.53 mmol) was weighed into a 25 mL single-necked flask. THF (5 mL) was added. Lithium hydroxide monohydrate (33.4 mg, 0.58 mmol) was then weighed, dissolved in water (2 mL), and added to the system. The reaction was allowed to react at room temperature for 2 hours. LCMS monitored the reaction to be complete. The reaction solution was directly evaporated to dryness under reduced pressure to obtain the target compound, Intermediate 8 (140 mg, 0.43 mmol, 80.7% yield). MS Calcd: 327.07; MS Found: 328.06 ([M+H] + ).

[0239] Intermediate 9:

[0240] Step 1: Intermediate 3a (300 mg, 1.22 mmol), 5-chloro-2-methoxyphenylboronic acid (227.2 mg, 1.22 mmol), Pd(dppf)Cl2 (89.1 mg, 0.12 mmol), and potassium carbonate (336.4 mg, 2.44 mmol) were placed in a 25 mL single-necked flask. 1,4-dioxane (10 mL) and water (2 mL) were added. The atmosphere was replaced with nitrogen three times and the mixture was allowed to react at 90°C overnight. The reaction was monitored for completion by LCMS. The reaction solution was concentrated and the residue was purified by column chromatography to obtain the target compound, Intermediate 9a (120 mg, 0.39 mmol, 32% yield). MS Calcd: 307.06; MS Found: 307.79 ([M+H] + ).

[0241] Step 2: Intermediate 9a (120 mg, 0.39 mmol) was weighed into a 25 mL single-necked flask and THF (5 mL) was added. Lithium hydroxide monohydrate (81.9 mg, 1.95 mmol) was then weighed, dissolved in water (1 mL), and added to the mixture. Stirring was continued at room temperature overnight. LCMS confirmed the reaction was complete. 1N dilute hydrochloric acid was then added to the mixture to adjust the pH to approximately 4. A solid precipitated and was filtered to obtain the filter cake, yielding the target compound, Intermediate 9 (90 mg, 0.31 mmol, 78.6% yield). MS Calcd: 293.05; MS Found: 294.04 ([M+H] + ).

[0242] Intermediate 11:

[0243] Step 1: Place Intermediate 3a (300 mg, 1.22 mmol), 2-methoxy-5-methylphenylboronic acid (203 mg, 1.22 mmol), Pd(dppf)Cl2 (79 mg, 0.12 mmol), and potassium carbonate (336 mg, 2.44 mmol) in a 50 mL single-necked flask. Add 1,4-dioxane (8 mL) and water (2 mL). The atmosphere was replaced with nitrogen three times and the reaction was allowed to proceed at 80°C overnight. The reaction was monitored for completion by LCMS. The reaction solution was concentrated and the residue was purified by column chromatography to obtain the target compound, Intermediate 11a (240 mg, 0.84 mmol, 68.5% yield). MS Calcd: 287.12; MS Found: 288.12 ([M+H] + ).

[0244] Step 2: Weigh intermediate 11a (240 mg, 0.84 mmol) into a 25 mL single-necked flask and add THF (5 mL). Weigh lithium hydroxide monohydrate (175 mg, 4.18 mmol), dissolve it in water (2 mL), and add it to the system. Stir at room temperature overnight. LCMS monitoring confirmed the reaction was complete. The reaction solution was concentrated to remove the organic solvent, and the residue was dissolved in water. 1N dilute hydrochloric acid was then slowly added to adjust the pH to approximately 4. A solid precipitated and was filtered. The filter cake was collected to obtain the target compound, intermediate 11 (220 mg, 0.80 mmol, 96.4% yield). MS Calcd: 273.10; MS Found: 274.12 ([M+H] + ).

[0245] Intermediate 16:

[0246] Step 1: To a 100 mL eggplant-shaped flask, sodium hydroxide (1100 mg, 28.05 mmol) and THF (20 mL) were added portionwise under ice-cooling. After stirring on ice for 30 minutes, carbon disulfide (1300 mg, 16.83 mmol) was slowly added dropwise. Stirring was continued on ice for 30 minutes. Finally, iodomethane (1.36 mL, 16.83 mmol) was added and stirring was continued for 30 minutes. The reaction was monitored for completion by LCMS. The reaction mixture was quenched with water and extracted with EA (50 mL x 3). The organic phases were combined, washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, and the residue was purified by column chromatography to obtain the target compound, Intermediate 16b (2500 mg, 10.74 mmol, 76.6% yield).

[0247] Step 2: Intermediate 16b (2500 mg, 10.74 mmol) and methanol (60 mL) were weighed into a 250 mL single-necked flask. Hydrazine hydrate (0.52 mL, 10.74 mmol) was slowly added under an ice bath, and the mixture was allowed to warm to room temperature for 2 hours. LCMS monitored the reaction to completion. After concentration under reduced pressure, methanol (20 mL) was added. Triethylamine (3.73 mL, 26.86 mmol) and cyanogen bromide (1400 mg, 12.89 mmol) were added under an ice bath, and the mixture was allowed to warm to room temperature and stirred for 2 hours. LCMS monitored the reaction to completion. The solid was collected by filtration and washed with a small amount of methanol to obtain Intermediate 16 (2390 mg, 9.89 mmol, 92% yield). MS Calcd: 241.01; MS Found: 242.00 ([M+H] + ).

[0248] Intermediate 23:

[0249] Step 1: Place Intermediate 3a (3 g, 12.19 mmol), pinacol diboronate (4.6 g, 18.29 mmol), Pd(dppf)Cl2 (0.9 g, 1.22 mmol), and potassium carbonate (3.4 g, 24.38 mmol) in a 100 mL single-necked flask. Add 1,4-dioxane (30 mL). The atmosphere was purged with nitrogen three times and the reaction was allowed to proceed at 80°C overnight. The reaction was monitored for completion by LCMS. The reaction solution was concentrated and the residue was purified by column chromatography to afford the target compound, Intermediate 23a (1.8 g, 6.14 mmol, 50.4% yield). MS Calcd: 293.14; MS Found: 293.93 ([M+H] + ).

[0250] Step 2: Place Intermediate 23a (200 mg, 0.68 mmol), 2-difluoromethoxy-bromobenzene (152 mg, 0.68 mmol), Pd(dtbpf)Cl2 (44 mg, 0.07 mmol), and potassium carbonate (188 mg, 1.36 mmol) in a 25 mL single-necked flask. Add 1,4-dioxane (8 mL) and water (2 mL). The atmosphere was replaced with nitrogen three times and the mixture was allowed to react at 80°C overnight. The reaction was monitored for completion by LCMS. The reaction solution was concentrated and the residue was purified by column chromatography to obtain the target compound, Intermediate 23b (70 mg, 0.23 mmol, 33.2% yield). MS Calcd: 309.08; MS Found: 310.08 ([M+H] + ).

[0251] Step 3: Weigh intermediate 23b (70 mg, 0.23 mmol) into a 25 mL single-necked flask and add THF (5 mL). Weigh lithium hydroxide monohydrate (48 mg, 1.13 mmol), dissolve it in water (1 mL), and add it to the system. Stir at room temperature overnight. LCMS monitoring confirmed the completion of the reaction. The reaction solution was concentrated, and the residue was dissolved in water. 1N dilute hydrochloric acid was then slowly added to adjust the pH to approximately 4. A solid precipitated and was collected by filtration to obtain the target compound, intermediate 23 (60 mg, 0.20 mmol, 89.8% yield). MS Calcd: 295.07; MS Found: 296.12 ([M+H] + ).

[0252] Intermediate 25:

[0253] Step 1: Intermediate 25a (500 mg, 2.02 mmol), pinacol diboronate (1023 mg, 4.03 mmol), Pd(dppf)Cl2 (295 mg, 0.4 mmol), and potassium acetate (593 mg, 6.05 mmol) were weighed into a 50 mL single-necked flask. 1,4-dioxane (8 mL) was added, and the atmosphere was purged with nitrogen three times. The reaction was allowed to proceed at 90°C overnight. TLC revealed the formation of a new spot. The reaction solution was concentrated, and the residue was purified by column chromatography to obtain the target compound, Intermediate 25b (488 mg, 1.49 mmol, 73.8% yield).

[0254] Step 2: Intermediate 25b (250 mg, 0.85 mmol), intermediate 3a (208.5 mg, 0.85 mmol), potassium carbonate (351.2 mg, 2.54 mmol), and Pd(dtbpf)Cl2 (109.7 mg, 0.17 mmol) were weighed into a 50 mL single-necked flask. 1,4-dioxane (5 mL) and water (1 mL) were added. The atmosphere was purged with nitrogen three times after addition and the reaction was allowed to proceed at 80°C overnight. LCMS confirmed the reaction was complete. The reaction solution was concentrated, and the residue was purified by column chromatography to obtain the target compound, Intermediate 25c (220 mg, 0.63 mmol, 73.8% yield). MS Calcd: 334.08; MS Found: 334.99 ([M+H] + ).

[0255] Step 3: Weigh Intermediate 25c (140 mg, 0.42 mmol) and lithium hydroxide monohydrate (52.8 mg, 1.26 mmol) into a 25 mL single-necked flask. Then add THF (6 mL) and water (2 mL). After complete addition, react at room temperature for 2 hours. LCMS monitoring confirmed the completion of the reaction. Slowly add 1N dilute hydrochloric acid to the reaction solution to adjust the pH to approximately 5. Then, extract three times with ethyl acetate (10 mL). The organic phase was concentrated to yield the target compound, Intermediate 25 (99 mg, 0.29 mmol, 69.9% yield). MS Calcd: 320.06; MS Found: 320.99 ([M+H] + ).

[0256] Intermediate 26a:

[0257] Step 1: Weigh methyl 5-bromo-2-hydroxyisonicotinate (1500 mg, 6.47 mmol) and cesium carbonate (4212.9 mg, 12.93 mmol) into a 250 mL single-necked flask. Add DMF (20 mL). Then, add 2-chloro-N,N-dimethylacetamide (786.2 mg, 6.47 mmol) while stirring at room temperature. After addition, react at room temperature for 2 hours. LCMS analysis confirmed the reaction was complete. The reaction solution was slowly quenched by adding ice water and extracted with EA (50 mL x 3). The combined organic phases were washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, and the organic phase was evaporated to dryness under reduced pressure. The residue was purified by column chromatography to obtain the target compound, Intermediate 26a (1.6 g, 4.54 mmol, 70.2% yield). MS Calcd: 316.01; MS Found: 318.96, 316.96 ([M+H] + ).

[0258] Intermediate 29:

[0259] Step 1: Sodium hydride (60% dispersion in mineral oil) (2219.2 mg, 55.48 mmol) and THF (20 mL) were added portionwise to a 100 mL eggplant-shaped flask. Under ice-cooling, Intermediate 29a (2000 mg, 27.74 mmol) was added portionwise. After stirring on ice for 1 hour, carbon disulfide (2.49 mL, 41.61 mmol) was slowly added dropwise. Stirring on ice for another hour was continued. Finally, iodomethane (3.37 mL, 41.61 mmol) was added and the mixture was allowed to warm to room temperature overnight. The reaction was monitored for completion by LCMS. The reaction mixture was quenched with water and extracted with EA (50 mL x 3). The organic phases were combined, washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, and then spun down to dryness to obtain the crude target compound, Intermediate 29b (4100 mg, 25.26 mmol, 91.1% yield). MS Calcd:162.02; MS Found:163.05([M+H] + ).

[0260] Step 2: Intermediate 29b (4000 mg, 24.65 mmol) and methanol (20 mL) were weighed into a 100 mL single-necked flask. Hydrazine hydrate (1.44 mL, 29.57 mmol) was slowly added under an ice bath and the mixture was allowed to warm to room temperature for 2 hours. LCMS monitored the reaction for completion. The reaction mixture was quenched with water and extracted with EA (50 mL × 3). The combined organic phases were washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, and the organic phase was spun down to obtain the target compound, Intermediate 29c (3200 mg, 21.89 mmol, 88.8% yield). MS Calcd: 146.05; MS Found: 147.05 ([M+H] + ).

[0261] Step 3: In a 100 mL single-necked flask, intermediate 29c (5000 mg, 34.20 mmol), triethylamine (14.22 mL, 102.60 mmol), and methanol (20 mL) were added. Cyanogen bromide (3983.9 mg, 37.62 mmol) was slowly added portionwise under an ice bath. The mixture was warmed to room temperature and stirred for 2 hours. LCMS monitored the reaction for completion. The reaction mixture was quenched with water and extracted with EA (50 mL × 3). The organic phases were combined, washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, and the organic phase was spin-dried to obtain the target compound, intermediate 29 (5500 mg, 16.06 mmol, 47.0% yield, 50% purity). MS Calcd: 171.05; MS Found: 172.07 ([M+H] + ).

[0262] Intermediate 30:

[0263] Step 1: Weigh methyl 5-bromo-2-hydroxyisonicotinate (2000 mg, 8.62 mmol) and cesium carbonate (5617 mg, 17.24 mmol) into a 100 mL single-necked flask. Add DMF (10 mL). Slowly add iodoethane (1613 mg, 10.34 mmol) dropwise under an ice bath. Stir at room temperature overnight. LCMS monitored the reaction for completion. The reaction mixture was quenched with water and extracted with EA (50 mL x 3). The combined organic phases were washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, and spun down to obtain the target compound, Intermediate 30a (1800 mg, 80% purity, 5.54 mmol, 64% yield). MS Calcd: 258.98; MS Found: 260.01 ([M+H] + ).

[0264] Step 2: Intermediate 30a (500 mg, 1.92 mmol), (2-chloro-5-methoxypyridin-4-yl)boronic acid (540 mg, 2.88 mmol), Pd(dppf)Cl2 (140 mg, 0.19 mmol), and potassium carbonate (531 mg, 3.84 mmol) were weighed into a 100 mL single-necked flask. 1,4-dioxane (15 mL) and water (3 mL) were added. The atmosphere was replaced with nitrogen three times and the reaction was allowed to proceed at 100°C overnight. The reaction was monitored for completion by LCMS. The reaction solution was concentrated and the residue was purified by column chromatography to obtain the target compound, Intermediate 30b (150 mg, 0.46 mmol, 24% yield). MS Calcd: 322.07; MS Found: 323.08 ([M+H] + ).

[0265] Step 3: Intermediate 30b (150 mg, 0.46 mmol) was weighed into a 25 mL single-necked flask and THF (2 mL) was added. Lithium hydroxide monohydrate (21 mg, 0.51 mmol) was then dissolved in water (2 mL) and added to the system. The mixture was allowed to react at room temperature for 2 hours. LCMS monitored the reaction to be complete. The reaction solution was dried to give Intermediate 30 (80 mg, 0.25 mmol, 55.1% yield). MS Calcd: 308.06; MS Found: 309.10 ([M+H] + ).

[0266] Intermediate 31:

[0267] Step 1: Methyl 5-bromo-2-hydroxyisonicotinate (2000 mg, 8.62 mmol) and cesium carbonate (5617 mg, 17.24 mmol) were weighed into a 100 mL single-necked flask. DMF (10 mL) was added, and 2-iodopropane (1758 mg, 10.34 mmol) was slowly added dropwise under an ice bath. The mixture was stirred at room temperature overnight. LCMS monitored the reaction completion. The reaction solution was quenched with water and extracted with EA (50 mL x 3). The organic phases were combined, washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, and spun down to obtain the crude target compound, Intermediate 31a (2100 mg, 60% purity, 4.60 mmol, 53% yield). MS Calcd: 273.00; MS Found: 274.03 ([M+H] + ).

[0268] Step 2: Intermediate 31a (500 mg, 1.92 mmol), (2-chloro-5-methoxypyridin-4-yl)boronic acid (512 mg, 2.74 mmol), Pd(dppf)Cl2 (133 mg, 0.18 mmol), and potassium carbonate (504 mg, 3.65 mmol) were weighed into a 100 mL single-necked flask. 1,4-dioxane (15 mL) and water (3 mL) were added. The atmosphere was replaced with nitrogen three times and the reaction was allowed to proceed at 100°C overnight. The reaction was monitored for completion by LCMS. The reaction solution was concentrated and the residue was purified by column chromatography to obtain the target compound, Intermediate 31b (450 mg, 1.34 mmol, 73% yield). MS Calcd: 336.09; MS Found: 337.10 ([M+H] + ).

[0269] Step 3: Intermediate 31b (450 mg, 1.34 mmol) was weighed into a 25 mL single-necked flask and THF (2 mL) was added. Lithium hydroxide monohydrate (61 mg, 1.47 mmol) was then dissolved in water (2 mL) and added to the system. The mixture was allowed to react at room temperature for 2 hours. LCMS monitored the reaction to completion. The reaction solution was directly dried under reduced pressure to obtain Intermediate 31 (380 mg, 1.15 mmol, 86% yield). MS Calcd: 322.07; MS Found: 323.08 ([M+H] + Intermediate 32:

[0270] Step 1: Intermediate 32a (1000 mg, 7.93 mmol) and THF (20 mL) were placed in a 100 mL eggplant flask. Sodium hydride (60%, dispersed in mineral oil) (476.0 mg, 11.90 mmol) was added under ice-cooling and stirred for 30 minutes. Intermediate 1b (1.42 g, 7.93 mmol) was then added and stirred for 2 hours. TLC monitoring indicated the formation of new spots. The reaction mixture was diluted with EA (15 mL), followed by addition of saturated ammonium chloride solution (2 mL). Extraction was performed with EA (50 mL x 3). The organic phases were combined, washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, and concentrated. The residue was purified by column chromatography to obtain the target compound, Intermediate 32 (132 mg, 0.56 mmol, 7.0% yield). MS Calcd: 225.04; MS Found: 226.07 ([M+H] + Intermediate 33:

[0271] Step 1: Intermediate 5a (450 mg, 1.46 mmol), methylboronic acid (175 mg, 2.92 mmol), Pd(dppf)Cl2 (107 mg, 0.15 mmol), and potassium carbonate (402 mg, 2.92 mmol) were placed in a 25 mL single-necked flask. 1,4-dioxane (10 mL) and water (2 mL) were added. The atmosphere was replaced with nitrogen three times and the reaction was allowed to proceed at 80°C overnight. The reaction was monitored for completion by LCMS. The reaction solution was concentrated and the residue was purified by column chromatography to obtain the target compound, Intermediate 33a (200 mg, 0.69 mmol, 47.6% yield). MS Calcd: 288.11; MS Found: 289.10 ([M+H] + ).

[0272] Step 2: Weigh intermediate 33a (200 mg, 0.69 mmol) into a 10 mL single-necked flask and add THF (5 mL). Weigh lithium hydroxide monohydrate (146 mg, 3.47 mmol), dissolve it in water (1 mL), and add it to the system. Stir at room temperature overnight. LCMS monitoring confirmed the reaction was complete. The reaction solution was concentrated, and the residue was dissolved in water. 1N dilute hydrochloric acid was then slowly added to adjust the pH to approximately 4. Extraction was performed with EA. The organic phase was dried over anhydrous sodium sulfate and concentrated to obtain the target compound, intermediate 33 (100 mg, 0.36 mmol, 52.5% yield). MS Calcd: 274.10; MS Found: 275.10 ([M+H] + ).

[0273] Intermediate 34:

[0274] Step 1: Intermediate 34a (1 g, 4.65 mmol) was placed in a 50 mL single-necked vial, and DCM (15 mL) was added. DAST (2.2 g, 13.95 mmol) was added under an ice bath, and the mixture was reacted at 45°C for 5 hours. The reaction was monitored for completion by LCMS. The reaction mixture was quenched by addition of saturated aqueous ammonium chloride and extracted with EA (50 mL x 3). The combined organic phases were washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, filtered, and the organic phase was concentrated. The residue was purified by column chromatography to afford the target compound, Intermediate 34b (800 mg, 3.38 mmol, 72.6% yield).

[0275] Step 2: Intermediate 23a (200 mg, 0.68 mmol), intermediate 34b (243 mg, 1.02 mmol), Pd(dtbpf)Cl2 (44 mg, 0.07 mmol), and potassium carbonate (188 mg, 1.36 mmol) were weighed into a 25 mL single-necked flask. 1,4-dioxane (8 mL) and water (2 mL) were added. The atmosphere was replaced with nitrogen three times and the mixture was allowed to react at 80°C overnight. The reaction was monitored for completion by LCMS. The reaction solution was concentrated and the residue was purified by column chromatography to obtain the target compound, intermediate 34c (160 mg, 0.49 mmol, 72.5% yield). MS Calcd: 323.10; MS Found: 324.13 ([M+H] + ).

[0276] Step 3: Weigh intermediate 34c (160 mg, 0.49 mmol) into a 25 mL single-necked flask and add THF (10 mL). Weigh lithium hydroxide monohydrate (104 mg, 2.47 mmol), dissolve it in water (2 mL), and add it to the system. Stir at room temperature overnight. LCMS monitoring confirmed the completion of the reaction. The reaction solution was concentrated, and the residue was dissolved in water. 1N dilute hydrochloric acid was then slowly added to adjust the pH to approximately 4. A solid precipitated and was collected by filtration to obtain the target compound, intermediate 34 (135 mg, 0.44 mmol, 88.2% yield). MS Calcd: 309.08; MS Found: 310.09 ([M+H] + ).

[0277] Intermediate 36:

[0278] Step 1: Intermediate 26a (500 mg, 1.58 mmol), 5-trifluoromethyl-2-methoxyphenylboronic acid (347.6 mg, 1.58 mmol), Pd(dppf)Cl2 (115.6 mg, 0.16 mmol), and potassium carbonate (655.1 mg, 4.74 mmol) were weighed into a 100 mL single-necked flask. 1,4-dioxane (20 mL) and water (4 mL) were added. The atmosphere was replaced with nitrogen three times and the mixture was allowed to react at 90°C overnight. The reaction was monitored for completion by LCMS. The reaction solution was concentrated and the residue was purified by column chromatography to obtain the target compound, Intermediate 36a (80 mg, 0.19 mmol, 12.3% yield). MS Calcd: 412.12; MS Found: 413.11 ([M+H] + ).

[0279] Step 2: Intermediate 36a (80 mg, 0.19 mmol) was weighed into a 25 mL single-necked flask. THF (2 mL) was added. Lithium hydroxide monohydrate (9.0 mg, 0.21 mmol) was then dissolved in water (2 mL) and added to the mixture. The mixture was allowed to react at room temperature for 2 hours. LCMS confirmed the reaction was complete. The reaction mixture was then dried under reduced pressure to afford Intermediate 36 (60 mg, 0.15 mmol, 77.9% yield). MS Calcd: 398.11; MS Found: 399.16 ([M+H] + ).

[0280] Intermediate 37:

[0281] Step 1: Intermediate 37a (1018 mg, 5.78 mmol) was weighed into a 100 mL single-necked flask and THF (25 mL) was added. Sodium hydride (60%, dispersed in mineral oil) (267 mg, 6.67 mmol) was added portionwise under an ice bath and stirred for 1 hour. Intermediate 1b (800 mg, 4.44 mmol) was then added and allowed to react for 3 hours. LCMS monitored the reaction completion. The reaction solution was quenched with water and extracted with EA (50 mL x 3). The combined organic phases were washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, and concentrated. The residue was purified by column chromatography to obtain the target compound, Intermediate 37 (350 mg, 1.27 mmol, 28.6% yield). MS Calcd: 275.03; MS Found: 276.01 ([M+H] + ).

[0282] Intermediate 38:

[0283] Step 1: Sodium hydride (60% dispersion in mineral oil) (1201.6 mg, 30.04 mmol) and THF (15 mL) were added portionwise to a 100 mL eggplant-shaped flask. Intermediate 38a (1000 mg, 6.66 mmol) was added portionwise under ice-cooling. After stirring on ice-cooling for 1 hour, carbon disulfide (1.35 mL, 22.52 mmol) was slowly added dropwise. Stirring on ice-cooling for another 1 hour was continued. Finally, iodomethane (1.83 mL, 22.52 mmol) was added and the mixture was allowed to warm to room temperature overnight. LCMS monitored the reaction for completion. The reaction mixture was quenched with water and extracted with EA (50 mL x 3). The organic phases were combined, washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, and evaporated to dryness under reduced pressure to afford crude intermediate 38b (2800 mg, 12.54 mmol, 83.5% yield). MS Calcd:223.01;MS Found:224.10([M+H] + ).

[0284] Step 2: Intermediate 38b (2700 mg, 12.09 mmol) and methanol (20 mL) were weighed into a 100 mL single-necked flask. Hydrazine hydrate (0.71 mL, 14.51 mmol) was slowly added under an ice bath and the mixture was allowed to warm to room temperature for 2 hours. TLC monitored the reaction for completion. The reaction mixture was concentrated under reduced pressure to remove the organic solvent. The residue was added with 100 mL of EA, washed with saturated brine (50 mL x 3), and dried over anhydrous sodium sulfate. The organic phase was then dried to afford the target compound, Intermediate 38c (2300 mg, 7.77 mmol, 64.2% yield).

[0285] Step 3: In a 100 mL single-necked flask, add intermediate 38c (2500 mg, 12.06 mmol), triethylamine (5.02 mL, 36.18 mmol), and methanol (20 mL). Cyanogen bromide (1404.8 mg, 13.27 mmol) was slowly added portionwise under an ice bath. The mixture was allowed to warm to room temperature and stirred for 2 hours. LCMS monitored the reaction to completion. The reaction mixture was quenched with water and extracted with EA (50 mL × 3). The organic phases were combined, washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, and the organic phase was spun down to give the target compound, intermediate 38 (2300 mg, 9.90 mmol, 82.1%). MS Calcd: 232.04; MS Found: 233.07 ([M+H] + ).

[0286] Intermediate 39:

[0287] Step 1: Intermediate 3a (500 mg, 2.03 mmol), 2-difluoromethyl-5-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaboran-2-yl)pyridine (540 mg, 2.88 mmol), Pd(dtbpf)Cl2 (131.2 mg, 0.20 mmol), and potassium carbonate (842.3 mg, 6.10 mmol) were weighed into a 100 mL single-necked flask. 1,4-Dioxane (15 mL) and water (3 mL) were added. The atmosphere was purged with nitrogen three times and the reaction was allowed to proceed at 100°C overnight. The reaction was complete as monitored by LCMS. The reaction solution was concentrated, and the residue was purified by column chromatography to obtain the target compound, Intermediate 39a (620 mg, 1.91 mmol, 94.1% yield). MS Calcd: 324.09; MS Found: 325.10 ([M+H] + ).

[0288] Step 2: Intermediate 39a (660 mg, 2.04 mmol) was weighed into a 25 mL single-necked flask and THF (2 mL) was added. Lithium hydroxide monohydrate (94.0 mg, 2.24 mmol) was then dissolved in water (2 mL) and added to the mixture. The mixture was allowed to react at room temperature for 2 hours. LCMS monitored the reaction until complete. The reaction solution was directly dried under reduced pressure to afford Intermediate 39 (600 mg, 1.61 mmol, 78.8%). MS Calcd: 310.08; MS Found: 311.10 ([M+H] + Intermediate 40:

[0289] Step 1: Intermediate 40a (1800 mg, 14.73 mmol) and THF (20 mL) were placed in a 100 mL eggplant flask. Sodium hydride (60%, dispersed in mineral oil) (589.2 mg, 14.73 mmol) was added under ice-cooling and stirred for 1 hour. Intermediate 1b (1.5 g, 8.33 mmol) was then added and stirred for 2 hours. LCMS analysis revealed a large amount of product. The reaction mixture was diluted with EA (15 mL), followed by aqueous ammonium chloride (30 mL). After the addition was complete, the aqueous phase was separated, the organic phase was concentrated, and the residue was purified by column chromatography to obtain the target compound, Intermediate 40 (220 mg, 0.89 mmol, 9.1% yield). MS Calcd: 221.06; MS Found: 222.07 ([M+H] + ).

[0290] Intermediate 41:

[0291] Step 1: Intermediate 41a (500 mg, 3.93 mmol) and THF (20 mL) were placed in a 100 mL eggplant flask. Sodium hydride (60% dispersion in mineral oil) (235.8 mg, 5.90 mmol) was added under ice-cooling and stirred for 30 minutes. Intermediate 1b (919.6 mg, 5.11 mmol) was then added and stirred for 2 hours. LCMS analysis revealed a large amount of product. The reaction mixture was quenched with water and extracted with EA (50 mL × 3). The organic phases were combined, washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, and the organic phases were concentrated. The residue was purified by column chromatography to obtain the target compound, Intermediate 41 (277 mg, 1.16 mmol, 29.6% yield). MS Calcd: 226.03; MS Found: 227.01 ([M+H] + ).

[0292] Intermediate 42:

[0293] Step 1: Intermediate 42a (590.8 mg, 3.34 mmol) and THF (10 mL) were placed in a 100 mL eggplant flask. Sodium hydride (166.8 mg, 4.17 mmol) was added under ice-cooling and stirred for 30 minutes. Intermediate 1b (500 mg, 2.78 mmol) was then added and stirred for 2 hours. LCMS confirmed the formation of the product. The reaction mixture was quenched with water and extracted with EA (50 mL × 3). The organic phases were combined, washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, and concentrated. The residue was purified by column chromatography to obtain the target compound, Intermediate 42 (298 mg, 0.97 mmol, 34.9% yield). MS Calcd: 276.03; MS Found: 277.01 ([M+H] + ).

[0294] Intermediate 43:

[0295] Step 1: Intermediate 26a (400 mg, 1.26 mmol), 5-chloro-2-methoxyphenylboronic acid (235.1 mg, 1.26 mmol), Pd(dppf)Cl2 (92.2 mg, 0.13 mmol), and potassium carbonate (348.2 mg, 2.52 mmol) were weighed into a 50 mL single-necked flask. 1,4-dioxane (8 mL) and water (1.5 mL) were added. The atmosphere was replaced with nitrogen three times and the reaction was carried out at 80°C for 4 hours. The reaction was monitored for completion by LCMS. The reaction solution was concentrated and the residue was purified by column chromatography to obtain the target compound, Intermediate 43a (180 mg, 0.48 mmol, 37.7% yield). MS Calcd: 378.10; MS Found: 379.00 ([M+H] + ).

[0296] Step 2: Weigh intermediate 43a (180 mg, 0.48 mmol) into a 25 mL single-necked flask and add THF (5 mL). Weigh lithium hydroxide monohydrate (99.8 mg, 2.38 mmol), dissolve it in water (2 mL), and add it to the system. After the addition is complete, react at 50°C for 2 hours. LCMS monitors the reaction for completion. Add 2 mL of aqueous ammonium chloride to the reaction solution, then slowly add 1N dilute hydrochloric acid to adjust the pH to approximately 4. Extract with ethyl acetate (10 mL x 3). Combine the organic phases, dry over anhydrous sodium sulfate, and concentrate to obtain the target compound, intermediate 43 (150 mg, 0.41 mmol, 86.6% yield). MS Calcd: 364.08; MS Found: 365.10 ([M+H] + ).

[0297] Intermediate 44:

[0298] Step 1: Intermediate 44a (2 g, 10.70 mmol) was placed in a 50 mL single-necked flask and added with DMF (15 mL). Cesium carbonate (7 g, 21.39 mmol) and 2-bromo-2,2-difluoroacetic acid (2.8 g, 16.04 mmol) were added at room temperature and reacted at 80°C for 5 hours. The reaction was monitored for completion by TLC. The reaction solution was quenched by addition of saturated sodium chloride solution and extracted with EA (50 mL x 3). The combined organic phases were washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, and concentrated. The residue was purified by column chromatography to obtain the target compound, Intermediate 44b (1.8 g, 7.59 mmol, 71.0% yield).

[0299] Step 2: Intermediate 44b (339.6 mg, 1.43 mmol), Intermediate 23a (350 mg, 1.19 mmol), Pd(dtbpf)Cl2 (77.7 mg, 0.12 mmol), and potassium carbonate (330.1 mg, 2.39 mmol) were weighed into a 50 mL single-necked flask. 1,4-dioxane (8 mL) and water (1.5 mL) were added. The atmosphere was replaced with nitrogen three times and the reaction was carried out at 80°C for 5 hours. The reaction was monitored for completion by LCMS. The reaction solution was concentrated and the residue was purified by column chromatography to obtain the target compound, Intermediate 44c (170 mg, 0.53 mmol, 44.0% yield). MS Calcd: 323.10; MS Found: 323.96 ([M+H] + ).

[0300] Step 3: Weigh intermediate 44c (170 mg, 0.53 mmol) into a 25 mL single-necked flask and add THF (5 mL). Weigh lithium hydroxide monohydrate (110.4 mg, 2.63 mmol), dissolve it in water (1 mL), and add it to the system. After the addition is complete, react at 50°C for 2 hours. LCMS monitors the reaction for completion. Add 2 mL of aqueous ammonium chloride to the reaction solution, then slowly add 1N dilute hydrochloric acid to adjust the pH to approximately 4. Extract with ethyl acetate (10 mL x 3). Combine the organic phases, dry over anhydrous sodium sulfate, and concentrate to obtain the target compound, intermediate 44 (140 mg, 0.45 mmol, 86.1% yield). MS Calcd: 309.08; MS Found: 310.12 ([M+H] + ).

[0301] Intermediate 45:

[0302] Step 1: In a 100 mL single-necked flask, add intermediate 45a (5.7 g, 19.6 mmol) and DCM (30 mL). DAST (9.5 g, 58 mmol) was slowly added dropwise under an ice bath. The mixture was allowed to warm to room temperature and stirred for 2 hours. LCMS monitored the reaction for completion. The reaction mixture was quenched with water and extracted with DCM (100 mL x 3). The combined organic phases were washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, and concentrated. The residue was purified by column chromatography to afford the target compound, intermediate 45b (4.5 g, 14.5 mmol, 73.3% yield). MS Calcd: 306.99; MS Found: 308.10 ([M+H] + ).

[0303] Step 2: In a 100 mL single-necked flask, intermediate 45b (2 g, 6.5 mmol), pinacol diboronate (2.4 g, 9.77 mmol), Pd(dppf)Cl2 (476 mg, 0.65 mmol), potassium acetate (1.9 g, 19.5 mmol), and toluene (15 mL) were added. The atmosphere was purged with nitrogen three times and stirred at 90°C overnight under a nitrogen atmosphere. LCMS monitored the reaction for completion. The reaction mixture was filtered, and the filtrate was extracted with EA (100 mL x 3). The combined organic phases were washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, and concentrated. The residue was purified by column chromatography to afford the target compound, intermediate 45c (1.5 g, 5.2 mmol, 80.8% yield). MS Calcd: 285.13; MS Found: 286.18 ([M+H] + ).

[0304] Step 3: In a 100 mL single-necked flask, Intermediate 3a, Intermediate 45c (695 mg, 2.44 mmol), Pd(dtbpf)Cl2 (131 mg, 0.2 mmol), potassium carbonate (842 mg, 6.1 mmol), and 1,4-dioxane (15 mL) and water (3 mL) were added. The atmosphere was purged with nitrogen three times and stirred at 85°C overnight. The reaction was monitored for completion by LCMS. The reaction solution was concentrated and the residue was purified by column chromatography to obtain the target compound, Intermediate 45d (620 mg, 1.9 mmol, 94.1% yield). MS Calcd: 324.09; MS Found: 325.10 ([M+H] + ).

[0305] Step 4: In a 100 mL single-necked flask, add Intermediate 45d (660 mg, 2.04 mmol), lithium hydroxide monohydrate (94 mg, 2.24 mmol), and solvents water (3 mL), methanol (3 mL), and THF (3 mL). Stir at room temperature overnight. LCMS monitored the reaction for completion. The organic phase was concentrated, and the residue was purified by column chromatography to obtain the crude target compound Intermediate 45 (600 mg, 1.6 mmol, 78.8% yield). MS Calcd: 310.08; MS Found: 311.10 ([M+H] + ).

[0306] Intermediate 47:

[0307] Step 1: Intermediate 47a (1000 mg, 8.12 mmol) and THF (30 mL) were placed in a 100 mL eggplant flask. Sodium hydride (60%, dispersed in mineral oil) (487.0 mg, 12.18 mmol) was added under ice-cooling and stirred for 30 minutes. Intermediate 1b (1899.4 mg, 10.55 mmol) was then added and stirred for 2 hours. LCMS confirmed the formation of the product. The reaction mixture was added to aqueous ammonium chloride (30 mL) and extracted with EA (15 mL x 3). After the addition was complete, the aqueous phase was separated, dried over anhydrous sodium sulfate, and the organic phase was concentrated. The residue was purified by column chromatography to obtain the target compound, Intermediate 47 (277 mg, 1.16 mmol, 29.6% yield). MS Calcd: 222.06; MS Found: 223.13 ([M+H] + ).

[0308] Intermediate 48:

[0309] Step 1: Intermediate 48a (2 g, 9.13 mmol) and THF (20 mL) were weighed into a 100 mL single-necked flask. The atmosphere was purged with nitrogen three times. n-Butyl lithium (10.9 mL, 2.5 M in hexane) was slowly added dropwise at -78°C and stirred at -78°C for 30 minutes. Triisopropyl borate (3.16 mL, 13.6 mmol) was slowly added dropwise at this temperature. Stirring was continued at this temperature for 30 minutes, then the temperature was raised to -40°C and stirred for 2 hours. The reaction was quenched by the addition of 10 mL of 1N hydrochloric acid in an ice bath. The reaction was monitored for completion by TLC. The mixture was extracted with EA (100 mL x 3). The organic phases were combined, washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, and concentrated. The residue was purified by column chromatography to obtain the target compound, Intermediate 48b (1.3 g, 7.0 mmol, 77% yield).

[0310] Step 2: To a 100 mL single-necked vial, intermediate 48b (538 mg, 2.93 mmol), intermediate 3a (600 mg, 2.4 mmol), Pd(dtbpf)Cl2 (157 mg, 0.2 mmol), potassium carbonate (1.0 g, 7.3 mmol), and 1,4-dioxane (15 mL) and water (3 mL) were added and stirred at 100°C overnight. LCMS monitored the reaction for completion. The reaction solution was concentrated, and the residue was purified by column chromatography to afford the target compound, intermediate 48c (400 mg, 1.31 mmol, 53.7% yield). MS Calcd: 305.11; MS Found: 306.23 ([M+H] + ).

[0311] Step 3: In a 100 mL single-necked flask, add Intermediate 48c (400 mg, 1.31 mmol), lithium hydroxide monohydrate (60 mg, 1.4 mmol), and solvents water (2 mL), methanol (2 mL), and THF (2 mL). Stir at room temperature overnight. LCMS monitored the reaction for completion. The organic phase was concentrated, and the residue was purified by column chromatography to obtain the crude target compound Intermediate 48 (300 mg, 0.8 mmol, 61.3% yield). MS Calcd: 291.09; MS Found: 292.10 ([M+H] + ).

[0312] Intermediate 49:

[0313] Step 1: Intermediate 49a (0.8 g, 6.67 mmol) was weighed into a 100 mL single-necked flask and THF (25 mL) was added. Sodium hydride (60% dispersion in mineral oil) (0.3 g, 8.33 mmol) was added portionwise under an ice bath and stirred for 1 hour. Intermediate 1b (1 g, 5.56 mmol) was then added and allowed to react for 3 hours. The reaction was monitored for completion by LCMS. The reaction was quenched with water and extracted with EA (100 mL x 3). The combined organic phases were washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, and concentrated. The residue was purified by column chromatography to afford the target compound, Intermediate 49 (800 mg, 3.60 mmol, 64.8% yield). MS Calcd: 222.06; MS Found: 223.10 ([M+H] + ).

[0314] Intermediate 50:

[0315] Step 1: Intermediate 50a (900 mg, 6.71 mmol) was weighed into a 100 mL single-necked flask and THF (25 mL) was added. Sodium hydride (60%, dispersed in mineral oil) (402.7 mg, 10.07 mmol) was added portionwise under an ice bath and stirred for 1 hour. Intermediate 1b (1450 mg, 8.05 mmol) was then added and allowed to react for 3 hours. The reaction was monitored for completion by LCMS. The reaction was quenched with water and extracted with EA (100 mL x 3). The combined organic phases were washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, and concentrated. The residue was purified by column chromatography to obtain the target compound, Intermediate 50 (860 mg, 3.69 mmol, 54.9% yield). MS Calcd: 233.04; MS Found: 234.06 ([M+H] + ).

[0316] Intermediate 51:

[0317] Step 1: Intermediate 51a (900 mg, 6.22 mmol) and THF (15 mL) were placed in a 100 mL eggplant flask. Sodium hydride (60% dispersion in mineral oil) (497.9 mg, 12.45 mmol) was added under ice-cooling and stirred for 30 minutes. Intermediate 1b (1120.3 mg, 6.22 mmol) was then added and stirred overnight. The reaction was monitored for completion by LCMS. The reaction was quenched with water and extracted with EA (100 mL x 3). The combined organic phases were washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, and concentrated. The residue was purified by column chromatography to afford the target compound, Intermediate 51 (522 mg, 2.03 mmol, 32.7% yield). MS Calcd: 243.00; MS Found: 243.95 ([M+H] + ).

[0318] Intermediate 52:

[0319] Step 1: To a 25 mL eggplant flask, reactant 52a (400 mg, 2.87 mmol), sodium hydride (60%, dispersed in mineral oil) (229.9 mg, 5.75 mmol), and THF (10 mL) were added. The mixture was stirred on ice for 30 minutes, followed by the addition of intermediate 1b (620.7 mg, 3.45 mmol). The mixture was allowed to warm to room temperature and stirred for 2 hours. LCMS monitored the reaction completion. The reaction was quenched with water and extracted with EA (100 mL x 3). The combined organic phases were washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, and concentrated. The residue was purified by column chromatography to afford the target compound, intermediate 52 (120 mg, 0.5 mmol, 17.5%). MS Calcd: 238.05; MS Found: 239.01 ([M+H] + ).

[0320] Intermediate 53:

[0321] Step 1: Intermediate 53a (200 mg, 1.27 mmol) and Intermediate 1b (273.2 mg, 1.52 mmol) were weighed into a 50 mL single-necked flask. Acetonitrile (10 mL) was added, followed by cesium carbonate (824.3 mg, 2.53 mmol). The mixture was heated to 50°C and stirred for 4 hours. LCMS monitored the reaction completion. The mixture was extracted with EA (100 mL x 3). The combined organic phases were washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, and concentrated. The residue was purified by column chromatography to obtain the target compound, Intermediate 53 (47 mg, 0.13 mmol, 13.2% yield). MS Calcd: 257.04; MS Found: 258.05 ([M+H] + ).

[0322] Intermediate 54:

[0323] Step 1: Place Intermediate 54a (2 g, 15.86 mmol) and p-toluenesulfonic acid (3 g, 15.86 mmol) in a 50 mL single-necked flask, add acetonitrile (20 mL), and add NBS (2.8 g, 15.86 mmol) under ice-cooling. Then, react at room temperature overnight. LCMS monitored the reaction completion, extracted with EA (100 mL × 3), combined organic phases, washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, concentrated, and the residue purified by column chromatography to obtain the target compound, Intermediate 54b (2.2 g, 10.73 mmol, 67.7% yield). MS Calcd: 203.96; MS Found: 202.96 ([MH] + ).

[0324] Step 2: Intermediate 54b (2 g, 9.76 mmol) was placed in a 50 mL single-necked flask and added with DMF (20 mL). Cesium carbonate (6.4 g, 19.51 mmol) and 2-bromo-2,2-difluoroacetic acid (2.6 g, 14.63 mmol) were then added at room temperature and allowed to react at 80°C for 5 hours. The reaction was monitored for completion by TLC. The reaction mixture was quenched with saturated sodium chloride solution and extracted with EA (100 mL x 3). The combined organic phases were washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, and concentrated. The residue was purified by column chromatography to afford the target compound, Intermediate 54c (1.6 g, 6.27 mmol, 64.3% yield).

[0325] Step 3: Intermediate 54c (173.4 mg, 0.68 mmol), Intermediate 23a (200 mg, 0.68 mmol), Pd(dtbpf)Cl2 (44.4 mg, 0.07 mmol), and potassium carbonate (188.6 mg, 1.36 mmol) were weighed into a 50 mL single-necked flask. 1,4-dioxane (8 mL) and water (1.5 mL) were added. The atmosphere was replaced with nitrogen three times and the reaction was carried out at 80°C for 3 hours. The reaction was monitored for completion by LCMS. The reaction solution was concentrated and the residue was purified by column chromatography to obtain the target compound, Intermediate 54d (40.2 mg, 0.12 mmol, 17.0% yield). MS Calcd: 341.09; MS Found: 342.09 ([M+H] + ).

[0326] Step 4: Intermediate 54d (40 mg, 0.12 mmol) was weighed into a 25 mL single-necked flask, THF (5 mL) was added, and lithium hydroxide monohydrate (24.6 mg, 0.59 mmol) was weighed, dissolved in water (1 mL), and added to the system. After the addition was complete, the mixture was reacted at 50°C for 2 hours. LCMS monitored the reaction for completion. 2 mL of aqueous ammonium chloride solution was added to the reaction solution, and then 1N dilute hydrochloric acid was slowly added to adjust the pH to approximately 4. The reaction solution was extracted with EA (10 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, and concentrated to obtain the target compound, Intermediate 54 (35 mg, 0.11 mmol, 91.1% yield). MS Calcd: 327.08; MS Found: 328.09 ([M+H] + ).

[0327] Intermediate 55:

[0328] Step 1: To a 25 mL eggplant flask, add Intermediate 55a (500 mg, 3.46 mmol), sodium hydride (60%, dispersed in mineral oil) (207.5 mg, 5.19 mmol), and THF (10 mL). Stir under ice for 30 minutes, then add Intermediate 1b (684.6 mg, 3.80 mmol). Warm to room temperature and stir for 2 hours. LCMS monitored the reaction for completion. The reaction mixture was quenched with water and extracted with EA (100 mL x 3). The combined organic phases were washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, and concentrated. The residue was purified by column chromatography to afford the target compound, Intermediate 55 (280 mg, 1.15 mmol, 33.2%). MS Calcd: 243.00; MS Found: 244.06 ([M+H] + )

[0329] Intermediate 56:

[0330] Step 1: To a 50 mL eggplant flask, add Intermediate 56a (1000 mg, 5.98 mmol) and THF (10 mL). Slowly add sodium hydride (60% dispersion in mineral oil) (358.9 mg, 8.97 mmol) under ice-cooling. Stirring is maintained on ice for 30 minutes, followed by the addition of Intermediate 1b (1184.2 mg, 6.58 mmol). The mixture is allowed to warm to room temperature and stirred for 2 hours. The reaction is monitored for completion by LCMS. The reaction mixture is quenched with water and extracted with EA (100 mL x 3). The combined organic phases are washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, and concentrated. The residue is purified by column chromatography to afford the target compound, Intermediate 56b (400 mg, 1.50 mmol, 25.1% yield). MS Calcd: 266.05; MS Found: 267.10 ([M+H] + ).

[0331] Step 2: 56b (227.8 mg, 0.86 mmol), HATU (487.9 mg, 1.28 mmol), and intermediate 8 (280 mg, 0.86 mmol) were weighed into a 25 mL single-necked flask. DMF (10 mL) and DIEA (331 mg, 2.57 mmol) were then added and allowed to react at room temperature overnight. LCMS monitored the reaction for completion. The reaction mixture was quenched with 20 mL of water and extracted with EA (100 mL x 3). The combined organic phases were washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, and concentrated. The residue was purified by column chromatography to afford the target compound, intermediate 56 (350 mg, 0.53 mmol, 61.9% yield). MS Calcd: 575.11; MS Found: 576.35 ([M+H] + ).

[0332] Intermediate 57:

[0333] Step 1: Intermediate 57a (500 mg, 3.48 mmol) was weighed into a 50 mL single-necked flask and THF (15 mL) was added. Sodium hydride (208.9 mg, 5.22 mmol, 60% dispersion in mineral oil) was added portionwise under an ice bath and stirred for 1 hour. Intermediate 1b (689.4 mg, 3.83 mmol) was then added and allowed to react for 3 hours. The reaction was monitored for completion by LCMS. The reaction solution was quenched with water and extracted with EA (100 mL x 3). The combined organic phases were washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, and concentrated. The residue was purified by column chromatography to afford the target compound, Intermediate 57 (70 mg, 0.29 mmol, 8.3% yield). MS Calcd: 242.00; MS Found: 243.15 ([M+H]+ ).

[0334] Intermediate 58

[0335] Step 1: Intermediate 58a (500 mg, 2.99 mmol), DHP (754.7 mg, 8.97 mmol), and PTSA (51.5 mg, 0.3 mmol) were weighed into a 50 mL single-necked flask. DCM (15 mL) was then added and the mixture was allowed to react at room temperature overnight. LCMS monitored the reaction for completion. 50 mL of saturated sodium bicarbonate solution was added to the reaction mixture, and the mixture was extracted with DCM (30 mL x 2). The organic phases were combined, dried over anhydrous sodium sulfate, and concentrated to obtain the target compound, Intermediate 58b (750 mg). The crude product was used directly in the next step without purification. MS Calcd: 251.12; MS Found: 252.24 ([M+H] + ).

[0336] Step 2: Weigh NaBH4 (338 mg, 8.95 mmol) and add 58b (750 mg, 2.98 mmol) and methanol (15 mL) to a 50 mL single-necked flask. Allow to react overnight at room temperature. LCMS monitored the reaction to completion. 100 mL of saturated ammonium chloride solution was added to the reaction solution, and EA was extracted (50 mL x 2). The organic phases were combined, dried over anhydrous sodium sulfate, and concentrated to obtain the target compound, intermediate 58c (750 mg). The crude product was used directly in the next step without purification. MS Calcd: 223.12; MS Found: 224.21 ([M+H] + ).

[0337] Step 3: DMP (2659 mg, 6.27 mmol) was weighed and added to a 50 mL single-necked vial containing 58c (700 mg, 3.13 mmol) and DCM (20 mL). The mixture was allowed to react at room temperature for 3 hours. LCMS monitored the reaction to be complete. 30 mL of saturated sodium thiosulfate solution and 30 mL of saturated sodium bicarbonate solution were added to the reaction mixture and stirred for 10 minutes. The mixture was extracted with DCM (50 mL x 2). The organic phases were combined, dried over anhydrous sodium sulfate, and concentrated to obtain the target compound intermediate 58d (700 mg). The crude product was used directly in the next step without purification. MS Calcd: 222.11; MS Found: 222.19 ([M+H] + ).

[0338] Step 4: DAST (1530 mg, 9.49 mmol) was weighed and added to a 50 mL single-necked flask containing 58d (700 mg, 3.16 mmol) and DCM (20 mL) under an ice bath. The mixture was then heated to 50°C and stirred for 1.5 hours. LCMS monitored the reaction to be complete. The reaction solution was added dropwise to ice water and stirred for 10 minutes. The base was adjusted with sodium bicarbonate solution and extracted with DCM (50 mL x 2). The organic phases were combined, dried over anhydrous sodium sulfate, and concentrated to obtain the target compound intermediate 58e (700 mg). The crude product was directly used in the next step without purification. MS Calcd: 243.11; MS Found: 244.07 ([M+H] + ).

[0339] Step 5: PTSA (99.1 mg, 0.58 mmol) was weighed and added to a 50 mL single-necked vial containing 58e (700 mg, 3.13 mmol) and methanol (15 mL). The mixture was allowed to react overnight at room temperature. LCMS monitored the reaction to completion. The reaction mixture was directly added to silica gel and purified by column chromatography to obtain the target intermediate 58f (200 mg, 1.26 mmol, 43.7% yield). MS Calcd: 159.05; MS Found: 160.04 ([M+H] + ).

[0340] Step 6: Sodium hydride (80.5 mg, 2.01 mmol, 60%, dispersed in mineral oil) was added to a 50 mL single-necked flask containing 58f (160 mg, 1.01 mmol) and THF (10 mL). The mixture was stirred for 20 minutes. Intermediate 1b (217.2 mg, 1.21 mmol) was then added to the reaction mixture and stirring continued for 2 hours. LCMS monitoring confirmed the reaction was complete. 10 mL of water was added to the reaction mixture and stirred for 10 minutes. The mixture was then extracted with EA (20 mL x 2). The organic phases were combined, dried over anhydrous sodium sulfate, and concentrated to afford the target compound, Intermediate 58 (130 mg, 0.50 mmol, 50% yield). MS Calcd: 258.04; MS Found: 258.99 ([M+H] + ).

[0341] Intermediate 59:

[0342] Step 1: To a 100 mL eggplant-shaped flask, add Intermediate 59a (900 mg, 5.66 mmol), Intermediate 1b (1220 mg, 6.79 mmol), and Cs2CO3 (5529.0 mg, 16.97 mmol). Stir at 50°C for 5 hours after complete addition. LCMS monitored the reaction for completion. The reaction mixture was quenched by ammonium chloride solution and extracted with EA (100 mL x 3). The combined organic phases were washed with saturated brine (50 mL) and dried over anhydrous sodium sulfate. The organic phases were concentrated and the residue was purified by column chromatography to obtain the target compound, Intermediate 59 (426 mg, 1.57 mmol, 27.7% yield). MS Calcd: 258.04; MS Found: 259.01 ([M+H] + ).

[0343] Intermediate 60:

[0344] Step 1: Sodium nitrite (1394 mg, 20.20 mmol) was dissolved in H₂O (40 mL) and added dropwise to Intermediate 60a (2000 mg, 10.10 mmol) and concentrated sulfuric acid (8 mL) in a 100 mL single-necked flask under an ice bath. The mixture was then heated to 100°C for 3 hours. TLC monitored the reaction for completion. The reaction solution was added dropwise to an ice-water mixture and extracted with EA (60 mL x 2). The organic phases were combined, dried over anhydrous sodium sulfate, and concentrated to afford the target compound, Intermediate 60b (800 mg, 4.02 mmol, 39.8% yield). MS Calcd: 197.94.

[0345] Step 2: Intermediate 60b (800 mg, 4.02 mmol), iodomethane (1141 mg, 8.04 mmol), and cesium carbonate (1965 mg, 6.03 mmol) were weighed into a 50 mL single-necked flask. DMF (20 mL) was then added and the mixture was allowed to react at room temperature overnight. LCMS monitored the reaction to be complete. 50 mL of saturated sodium bicarbonate solution was added to the reaction mixture, and the mixture was extracted with EA (30 mL x 2). The organic phases were combined, dried over anhydrous sodium sulfate, and concentrated to obtain the target compound, Intermediate 60c (500 mg, 2.35 mmol, 58.4% yield). MS Calcd: 211.96; MS Found: 212.99 ([M+H] + ).

[0346] Step 3: Intermediate 60c (200 mg, 0.94 mmol), 2-methoxy-5-methylphenylboronic acid (187 mg, 1.13 mmol), Pd(dtbpf)Cl2 (61 mg, 0.09 mmol), and potassium carbonate (260 mg, 1.88 mmol) were weighed into a 50 mL single-necked flask. 1,4-dioxane (10 mL) and water (2 mL) were added. The atmosphere was replaced with nitrogen three times and the mixture was allowed to react at 80°C overnight. The reaction was monitored for completion by LCMS. The reaction solution was concentrated and the residue was purified by column chromatography to obtain the target compound, Intermediate 60d (90 mg, 0.35 mmol, 37.7% yield). MS Calcd: 254.11; MS Found: 255.05 ([M+H] + ).

[0347] Step 4: Lawesson's reagent (143 mg, 0.35 mmol) was weighed and added to a 25 mL single-necked flask containing 60d (90 mg, 0.35 mmol) and THF (30 mL). Toluene (20 mL) was then added and the mixture was heated to 110°C for 2 hours. LCMS monitoring confirmed the completion of the reaction. 50 mL of saturated sodium bicarbonate solution was added to the reaction solution, and the mixture was extracted with EA (15 mL x 2). The organic phases were combined, dried over anhydrous sodium sulfate, and concentrated to obtain the target compound intermediate 60e (90 mg, 0.33 mmol, 94% yield). MS Calcd: 270.08; MS Found: 270.97 ([M+H] + ).

[0348] Step 5: Weigh intermediate 60e (90 mg, 0.33 mmol) into a 25 mL single-necked flask and add methanol (3 mL). Add potassium hydroxide aqueous solution (2 mL, 30%) to the system and react at 80°C overnight. LCMS monitored the reaction for completion. Slowly add 1N dilute hydrochloric acid to the reaction solution to adjust the pH to approximately 4. Extract with ethyl acetate (10 mL x 3). Combine the organic phases, dry over anhydrous sodium sulfate, and concentrate the residue. Purify by column chromatography to obtain the target compound, intermediate 60 (75 mg, 0.26 mmol, 77.9% yield). MS Calcd: 289.08; MS Found: 289.96 ([M+H] + ).

[0349] Intermediate 61:

[0350] Step 1: Sodium hydride (644.5 mg, 16.11 mmol, 60%, dispersed in mineral oil) was added to a 100 mL single-necked flask containing intermediate 61a (2000 mg, 10.74 mmol) and THF (30 mL). The mixture was stirred for 20 minutes. Intermediate 1b (2320 mg, 12.89 mmol) was then added to the reaction mixture, and stirring continued for 2 hours. LCMS confirmed the reaction was complete. 10 mL of water was added to the reaction mixture, and stirring was continued for 10 minutes. The mixture was extracted with EA (20 mL x 2). The organic phases were combined, dried over anhydrous sodium sulfate, and the concentrated crude product was purified by silica gel column chromatography to yield the target compound, intermediate 61 (500 mg, 1.75 mmol, 16.3% yield). MS Calcd: 285.02; MS Found: 286.06 ([M+H] + ).

[0351] Intermediate 62:

[0352] Step 1: Intermediate 62a (177.2 mg, 0.82 mmol), Intermediate 23a (200 mg, 0.68 mmol), Pd(dtbpf)Cl2 (44.4 mg, 0.07 mmol), and potassium carbonate (188.6 mg, 0.36 mmol) were weighed into a 50 mL single-necked flask. 1,4-dioxane (10 mL) and water (2 mL) were added. The atmosphere was replaced with nitrogen three times and the reaction was allowed to proceed at 80°C overnight. The reaction was monitored for completion by LCMS. The reaction solution was concentrated and the residue was purified by column chromatography to obtain the target compound, Intermediate 62b (130 mg, 0.43 mmol, 63.0% yield). MS Calcd: 303.09; MS Found: 304.13 ([M+H] + ).

[0353] Step 2: Weigh intermediate 62b (100 mg, 0.33 mmol) into a 25 mL single-necked flask and add THF (5 mL). Weigh lithium hydroxide monohydrate (41.6 mg, 0.99 mmol), dissolve it in water (1 mL), and add it to the system. After the addition is complete, react at 50°C for 1 hour. LCMS monitors the reaction for completion. Slowly add 1N dilute hydrochloric acid to the reaction solution to adjust the pH to approximately 4. Extract with ethyl acetate (10 mL x 3). Combine the organic phases, dry over anhydrous sodium sulfate, and concentrate to obtain the target compound, intermediate 62 (70 mg, 0.24 mmol, 73.4% yield). MS Calcd: 289.08; MS Found: 290.12 ([M+H] + ).

[0354] Example 1: Preparation of N-(5-chloropyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-yl)-5-(5-fluoro-2-methoxyphenyl)-1-methyl-2-oxo-1,2-dihydropyridine-4-carboxamide (Compound 5)

[0355] Step 1: Intermediate 6 (20 mg, 0.07 mmol), HATU (27.4 mg, 0.07 mmol), and Intermediate 1 (22.8 mg, 0.09 mmol) were weighed into a 25 mL single-necked vial. DMF (1 mL) and DIEA (27.9 mg, 0.21 mmol) were then added and allowed to react at room temperature overnight. LCMS monitored the reaction for completion. The reaction solution was purified by prep-HPLC to afford the title compound 5 (20 mg, 0.04 mmol, 54.5% yield). MS Calcd: 501.07; MS Found: 502.05 ([M+H] + ).

[0356] 1 H NMR (400MHz, DMSO-d6) δ12.88(brs,1H),8.66(d,J=2.4Hz,1H),8.02(dd,J=8.4,2.4Hz,1H),7.83(s,1H),7.6 2(d,J=8.4Hz,1H),7.22-7.08(m,2H),6.92-6.88(m,1H),6.69(s,1H),5.55(s,2H),3.52(s,3H),3.46(s,3H).

[0357] Example 2: Preparation of N-(5-chloropyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-yl)-5-(5-trifluoromethyl-2-methoxyphenyl)-1-methyl-2-oxo-1,2-dihydropyridine-4-carboxamide (Compound 7)

[0358] Step 1: Intermediate 8 (50 mg, 0.14 mmol), HATU (87.1 mg, 0.23 mmol), and intermediate 1 (48.2 mg, 0.20 mmol) were weighed into a 25 mL single-necked flask. DMF (2 mL) and DIEA (59.2 mg, 0.46 mmol) were then added and allowed to react at room temperature overnight. LCMS monitored the reaction for completion. The reaction solution was purified by prep-HPLC to afford the title compound 7 (15 mg, 0.03 mmol, 20.1% yield). MS Calcd: 551.06; MS Found: 552.06 ([M+H] + ).

[0359] 1 H NMR(400MHz,DMSO-d6)δ12.94(brs,1H),8.72–8.65(m,1H),8.02(dd,J=8.4,2.4Hz,1H),7.88(s,1 H),7.71–7.59(m,3H),7.11(d,J=8.4Hz,1H),6.73(s,1H),5.55(s,2H),3.56(s,3H),3.53(s,3H).

[0360] Example 3: Preparation of 5-(5-chloro-2-methoxyphenyl)-N-(5-(((5-chloropyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-yl)-1-methyl-2-oxo-1,2-dihydropyridine-4-carboxamide (Compound 8)

[0361] Step 1: Intermediate 9 (60 mg, 0.20 mmol), HATU (116.5 mg, 0.31 mmol), and Intermediate 1 (49.6 mg, 0.20 mmol) were weighed into a 25 mL single-necked flask. DMF (2 mL) and DIEA (79.2 mg, 0.61 mmol) were then added and allowed to react at room temperature overnight. LCMS monitored the reaction for completion. 5 mL of aqueous ammonium chloride was added to the reaction solution, and the mixture was extracted with DCM (10 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, and the residue was purified by prep-HPLC to obtain the target compound 8 (16 mg, 0.03 mmol, 14.9% yield). MS Calcd: 517.04; MS Found: 518.0 ([M+H] + ).

[0362] 1 H NMR (400MHz, DMSO-d6) δ12.88(brs,1H),8.67(s,1H),8.02(d,J=6.8Hz,1H),7.86(s,1H),7.62(d,J=8. 3Hz,1H),7.45–7.29(m,2H),6.94(d,J=8.7Hz,1H),6.70(s,1H),5.56(s,2H),3.53(s,3H),3.48(s,3H).

[0363] Example 4: Preparation of N-(5-((5-chloropyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-yl)-5-(2-methoxy-5-methylphenyl)-1-methyl-2-oxo-1,2-dihydropyridine-4-carboxamide (Compound 10)

[0364] Step 1: Intermediate 11 (80 mg, 0.29 mmol), intermediate 1 (71 mg, 0.29 mmol), HATU (137 mg, 0.44 mmol), DIEA (0.15 mL, 0.88 mmol), and DMF (2 mL) were weighed into a 10 mL single-necked vial and reacted overnight at room temperature. LCMS monitored the reaction for completion. The reaction solution was filtered and directly purified by prep-HPLC to obtain the title compound 10 (25 mg, 0.05 mmol, 16.7% yield). MS Calcd: 497.09; MS Found: 498.07 ([M+H] + ).

[0365] 1 H NMR(400MHz,DMSO-d6)δ12.84(brs,1H),8.66(s,1H),8.02(s,1H),7.75(s,1H),7.62(s,1H) ,7.10(s,2H),6.79(s,1H),6.65(s,1H),5.54(s,2H),3.52(s,3H),3.43(s,3H),2.29(s,3H).

[0366] Example 5: Preparation of N-(5-((5-chloropyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-yl)-5-(2-(difluoromethoxyphenyl)-1-methyl-2-oxo-1,2-dihydropyridine-4-carboxamide (Compound 22)

[0367] Step 1: Intermediate 23 (30 mg, 0.10 mmol), intermediate 1 (25 mg, 0.10 mmol), HATU (58 mg, 0.15 mmol), DIEA (0.05 mL, 0.30 mmol), and DMF (2 mL) were weighed into a 10 mL single-necked vial and reacted overnight at room temperature. LCMS monitored the reaction for completion. The reaction solution was filtered and directly purified by prep-HPLC to obtain the title compound 22 (16 mg, 0.03 mmol, 29.9% yield). MS Calcd: 519.06; MS Found: 519.98 ([M+H] + ).

[0368] 1H NMR (400MHz, DMSO-d6) δ12.98(brs,1H),8.66(d,J=2.3Hz,1H),8.01(dd,J=8.4,2.5Hz,1H),7.82(s,1H),7.60(d,J=8.4Hz,1H), 7.40(d,J=7.7Hz,2H),7.28(t,J=7.4Hz,1H),,7.13(d,J=7.9Hz,1H),8.16–6.93(m,1H),6.78(s,1H),5.54(s,2H),3.53(s,3H).

[0369] Example 6: Preparation of N-(5-((5-chloropyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-yl)-5-(5-cyano-2-(difluoromethoxyphenyl)-1-methyl-2-oxo-1,2-dihydropyridine-4-carboxamide (Compound 24)

[0370] Step 1: Intermediate 25 (50 mg, 0.16 mmol), HATU (148.8 mg, 0.39 mmol), and Intermediate 1 (38 mg, 0.16 mmol) were weighed into a 25 mL single-necked flask. DMF (2 mL) and DIEA (0.08 ml, 0.48 mmol) were then added. The mixture was allowed to react at room temperature for 2 hours. LCMS monitoring indicated product formation. The reaction mixture was purified by prep-HPLC to afford the title compound 24 (26 mg, 0.05 mmol, 29.9% yield). MS Calcd: 544.05; MS Found: 545.00 ([M+H] + ).

[0371] 1 H NMR (400MHz, DMSO-d6) δ12.96(brs,1H),8.64(dd,J=2.5,0.7Hz,1H),7.99(dd,J=8.4,2.5Hz,1H),7.92(s,2H),7.89(d,J=2. 1Hz,1H),7.59(dd,J=8.4,0.7Hz,1H),7.25(d,J=8.4Hz,1H),7.21(t,J=72.8Hz,1H),6.82(s,1H),5.53(s,2H),3.51(s,3H).

[0372] Example 7: Preparation of 2'-chloro-N-(5-(cyclopropylmethoxy)-1,3,4-thiadiazol-2-yl)-5'-methoxy-1-methyl-6-oxo-1,6-dihydro-[3,4'-bipyridine]-4-carboxamide (Compound 28)

[0373] Step 1: Intermediate 5 (50 mg, 0.17 mmol), HATU (96 mg, 0.25 mmol), and intermediate 29 (69 mg, 0.20 mmol) were weighed into a 25 mL single-necked flask. DMF (2 mL) and DIEA (65 mg, 0.51 mmol) were then added and the mixture was allowed to react at room temperature overnight. LCMS monitored the reaction for completion. The reaction solution was purified by prep-HPLC to afford the title compound 28 (5 mg, 0.01 mmol, 4.9% yield). MS Calcd: 447.08; MS Found: 448.04 ([M+H] + ).

[0374] 1 H NMR(400MHz,DMSO-d6)δ12.84(brs,1H),8.03(s,1H),7.93(s,1H),7.44(s,1 H),6.75(s,1H),4.22(d,J=7.2Hz,2H),3.58(s,3H),3.51(s,3H),1.35–1.24 (m,1H),0.62–0.55(m,2H),0.41–0.35(m,2H).

[0375] Example 8: Preparation of 2'-chloro-N-(5-((5-chloropyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-yl)-1-ethyl-5'-methoxy-6-oxo-1,6-dihydro-[3,4'-bipyridine]-4-carboxamide (Compound 29)

[0376] Step 1: Intermediate 30 (80 mg, 0.26 mmol), HATU (147 mg, 0.39 mmol), and intermediate 1 (94 mg, 0.39 mmol) were weighed into a 25 mL single-necked flask. DMF (2 mL) and DIEA (100 mg, 0.78 mmol) were then added and allowed to react at room temperature overnight. LCMS monitored the reaction for completion. The reaction solution was purified by prep-HPLC to afford the title compound 29 (10 mg, 0.02 mmol, 6.9% yield). MS Calcd: 532.05; MS Found: 533.10 ([M+H] + ).

[0377] 1H NMR (400 MHz, DMSO-d6) δ 8.65 (d, J = 2.5 Hz, 1H), 8.03-7.98 (m, 2H), 7.94 (s, 1H), 7.60 (d, J = 8.4 Hz, 1H), 7.49 (s, 1H), 6.74 (s, 1H), 5.52 (s, 2H), 3.99 (q, J = 7.2 Hz, 2H), 3.57 (s, 3H), 1.29 (t, J = 6.8 Hz, 3H). (Amide NH not shown)

[0378] Example 9: Preparation of 2'-chloro-N-(5-((5-chloropyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-yl)-1-isopropyl-5'-methoxy-6-oxo-1,6-dihydro-[3,4'-bipyridine]-4-carboxamide (Compound 30)

[0379] Step 1: Intermediate 31 (100 mg, 0.31 mmol), HATU (176 mg, 0.46 mmol), and Intermediate 1 (112 mg, 0.46 mmol) were weighed into a 25 mL single-necked vial. DMF (2 mL) and DIEA (120 mg, 0.93 mmol) were then added and allowed to react at room temperature overnight. LCMS monitored the reaction for completion. The reaction solution was purified by prep-HPLC to afford the title compound 30 (15 mg, 0.02 mmol, 8.0% yield). MS Calcd: 546.06; MS Found: 547.05 ([M+H] + ).

[0380] 1 H NMR (400MHz, DMSO-d6) δ12.97(brs,1H),8.68(d,J=2.4Hz,1H),8.28(s,1H),8.12(s,1H),8.03(dd,J=8.4,2.4Hz,1H) ,7.63(d,J=8.4Hz,1H),7.54(s,1H),7.12(s,1H),5.57(s,2H),5.41–5.27(m,1H),3.62(s,3H),1.38(d,J=6.0Hz,6H).

[0381] Example 10: Preparation of 2'-chloro-N-(5-((4-fluorobenzyl)oxy)-1,3,4-thiadiazol-2-yl)-5'-methoxy-1-methyl-6-oxo-1,6-dihydro-[3,4'-bipyridine]-4-carboxamide (Compound 31)

[0382] Step 1: Intermediate 5 (40 mg, 0.18 mmol), intermediate 32 (52.3 mg, 0.18 mmol), and HATU (202.6 mg, 0.53 mmol) were weighed into a 25 mL single-necked vial. DMF (1 mL) and DIEA (0.09 mL, 0.53 mmol) were added and reacted at room temperature for 2 hours. LCMS monitored the reaction for completion. The reaction mixture was purified by prep-HPLC to obtain the target compound 31 (11 mg, 0.02 mmol, 11.4% yield). MS Calcd: 501.07; MS Found: 502.05 ([M+H] + ).

[0383] 1 H NMR(400MHz,DMSO-d6)δ12.96(brs,1H),8.02(s,1H),7.95(s,1H),7.58–7.53(m,2H) ,7.44(s,1H),7.27–7.21(m,2H),6.74(s,1H),5.43(s,2H),3.56(s,3H),3.50(s,3H).

[0384] Example 11: Preparation of N-(5-((5-chloropyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-yl)-5'-methoxy-1,2'-dimethyl-6-oxo-1,6-dihydro-[3,4'-bipyridine]-4-carboxamide (Compound 32)

[0385] Step 1: Intermediate 33 (50 mg, 0.18 mmol), intermediate 1 (44 mg, 0.18 mmol), HATU (104 mg, 0.27 mmol), DIEA (0.09 mL, 0.55 mmol), and DMF (2 mL) were weighed into a 10 mL single-necked vial and reacted overnight at room temperature. LCMS monitored the reaction for completion. The reaction solution was filtered and directly purified by prep-HPLC to obtain the title compound 32 (3 mg, 0.01 mmol, 2.9% yield). MS Calcd: 498.09; MS Found: 499.07 ([M+H] + ).

[0386] 1H NMR (400 MHz, DMSO-d6) δ 8.66 (d, J = 2.3 Hz, 1H), 8.06 (s, 1H), 8.01 (dd, J = 8.4, 2.4 Hz, 1H), 7.83 (s, 1H), 7.60 (d, J = 8.4 Hz, 1H), 7.17 (s, 1H), 6.72 (s, 1H), 5.52 (s, 2H), 3.54 (s, 3H), 3.52 (s, 3H), 2.44 (s, 3H). (Amide NH not shown)

[0387] Example 12: Preparation of N-(5-((5-chloropyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-yl)-5-(5-(difluoromethyl)-2-methoxyphenyl)-1-methyl-2-oxo-1,2-dihydropyridine-4-carboxamide (Compound 33)

[0388] Step 1: Intermediate 34 (60 mg, 0.19 mmol), intermediate 1 (56 mg, 0.23 mmol), HATU (111 mg, 0.29 mmol), DIEA (0.10 mL, 0.58 mmol), and DMF (2 mL) were weighed into a 10 mL single-necked vial and reacted overnight at room temperature. LCMS monitored the reaction for completion. The reaction solution was filtered and directly purified by prep-HPLC to obtain the title compound 33 (15 mg, 0.03 mmol, 14.3% yield). MS Calcd: 533.07; MS Found: 534.05 ([M+H] + ).

[0389] 1 H NMR (400MHz, DMSO-d6) δ12.92(brs,1H),8.66(d,J=2.1Hz,1H),8.02(dd,J=8.4,2.5Hz,1H),7.84(s,1H),7.61(d,J=8.4Hz,1H),7.52(d,J=8.1Hz, 2H),7.16–6.85(m,2H),6.71(s,1H),5.56(s,2H),3.53(s,6H).

[0390] Example 13: Preparation of N-(5-((5-chloropyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-yl)-1-(2-(dimethylamino)-2-oxoethyl)-5-(2-methoxy-5-(trifluoromethyl)phenyl)-2-oxo-1,2-dihydropyridine-4-carboxamide (Compound 35)

[0391] Step 1: Intermediate 36 (40 mg, 0.10 mmol), HATU (57 mg, 0.39 mmol), and intermediate 1 (29 mg, 0.12 mmol) were weighed into a 25 mL single-necked vial. DMF (2 mL) and DIEA (38 mg, 0.78 mmol) were then added and allowed to react at room temperature overnight. LCMS monitored the reaction for completion. The reaction solution was purified by prep-HPLC to afford the title compound 35 (6 mg, 0.01 mmol, 9.6% yield). MS Calcd: 622.10; MS Found: 623.11 ([M+H] + ).

[0392] 1 H NMR (400 MHz, DMSO-d6) δ 8.67 (d, J = 2.4 Hz, 1H), 8.01 (dd, J = 8.4, 2.4 Hz, 1H), 7.73–7.65 (m, 2H), 7.61 (d, J = 8.4 Hz, 1H), 7.53 (s, 1H), 7.11 (d, J = 8.4 Hz, 1H), 6.73 (s, 1H), 5.53 (s, 2H), 4.90 (s, 2H), 3.58 (s, 3H), 3.09 (s, 3H), 2.89 (s, 3H). (Amide NH not shown)

[0393] Example 14: Preparation of 2'-chloro-5'-methoxy-1-methyl-6-oxo-N-(5-((4-(trifluoromethyl)benzyl)oxy)-1,3,4-thiadiazol-2-yl)-1,6-dihydro-[3,4'-bipyridine]-4-carboxamide (Compound 36)

[0394] Step 1: Intermediate 5 (50 mg, 0.17 mmol), intermediate 37 (46.7 mg, 0.17 mmol), HATU (97 mg, 0.25 mmol), DIEA (0.09 mL, 0.51 mmol), and DMF (2 mL) were weighed into a 10 mL single-necked vial and reacted overnight at room temperature. LCMS monitored the reaction for completion. The reaction solution was filtered and directly purified by prep-HPLC to obtain the title compound 36 (15 mg, 0.03 mmol, 16.0% yield). MS Calcd: 551.06; MS Found: 552.05 ([M+H] + ).

[0395] 1H NMR(400MHz,DMSO-d6)δ13.02(brs,1H),8.04(d,J=15.1Hz,2H),7.77(d,J=2 1.6Hz,4H),7.50(s,1H),6.77(s,1H),5.62(s,2H),3.58(s,3H),3.53(s,3H).

[0396] Example 15: Preparation of 2'-chloro-N-(5-((4-cyanobenzyl)oxy)-1,3,4-thiadiazol-2-yl)-5'-methoxy-1-methyl-6-oxo-1,6-dihydro-[3,4'-bipyridine]-4-carboxamide (Compound 77)

[0397] Step 1: Intermediate 5 (50 mg, 0.17 mmol), HATU (77.4 mg, 0.20 mmol), and intermediate 38 (47.3 mg, 0.20 mmol) were weighed into a 25 mL single-necked flask. DMF (1 mL) and DIEA (65 mg, 0.51 mmol) were then added and the mixture was allowed to react at room temperature overnight. LCMS monitored the reaction for completion. The reaction solution was purified by prep-HPLC to afford the title compound 77 (20 mg, 0.04 mmol, 23.2% yield). MS Calcd: 508.07; MS Found: 509.08 ([M+H] + ).

[0398] 1 H NMR(400MHz,DMSO-d6)δ13.03(brs,1H)8.05(s,1H),8.00(s,1H),7.92–7.85(m,2H), 7.73–7.65(m,2H),7.48(s,1H),6.77(s,1H),5.60(s,2H),3.58(s,3H),3.53(s,3H).

[0399] Example 16: Preparation of 5-(5-trifluoromethyl-2-methoxyphenyl)-N-(5-(4-cyanobenzyloxy)-1,3,4-thiadiazol-2-yl)-1-methyl-2-oxo-1,2-dihydropyridine-4-carboxamide (Compound 78)

[0400] Step 1: Intermediate 8 (100 mg, 0.31 mmol), HATU (139.4 mg, 0.37 mmol), and intermediate 38 (85.2 mg, 0.37 mmol) were weighed into a 25 mL single-necked flask. DMF (2 mL) and DIEA (118 mg, 0.92 mmol) were then added and the mixture was allowed to react overnight at room temperature. LCMS monitoring confirmed the reaction was complete. The reaction solution was purified by prep-HPLC to yield the title compound 78 (40 mg, 0.07 mmol, 24.2%). MS Calcd: 541.10; MS Found: 542.14 ([M+H] + ).

[0401] 1 H NMR(400MHz,DMSO-d6)δ12.94(brs,1H),7.96–7.82(m,3H),7.73–7.62(m,4H ),7.10(d,J=8.4Hz,1H),6.72(s,1H),5.59(s,2H),3.56(s,3H),3.53(s,3H).

[0402] Example 17: Preparation of 5-(5-chloro-2-methoxyphenyl)-N-(5-((4-cyanobenzyl)oxy)-1,3,4-thiadiazol-2-yl)-1-methyl-2-oxo-1,2-dihydropyridine-4-carboxamide (Compound 79)

[0403] Step 1: Intermediate 9 (50 mg, 0.17 mmol), HATU (77.4 mg, 0.20 mmol), and intermediate 38 (47.3 mg, 0.20 mmol) were weighed into a 25 mL single-necked vial. DMF (1 mL) and DIEA (65 mg, 0.51 mmol) were then added and allowed to react at room temperature overnight. LCMS monitored the reaction for completion. The reaction solution was purified by prep-HPLC to yield the title compound 79 (15 mg, 0.03 mmol, 17.3%). MS Calcd: 507.08; MS Found: 508.10 ([M+H] + ).

[0404] 1 H NMR (400MHz, DMSO-d6) δ12.89(brs,1H),7.91(d,J=8.4Hz,2H),7.85(s,1H),7.70(d,J=8.4Hz,2H ),7.39–7.32(m,2H),6.93(d,J=8.7Hz,1H),6.70(s,1H),5.59(s,2H),3.52(s,3H),3.48(s,3H).

[0405] Example 18: Preparation of 5-(5-chloro-2-methoxyphenyl)-N-(5-(((4-chlorobenzyl)oxy)-1,3,4-thiadiazol-2-yl)-1-methyl-2-oxo-1,2-dihydropyridine-4-carboxamide (Compound 81)

[0406] Step 1: Intermediate 9 (40 mg, 0.14 mmol), intermediate 16 (33 mg, 0.14 mmol), PyBOP (142 mg, 0.27 mmol), DIEA (0.07 mL, 0.41 mmol), and DMF (2 mL) were weighed into a 10 mL single-necked vial and reacted overnight at room temperature. LCMS monitored the reaction for completion. The reaction solution was filtered and directly purified by prep-HPLC to obtain the target compound 81 (13 mg, 0.02 mmol, 18.3% yield). MS Calcd: 516.04; MS Found: 517.02 ([M+H] + ).

[0407] 1 H NMR(400MHz,DMSO-d6)δ12.85(brs,1H),7.85(s,1H),7.52(dd,J=20.0,8.5Hz,4H),7.35(dt, J=8.6,2.6Hz,2H),6.93(d,J=8.7Hz,1H),6.69(s,1H),5.48(s,2H),3.52(s,3H),3.47(s,3H).

[0408] Example 19: Preparation of N-(5-((4-chlorobenzyl)oxy)-1,3,4-thiadiazol-2-yl)-5-(2-methoxy-5-(trifluoromethyl)phenyl)-1-methyl-2-oxo-1,2-dihydropyridine-4-carboxamide (Compound 82)

[0409] Step 1: Intermediate 8 (50 mg, 0.15 mmol), intermediate 16 (37 mg, 0.15 mmol), HATU (87 mg, 0.23 mmol), DIEA (0.08 mL, 0.46 mmol), and DMF (2 mL) were weighed into a 10 mL single-necked vial and reacted overnight at room temperature. LCMS monitored the reaction for completion. The reaction solution was filtered and directly purified by prep-HPLC to obtain the title compound 82 (10 mg, 0.02 mmol, 11.8% yield). MS Calcd: 550.07; MS Found: 551.10 ([M+H] + ).

[0410] 1H NMR (400MHz, DMSO-d6) δ12.56(brs,1H),7.86(s,1H),7.66(d,J=13.8Hz,2H),7.51(d,J= 10.7Hz,4H),7.09(d,J=8.3Hz,1H),6.72(s,1H),5.47(s,2H),3.56(s,3H),3.53(s,3H).

[0411] Example 20: Preparation of N-(5-((4-chlorobenzyl)oxy)-1,3,4-thiadiazol-2-yl)-2'-(difluoromethyl)-5'-methoxy-1-methyl-6-oxo-1,6-dihydro-[3,4'-bipyridine]-4-carboxamide (Compound 103)

[0412] Step 1: Intermediate 39 (100 mg, 0.32 mmol), HATU (147.0 mg, 0.39 mmol), and intermediate 16 (92.8 mg, 0.38 mmol) were weighed into a 25 mL single-necked flask. DMF (2 mL) and DIEA (124.0 mg, 0.96 mmol) were then added and the mixture was allowed to react at room temperature overnight. LCMS monitored the reaction for completion. The reaction mixture was purified by prep-HPLC to afford the title compound 103 (45 mg, 0.08 mmol, 26.3% yield). MS Calcd: 534.07; MS Found: 535.28 ([M+H] + ).

[0413] 1 H NMR (400MHz, DMSO-d6) δ13.04(s,1H),8.67(d,J=2.4Hz,1H),8.35(s,1H),8.06–7.96(m,2H),7.67(s,1 H),7.62(d,J=8.4Hz,1H),6.95(t,J=55.2Hz,1H),6.78(s,1H),5.56(s,2H),3.66(s,3H),3.54(s,3H).

[0414] Example 21: Preparation of 2'-chloro-5'-methoxy-1-methyl-N-(5-((4-methylbenzyl)oxy)-1,3,4-thiadiazol-2-yl)-6-oxo-1,6-dihydro-[3,4'-bipyridine]-4-carboxamide (Compound 104)

[0415] Step 1: Intermediate 40 (50 mg, 0.23 mmol), intermediate 5 (66.6 mg, 0.23 mmol), and PyBOP (352.7 mg, 0.68 mmol) were weighed into a 25 mL single-necked flask. DMF (1 mL) and DIEA (0.11 mL, 0.68 mmol) were added and reacted at room temperature for 2 hours. LCMS monitored the reaction for completion. The reaction solution was purified by prep-HPLC to obtain the target compound 104 (26 mg, 0.05 mmol, 22.2% yield). MS Calcd: 497.09; MS Found: 498.30 ([M+H] + ).

[0416] 1 H NMR (400MHz, DMSO-d6) δ12.96(s,1H),8.03(s,1H),7.99(s,1H),7.47(s,1H),7.37(d,J=8.0Hz ,2H),7.22(d,J=7.8Hz,2H),6.75(s,1H),5.42(s,2H),3.56(s,3H),3.51(s,3H),2.32(s,3H).

[0417] Example 22: Preparation of 5-(5-chloro-2-methoxyphenyl)-N-(5-(((5-fluoropyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-yl)-1-methyl-2-oxo-1,2-dihydropyridine-4-carboxamide (Compound 85)

[0418] Step 1: Intermediate 41 (40 mg, 0.17 mmol), intermediate 9 (62.3 mg, 0.20 mmol), and PyBOP (262.3 mg, 0.50 mmol) were weighed into a 25 mL single-necked flask. DMF (1.5 mL) and DIEA (0.08 mL, 0.50 mmol) were added and reacted at room temperature for 2 hours. LCMS monitored the reaction for completion. The reaction solution was purified by prep-HPLC to afford the target compound 85 (30 mg, 0.06 mmol, 34.9% yield). MS Calcd: 501.07; MS Found: 502.13 ([M+H] + ).

[0419] 1H NMR (400 MHz, DMSO-d6) δ 8.59 (d, J = 2.9 Hz, 1H), 7.82–7.75 (m, 2H), 7.64 (dd, J = 8.7, 4.6 Hz, 1H), 7.34–7.29 (m, 2H), 6.90 (d, J = 8.5 Hz, 1H), 6.67 (s, 1H), 5.50 (s, 2H), 3.50 (s, 3H), 3.46 (s, 3H) (amide NH not shown)

[0420] Example 23: Preparation of 5-(5-chloro-2-methoxyphenyl)-1-methyl-2-oxo-N-(5-(trifluoromethyl)pyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-yl)-1,2-dihydropyridine-4-carboxamide (Compound 89)

[0421] Step 1: Intermediate 42 (50 mg, 0.18 mmol), intermediate 9 (53.2 mg, 0.18 mmol), and PyBOP (281.0 mg, 0.54 mmol) were weighed into a 25 mL single-necked flask. DMF (1.5 mL) and DIEA (0.09 mL, 0.54 mmol) were added and reacted at room temperature for 2 hours. LCMS monitored the reaction for completion. The reaction mixture was purified by prep-HPLC to obtain the target compound 89 (22 mg, 0.04 mmol, 21.0% yield). MS Calcd: 551.06; MS Found: 552.00 ([M+H] + ).

[0422] 1 H NMR (400MHz, DMSO-d6) δ12.96(brs,1H),8.98(s,1H),8.27(dd,J=8.3,2.4Hz,1H),7.80(s,1H),7.76(d,J= 8.2Hz,1H),7.35-7.29(m,2H),6.91(d,J=8.6Hz,1H),6.67(s,1H),5.64(s,2H),3.50(s,3H),3.49(s,3H).

[0423] Example 24: Preparation of N-(5-((5-fluoropyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-yl)-5-(2-methoxy-5-methylphenyl)-1-methyl-2-oxo-1,2-dihydropyridine-4-carboxamide (Compound 88)

[0424] Step 1: Intermediate 41 (40 mg, 0.17 mmol), intermediate 11 (55.1 mg, 0.20 mmol), and PyBOP (262.3 mg, 0.50 mmol) were weighed into a 25 mL single-necked flask. DMF (1.5 mL) and DIEA (0.08 mL, 0.50 mmol) were added and reacted at room temperature for 2 hours. LCMS monitored the reaction for completion. The reaction solution was purified by prep-HPLC to obtain the target compound 88 (40 mg, 0.08 mmol, 48.5% yield). MS Calcd: 481.12; MS Found: 481.97 ([M+H] + ).

[0425] 1 H NMR (400 MHz, DMSO-d6) δ 8.59 (d, J = 2.9 Hz, 1H), 7.79 (td, J = 8.8, 3.0 Hz, 1H), 7.71 (s, 1H), 7.64 (dd, J = 8.7, 4.5 Hz, 1H), 7.08 (s, 1H), 7.06 (s, 1H), 6.76 (d, J = 8.0 Hz, 1H), 6.64 (s, 1H), 5.51 (s, 2H), 3.50 (s, 3H), 3.42 (s, 3H), 2.27 (s, 3H) (amide NH not shown).

[0426] Example 25: Preparation of 5-(5-chloro-2-methoxyphenyl)-N-(5-(((5-chloropyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-yl)-1-(2-(dimethylamino)-2-oxoethyl)-2-oxo-1,2-dihydropyridine-4-carboxamide (Compound 105)

[0427] Step 1: Intermediate 43 (50 mg, 0.14 mmol) was weighed into a 25 mL single-necked flask. HATU (78.2 mg, 0.21 mmol) and DMF (1 mL) were added, followed by DIEA (0.07 mL, 0.41 mmol) and stirred for 5 minutes. Finally, Intermediate 1 (33.3 mg, 0.14 mmol) was added and allowed to react at room temperature for 1 hour. LCMS monitored the reaction for completion. 5 mL of aqueous ammonium chloride was added to the reaction solution, and the mixture was extracted with DCM (10 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, and the residue was purified by prep-HPLC to obtain the target compound 105 (5 mg, 0.01 mmol, 6.1% yield). MS Calcd: 588.07; MS Found: 589.12 ([M+H] + ).

[0428] 1H NMR (400MHz, DMSO-d6) δ12.94(s,1H),8.66(s,1H),8.01(d,J=8.3Hz,1H),7.71(s,1H),7.61(d,J=8.4Hz,1H),7.35(d,J=8. 5Hz,1H),7.27(s,1H),6.94(d,J=8.7Hz,1H),6.71(s,1H),5.55(s,2H),4.88(s,2H),3.49(s,3H),3.07(s,3H),2.88(s,3H).

[0429] Example 26: Preparation of N-(5-(((5-chloropyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-yl)-5-(2-(difluoromethoxy]-5-methylphenyl)-1-methyl-2-oxo-1,2-dihydropyridine-4-carboxamide (Compound 95)

[0430] Step 1: Intermediate 44 (50 mg, 0.16 mmol) was weighed into a 25 mL single-necked flask. HATU (92.2 mg, 0.24 mmol) and DMF (1 mL) were added, followed by DIEA (0.08 mL, 0.48 mmol) and stirring for 5 minutes. Finally, Intermediate 1 (39.2 mg, 0.16 mmol) was added and allowed to react at room temperature for 1 hour. LCMS monitored the reaction for completion. 5 mL of aqueous ammonium chloride was added to the reaction solution, and the mixture was extracted with DCM (10 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, and the residue was purified by prep-HPLC to obtain the target compound 95 (29 mg, 0.05 mmol, 32.8% yield). MS Calcd: 533.07; MS Found: 534.05 ([M+H] + ).

[0431] 1 H NMR (400MHz, DMSO-d6) δ12.97(s,1H),8.66(d,J=2.3Hz,1H),8.01(dd,J=8.4,2.5Hz,1H),7.83(s,1H),7.61(d,J=8.4Hz, 1H),7.25–7.16(m,2H),7.00(d,J=8.2Hz,1H),6.92(t,J=80Hz,1H),6.78(s,1H),5.56(s,2H),3.53(s,3H),2.33(s,3H).

[0432] Example 27: Preparation of 5-(2-methoxy-5-methylphenyl)-1-methyl-2-oxo-N-(5-((4-(trifluoromethyl)benzyl)oxy)-1,3,4-thiadiazol-2-yl)-1,2-dihydropyridine-4-carboxamide (Compound 108)

[0433] Step 1: Intermediate 11 (50 mg, 0.18 mmol) was weighed into a 25 mL single-necked flask. HATU (104.3 mg, 0.27 mmol) and DMF (1 mL) were added, followed by DIEA (0.09 mL, 0.55 mmol) and stirring for 5 minutes. Finally, intermediate 37 (50.3 mg, 0.18 mmol) was added and allowed to react at room temperature for 1 hour. LCMS monitored the reaction for completion. 5 mL of aqueous ammonium chloride was added to the reaction solution, and the mixture was extracted with DCM (10 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, and the residue was purified by prep-HPLC to obtain the target compound 108 (25 mg, 0.05 mmol, 25.7% yield). MS Calcd: 530.12; MS Found: 531.11 ([M+H] + ).

[0434] 1 H NMR (400MHz, DMSO-d6) δ12.83(s,1H),7.80(d,J=8.2Hz,2H),7.76(s,1H),7.72(d,J=8.2Hz,2H),7.09(d,J=9.9Hz,2H),6.78(d,J=8.1Hz,1H),6.66 (s,1H),5.60(s,2H),3.52(s,3H),3.43(s,3H),2.29(s,3H).

[0435] Example 28: Preparation of 2'-chloro-5'-methoxy-1-methyl-6-oxo-N-(5-(trifluoromethyl)pyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-yl)-1,6-dihydro-[3,4'-bipyridine]-4-carboxamide (Compound 84)

[0436] Step 1: Intermediate 42 (50 mg, 0.18 mmol), intermediate 5 (53.2 mg, 0.18 mmol), and PyBOP (281.0 mg, 0.54 mmol) were weighed into a 25 mL single-necked flask. DMF (1.5 mL) and DIEA (0.09 mL, 0.54 mmol) were added and reacted at room temperature for 2 hours. LCMS monitored the reaction for completion. The reaction solution was purified by prep-HPLC to afford the target compound 84 (30 mg, 0.05 mmol, 29.3% yield). MS Calcd: 552.06; MS Found: 552.94 ([M+H] + ).

[0437] 1 H NMR (400 MHz, DMSO-d6) δ 8.97 (s, 1H), 8.26 (dd, J = 8.3, 2.4 Hz, 1H), 8.02 (s, 1H), 7.95 (s, 1H), 7.75 (d, J = 8.2 Hz, 1H), 7.45 (s, 1H), 6.74 (s, 1H), 5.64 (s, 2H), 3.50 (s, 3H), 3.49 (s, 3H) (amide NH not shown)

[0438] Example 29: Preparation of 2'-chloro-N-(5-((5-fluoropyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-yl)-5'-methoxy-1-methyl-6-oxo-1,6-dihydro-[3,4'-bipyridine]-4-carboxamide (Compound 83)

[0439] Step 1: Intermediate 41 (24 mg, 0.11 mmol), intermediate 5 (31.3 mg, 0.11 mmol), and PyBOP (165.6 mg, 0.32 mmol) were weighed into a 25 mL single-necked flask. DMF (1 mL) and DIEA (0.05 mL, 0.32 mmol) were added and the mixture was allowed to react overnight at room temperature. LCMS monitored the reaction for completion. The reaction mixture was purified by prep-HPLC to afford the target compound 83 (27 mg, 0.05 mmol, 49.6% yield). MS Calcd: 502.06; MS Found: 503.10 ([M+H] + ).

[0440] 1H NMR (400MHz, DMSO-d6) δ12.96(brs,1H),8.59(d,J=2.9Hz,1H),8.02(s,1H),7.92(s,1H),7.79(td,J=8.7, 3.0Hz,1H),7.64(dd,J=8.7,4.5Hz,1H),7.43(s,1H),6.74(s,1H),5.50(s,2H),3.56(s,3H),3.50(s,3H).

[0441] Example 30: Preparation of N-(5-((5-chloropyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-yl)-2'-(difluoromethyl)-5'-methoxy-1-methyl-6-oxo-1,6-dihydro-[3,4'-bipyridine]-4-carboxamide (Compound 80)

[0442] Step 1: Intermediate 45 (50 mg, 0.16 mmol), HATU (73 mg, 0.20 mmol), and Intermediate 1 (46 mg, 0.19 mmol) were weighed into a 25 mL single-necked vial. DMF (2 mL) and DIEA (62 mg, 0.48 mmol) were then added and allowed to react at room temperature overnight. LCMS monitored the reaction for completion. The reaction solution was purified by prep-HPLC to afford the title compound 80 (30 mg, 0.06 mmol, 34.4% yield). MS Calcd: 534.07; MS Found: 535.07 ([M+H] + ).

[0443] 1 H NMR (400MHz, DMSO-d6) δ13.04(s,1H),8.66(d,J=2.4Hz,1H),8.34(s,1H),8.03–7.97(m,2H),7.67(s,1 H),7.61(d,J=8.4Hz,1H),6.95(t,J=55.2Hz,1H),6.78(s,1H),5.55(s,2H),3.65(s,3H),3.54(s,3H).

[0444] Example 31: Preparation of 5-(5-fluoro-2-methoxyphenyl)-1-methyl-2-oxo-N-(5-(trifluoromethyl)pyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-yl)-1,2-dihydropyridine-4-carboxamide (Compound 90)

[0445] Step 1: Intermediate 42 (49.8 mg, 0.18 mmol), intermediate 6 (50 mg, 0.18 mmol), and PyBOP (281.5 mg, 0.54 mmol) were weighed into a 25 mL single-necked flask. DMF (1.5 mL) and DIEA (0.09 mL, 0.54 mmol) were added and the mixture was allowed to react overnight at room temperature. LCMS analysis revealed a small amount of product. The reaction mixture was purified by prep-HPLC to afford the target compound 90 (5 mg, 0.01 mmol, 4.8% yield). MS Calcd: 535.09; MS Found: 536.10 ([M+H] + ).

[0446] 1 H NMR (400 MHz, DMSO-d6) δ 8.98 (d, J = 2.2 Hz, 1H), 8.27 (dd, J = 8.3, 2.4 Hz, 1H), 7.79–7.72 (m, 2H), 7.17–7.05 (m, 2H), 6.88 (dd, J = 9.0, 4.6 Hz, 1H), 6.67 (s, 1H), 5.63 (s, 2H), 3.49 (s, 3H), 3.45 (s, 3H) (amide NH not shown).

[0447] Example 32: Preparation of 2'-(difluoromethyl)-5'-methoxy-1-methyl-6-oxo-N-(5-((4-(trifluoromethyl)benzyl)oxy)-1,3,4-thiadiazol-2-yl)-1,6-dihydro-[3,4'-bipyridine]-4-carboxamide (Compound 109)

[0448] Step 1: Intermediate 45 (50 mg, 0.16 mmol), HATU (91 mg, 0.24 mmol), and intermediate 37 (52 mg, 0.24 mmol) were weighed into a 25 mL single-necked vial. DMF (2 mL) and DIEA (62 mg, 0.48 mmol) were then added and allowed to react at room temperature overnight. LCMS monitored the reaction for completion. The reaction solution was purified by prep-HPLC to afford the title compound 109 (20 mg, 0.03 mmol, 21.8% yield). MS Calcd: 567.10; MS Found: 568.07 ([M+H] + ).

[0449] 1H NMR (400MHz, DMSO-d6) δ13.02(s,1H),8.34(s,1H),7.99(s,1H),7.80(d,J=8.0Hz,2H),7.72(d,J=8.0Hz,2H),7.66(s,1H),6.94(t,J=55.2Hz,1H), 6.77(s,1H),5.60(s,2H),3.65(s,3H),3.54(s,3H).

[0450] Example 33: Preparation of 5-(2-methoxy-5-methylphenyl)-1-methyl-2-oxo-N-(5-((5-(trifluoromethyl)pyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-yl)-1,2-dihydropyridine-4-carboxamide (Compound 91)

[0451] Step 1: Intermediate 11 (35 mg, 0.13 mmol), HATU (73 mg, 0.19 mmol), and intermediate 42 (42 mg, 0.15 mmol) were weighed into a 25 mL single-necked flask. DMF (2 mL) and DIEA (9 mg, 0.38 mmol) were then added and the mixture was allowed to react at room temperature overnight. LCMS monitored the reaction for completion. The reaction solution was purified by prep-HPLC to afford the title compound 91 (15 mg, 0.03 mmol, 21.9% yield). MS Calcd: 531.12; MS Found: 532.10 ([M+H] + ).

[0452] 1 H NMR (400MHz, DMSO-d6) δ12.84(s,1H),9.00(s,1H),8.29(dd,J=8.4,2.4Hz,1H),7.81–7.71(m,2H),7.09( d,J=8.4Hz,2H),6.78(d,J=8.0Hz,1H),6.65(s,1H),5.66(s,2H),3.52(s,3H),3.44(s,3H),2.29(s,3H).

[0453] Example 34: Preparation of 2'-chloro-5'-methoxy-1-methyl-N-(5-((5-methylpyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-yl)-6-oxo-1,6-dihydro-[3,4'-bipyridine]-4-carboxamide (Compound 110)

[0454] Step 1: Intermediate 47 (40.8 mg, 0.18 mmol), intermediate 5 (53 mg, 0.18 mmol), and PyBOP (280.9 mg, 0.54 mmol) were weighed into a 25 mL single-necked flask. DMF (1.5 mL) and DIEA (0.09 mL, 0.54 mmol) were added and the mixture was allowed to react overnight at room temperature. LCMS analysis indicated the presence of product. The reaction mixture was purified by prep-HPLC to afford the target compound 110 (36 mg, 0.06 mmol, 36.1% yield). MS Calcd: 498.09; MS Found: 499.06 ([M+H] + ).

[0455] 1 H NMR (400MHz, DMSO-d6) δ12.97(brs,1H),8.42(d,J=2.2Hz,1H),8.03(s,1H),7.97(s,1H),7.66(dd,J=8.0,2. 2Hz,1H),7.46(s,1H),7.44(d,J=8Hz,1H),6.75(s,1H),5.47(s,2H),3.56(s,3H),3.50(s,3H),2.31(s,3H).

[0456] Example 35: Preparation of N-(5-((6-chloropyridin-3-yl)methoxy)-1,3,4-thiadiazol-2-yl)-5-(4-fluoro-2-methoxy-5-methylphenyl)-1-methyl-2-oxo-1,2-dihydropyridine-4-carboxamide (Compound 94)

[0457] Step 1: Intermediate 48 (100 mg, 0.34 mmol), HATU (195 mg, 0.51 mmol), and Intermediate 1 (100 mg, 0.41 mmol) were weighed into a 25 mL single-necked vial. DMF (2 mL) and DIEA (133 mg, 1.03 mmol) were then added and allowed to react at room temperature overnight. LCMS monitored the reaction for completion. The reaction solution was purified by prep-HPLC to afford the title compound 94 (20 mg, 0.04 mmol, 10.8% yield). MS Calcd: 515.08; MS Found: 516.05 ([M+H] + ).

[0458] 1H NMR (400MHz, DMSO-d6) δ12.86(s,1H),8.67(d,J=2.4Hz,1H),8.02(dd,J=8.4,2.4Hz,1H),7.75(s,1H),7.62(d,J=8.4H z,1H),7.20(d,J=8.8Hz,1H),6.78(d,J=11.6Hz,1H),6.67(s,1H),5.55(s,2H),3.52(s,3H),3.46(s,3H),2.21(s,3H).

[0459] Example 36: Preparation of 5-(2-(difluoromethoxy)-5-methylphenyl)-1-methyl-2-oxo-N-(5-(trifluoromethyl)pyridin-2-yl)methoxy-1,3,4-thiadiazol-2-yl)-1,2-dihydropyridine-4-carboxamide (Compound 111)

[0460] Step 1: Intermediate 42 (44.6 mg, 0.16 mmol), intermediate 44 (50 mg, 0.16 mmol), and PyBOP (252.4 mg, 0.48 mmol) were weighed into a 25 mL single-necked flask. DMF (1.5 mL) and DIEA (0.08 mL, 0.48 mmol) were added and reacted at room temperature for 2 hours. LCMS monitoring indicated product formation. The reaction solution was purified by prep-HPLC to obtain the target compound 111 (21 mg, 0.04 mmol, 22.4% yield). MS Calcd: 567.10; MS Found: 568.10 ([M+H] + ).

[0461] 1 H NMR (400MHz, DMSO-d6) δ12.97(brs,1H),8.99(s,1H),8.27(dd,J=8.5,2.4Hz,1H),7.81(s,1H),7.76(d,J=8.2Hz,1H) ,7.22–7.15(m,2H),6.98(d,J=8.2Hz,1H),6.90(t,J=76Hz,1H),6.76(s,1H),5.65(s,2H),3.51(s,3H),2.31(s,3H).

[0462] Example 37: Preparation of 5-(5-chloro-2-methoxyphenyl)-1-methyl-N-(5-((5-methylpyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-yl)-2-oxo-1,2-dihydropyridine-4-carboxamide (Compound 112)

[0463] Step 1: Intermediate 47 (37.8 mg, 0.17 mmol), intermediate 9 (50 mg, 0.17 mmol), and PyBOP (265.8 mg, 0.51 mmol) were weighed into a 25 mL single-necked flask. DMF (1.5 mL) and DIEA (0.08 mL, 0.51 mmol) were added and the mixture was allowed to react overnight at room temperature. LCMS analysis indicated the presence of product. The reaction mixture was purified by prep-HPLC to afford the target compound 112 (33 mg, 0.06 mmol, 35.0% yield). MS Calcd: 497.09; MS Found: 498.10 ([M+H] + ).

[0464] 1 H NMR (400MHz, DMSO-d6) δ12.84(s,1H),8.42(s,1H),7.83(s,1H),7.66(dd,J=7.9,2.3Hz,1H),7.43(d,J=7.9Hz,1H),7.36–7.29(m,2H),6.91(d,J=8.7 Hz,1H),6.67(s,1H),5.47(s,2H),3.50(s,3H),3.46(s,3H),2.31(s,3H).

[0465] Example 38: Preparation of 5-(2-methoxy-5-methylphenyl)-1-methyl-N-(5-((6-methylpyridin-3-yl)methoxy)-1,3,4-thiadiazol-2-yl)-2-oxo-1,2-dihydropyridine-4-carboxamide (Compound 113)

[0466] Step 1: Intermediate 5 (50 mg, 0.17 mmol) was weighed into a 25 mL single-necked flask. HATU (96.8 mg, 0.25 mmol) and DMF (1 mL) were added, followed by DIEA (0.08 mL, 0.51 mmol) and stirring for 5 minutes. Finally, Intermediate 49 (37.7 mg, 0.17 mmol) was added and allowed to react at room temperature for 1 hour. LCMS monitored the reaction for completion. 5 mL of aqueous ammonium chloride was added to the reaction solution, and the mixture was extracted with DCM (10 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, and the residue was purified by prep-HPLC to obtain the target compound 113 (formate salt) (12 mg, 0.02 mmol, 12.6% yield). MS Calcd: 498.09; MS Found: 499.10 ([M+H] + ).

[0467] 1H NMR (400 MHz, DMSO-d6) δ 8.57 (s, 1H), 8.27 (s, 1H), 8.02 (s, 1H), 7.89 (s, 1H), 7.81 (d, J = 6.7 Hz, 1H), 7.41 (s, 1H), 7.30 (d, J = 7.2 Hz, 1H), 6.75 (s, 1H), 5.43 (s, 2H), 3.56 (s, 3H), 3.51 (s, 3H), 2.48 (s, 3H) (amide NH not shown).

[0468] Example 39: Preparation of N-(5-((5-cyanopyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-yl)-5-(5-(difluoromethyl)-2-methoxyphenyl)-1-methyl-2-oxo-1,2-dihydropyridine-4-carboxamide (Compound 114)

[0469] Step 1: Intermediate 34 (30 mg, 0.10 mmol) was weighed into a 25 mL single-necked flask. HATU (55.3 mg, 0.15 mmol) and DMF (1 mL) were added, followed by DIEA (0.05 mL, 0.29 mmol) and stirring for 5 minutes. Finally, Intermediate 50 (27.1 mg, 0.12 mmol) was added and allowed to react at room temperature for 1 hour. LCMS monitored the reaction for completion. 5 mL of aqueous ammonium chloride was added to the reaction solution, and the mixture was extracted with DCM (10 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, and the residue was purified by prep-HPLC to obtain the target compound 114 (19 mg, 0.04 mmol, 37.0% yield). MS Calcd: 524.11; MS Found: 525.11 ([M+H] + ).

[0470] 1 H NMR (400MHz, DMSO-d6) δ12.95(s,1H),9.06(d,J=1.4Hz,1H),8.40(dd,J=8.2,2.0Hz,1H),7.84(s,1H), 7.76(d,J=8.3Hz,1H),7.53(d,J=8.5Hz,2H),7.18–6.86(m,2H),6.72(s,1H),5.66(s,2H),3.54(s,6H).

[0471] Example 40: Preparation of 2'-chloro-N-(5-((5-cyanopyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-yl)-5'-methoxy-1-methyl-6-oxo-1,6-dihydro-[3,4'-bipyridine]-4-carboxamide (Compound 115)

[0472] Step 1: Intermediate 50 (40.8 mg, 0.17 mmol), intermediate 5 (55.6 mg, 0.19 mmol), and PyBOP (267.8 mg, 0.51 mmol) were weighed into a 25 mL single-necked flask. DMF (1.5 mL) and DIEA (0.09 mL, 0.51 mmol) were added and the mixture was allowed to react overnight at room temperature. LCMS analysis indicated the presence of product. The reaction mixture was purified by prep-HPLC to afford the target compound 115 (40 mg, 0.08 mmol, 44.3% yield). MS Calcd: 509.07; MS Found: 510.00 ([M+H] + ).

[0473] 1 H NMR (400 MHz, DMSO-d6) δ 9.03 (d, J = 2.1 Hz, 1H), 8.35 (dd, J = 8.3, 2.1 Hz, 1H), 8.02 (s, 1H), 7.92 (s, 1H), 7.71 (d, J = 8.2 Hz, 1H), 7.43 (s, 1H), 6.74 (s, 1H), 5.61 (s, 2H), 3.56 (s, 3H), 3.49 (s, 3H) (amide NH not shown).

[0474] Example 41: Preparation of 5-(2-methoxy-5-methylphenyl)-1-methyl-N-(5-((5-methylpyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-yl)-2-oxo-1,2-dihydropyridine-4-carboxamide (Compound 116)

[0475] Step 1: Intermediate 47 (40.7 mg, 0.18 mmol), intermediate 11 (50 mg, 0.18 mmol), and PyBOP (285.6 mg, 0.55 mmol) were weighed into a 25 mL single-necked flask. DMF (1 mL) and DIEA (0.09 mL, 0.54 mmol) were added and reacted at room temperature for 2 hours. LCMS analysis revealed the presence of product. The reaction mixture was purified by prep-HPLC to afford the target compound 116 (22 mg, 0.05 mmol, 24.7% yield). MS Calcd: 477.15; MS Found: 478.05 ([M+H] + ).

[0476] 1H NMR (400MHz, DMSO-d6) δ12.84(s,1H),8.42(s,1H),7.74(s,1H),7.66(ddd,J=7.9,2.3,0.9Hz,1H),7.44(d,J=7.6Hz,1H) ,7.11–7.05(m,2H),6.77(d,J=8.1Hz,1H),6.64(s,1H),5.47(s,2H),3.50(s,3H),3.42(s,3H),2.31(s,3H),2.28(s,3H).

[0477] Example 42: Preparation of 5-(5-(difluoromethyl)-2-methoxyphenyl)-1-methyl-2-oxo-N-(5-(trifluoromethyl)pyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-yl)-1,2-dihydropyridine-4-carboxamide (Compound 117)

[0478] Step 1: Intermediate 42 (26.8 mg, 0.10 mmol), intermediate 34 (30 mg, 0.10 mmol), and PyBOP (151.4 mg, 0.29 mmol) were weighed into a 25 mL single-necked flask. DMF (1 mL) and DIEA (0.05 mL, 0.29 mmol) were added and reacted at room temperature for 2 hours. LCMS analysis revealed the presence of product. The reaction mixture was purified by prep-HPLC to afford the target compound 117 (14 mg, 0.02 mmol, 24.7% yield). MS Calcd: 567.10; MS Found: 568.28 ([M+H] + ).

[0479] 1 H NMR (400MHz, DMSO-d6) δ12.93 (s, 1H), 8.99 (s, 1H), 8.28 (dd, J = 8.5, 2.4Hz,1H),7.82(s,1H),7.76(d,J=8.2Hz,1H),7.53-7.47(m,2H),7.02(d ,J=8Hz,1H),6.99(t,J=56Hz,1H),6.69(s,1H),5.66(s,2H),3.52(s,6H).

[0480] Example 43: Preparation of N-(5-((5-cyanopyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-yl)-5-(2-methoxy-5-methylphenyl)-1-methyl-2-oxo-1,2-dihydropyridine-4-carboxamide (Compound 118)

[0481] Step 1: Intermediate 11 (50 mg, 0.18 mmol) was weighed into a 25 mL single-necked flask. HATU (104.3 mg, 0.27 mmol) and DMF (1 mL) were added, followed by DIEA (0.09 mL, 0.55 mmol) and stirring for 5 minutes. Finally, Intermediate 50 (51.2 mg, 0.22 mmol) was added and allowed to react at room temperature for 1 hour. LCMS monitored the reaction for completion. 5 mL of aqueous ammonium chloride was added to the reaction solution, and the mixture was extracted with DCM (10 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, and the residue was purified by prep-HPLC to obtain the target compound 118 (18 mg, 0.04 mmol, 20.0% yield). MS Calcd: 488.13; MS Found: 489.14 ([M+H] + ).

[0482] 1 H NMR (400MHz, DMSO-d6) δ12.85(s,1H),9.06(s,1H),8.39(dd,J=8.2,2.0Hz,1H),7.81–7.70(m,2H),7.10( d,J=8.6Hz,2H),6.79(d,J=8.0Hz,1H),6.66(s,1H),5.65(s,2H),3.52(s,3H),3.44(s,3H),2.30(s,3H).

[0483] Example 44: Preparation of 5-(5-chloro-2-methoxyphenyl)-N-(5-((5-cyanopyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-yl)-1-methyl-2-oxo-1,2-dihydropyridine-4-carboxamide (Compound 119)

[0484] Step 1: Intermediate 9 (50 mg, 0.17 mmol) was weighed into a 25 mL single-necked flask. HATU (97.0 mg, 0.26 mmol) and DMF (1 mL) were added, followed by DIEA (0.08 mL, 0.51 mmol) and stirring for 5 minutes. Finally, Intermediate 50 (47.6 mg, 0.20 mmol) was added and allowed to react at room temperature for 1 hour. LCMS monitored the reaction for completion. 5 mL of aqueous ammonium chloride was added to the reaction solution, and the mixture was extracted with DCM (10 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, and the residue was purified by prep-HPLC to obtain the target compound 119 (38 mg, 0.07 mmol, 43.4% yield). MS Calcd: 508.07; MS Found: 509.06 ([M+H] + ).

[0485] 1H NMR (400MHz, DMSO-d6) δ12.89(s,1H),9.05(d,J=1.4Hz,1H),8.38(dd,J=8.2,2.1Hz,1H),7.82(s,1H),7.74(d ,J=8.2Hz,1H),7.38–7.29(m,2H),6.92(d,J=8.6Hz,1H),6.69(s,1H),5.64(s,2H),3.51(s,3H),3.47(s,3H).

[0486] Example 45: Preparation of 5-(2-methoxy-5-methylphenyl)-1-methyl-N-(5-((6-methylpyridin-3-yl)methoxy)-1,3,4-thiadiazol-2-yl)-2-oxo-1,2-dihydropyridine-4-carboxamide (Compound 120)

[0487] Step 1: Intermediate 11 (50 mg, 0.18 mmol) was weighed into a 25 mL single-necked flask. HATU (104.3 mg, 0.27 mmol) and DMF (1 mL) were added, followed by DIEA (0.09 mL, 0.55 mmol) and stirring for 5 minutes. Finally, Intermediate 49 (48.0 mg, 0.22 mmol) was added and allowed to react at room temperature for 1 hour. LCMS monitored the reaction for completion. 5 mL of aqueous ammonium chloride was added to the reaction solution, and the mixture was extracted with DCM (10 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, and the residue was purified by prep-HPLC to obtain the target compound 120 (19 mg, 0.04 mmol, 21.2% yield). MS Calcd: 477.15; MS Found: 478.29 ([M+H] + ).

[0488] 1 H NMR (400MHz, DMSO-d6) δ12.71(s,1H),8.55(d,J=1.9Hz,1H),8.26(s,1H),7.79(dd,J=7.9,2.3Hz,1H),7.68(s,1H),7.29(d,J=7.9H z,1H),7.05(d,J=7.9Hz,2H),6.75(d,J=8.1Hz,1H),6.62(s,1H),5.43(s,2H),3.49(s,3H),3.41(s,3H),2.47(s,3H),2.26(s,3H).

[0489] Example 46: Preparation of N-(5-((4-cyanobenzyl)oxy)-1,3,4-thiadiazol-2-yl)-5-(2-(difluoromethoxy)phenyl)-1-methyl-2-oxo-1,2-dihydropyridine-4-carboxamide (Compound 121)

[0490] Step 1: Intermediate 44 (50 mg, 0.16 mmol), HATU (92 mg, 0.24 mmol), and intermediate 38 (41 mg, 0.18 mmol) were weighed into a 25 mL single-necked vial. DMF (2 mL) and DIEA (62 mg, 0.48 mmol) were then added and allowed to react at room temperature overnight. LCMS monitored the reaction for completion. The reaction solution was purified by prep-HPLC to afford the title compound 121 (15 mg, 0.03 mmol, 16.5% yield). MS Calcd: 523.11; MS Found: 524.09 ([M+H] + ).

[0491] 1 H NMR(400MHz,DMSO-d6)δ12.96(s,1H),7.93–7.86(m,2H),7.81(s,1H),7.72–7.65(m,2H),7.23–7.14(m ,2H),7.00(d,J=8.0Hz,1H),6.92(t,J=76Hz,1H),6.77(s,1H),5.59(s,2H),3.53(s,3H),2.32(s,3H).

[0492] Example 47: Preparation of N-(5-((5-cyanopyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-yl)-5-(2-(difluoromethoxy]-5-methylphenyl)-1-methyl-2-oxo-1,2-dihydropyridine-4-carboxamide (Compound 122)

[0493] Step 1: Intermediate 44 (50 mg, 0.16 mmol), HATU (92 mg, 0.24 mmol), and intermediate 50 (37 mg, 0.16 mmol) were weighed into a 25 mL single-necked vial. DMF (2 mL) and DIEA (62 mg, 0.48 mmol) were then added and allowed to react at room temperature overnight. LCMS monitored the reaction for completion. The reaction solution was purified by prep-HPLC to afford the title compound 122 (20 mg, 0.04 mmol, 23.0% yield). MS Calcd: 524.11; MS Found: 523.09 ([MH] + ).

[0494] 1 H NMR (400MHz, DMSO-d6) δ13.00 (s, 1H), 9.06 (d, J = 0.8Hz, 1H), 8.39 (dd, J=8.4,2.0Hz,1H),7.83(s,1H),7.78–7.67(m,1H),7.25–7.17(m,2H),7.01(d,J=8 .4Hz,1H),6.93(t=76Hz,1H),6.78(s,1H),5.66(s,2H),3.54(s,3H),2.34(s,3H).

[0495] Example 48: Preparation of 2'-chloro-N-(5-((5-chloropyrazin-2-yl)methoxy)-1,3,4-thiadiazol-2-yl)-5'-methoxy-1-methyl-6-oxo-1,6-dihydro-[3,4'-bipyridine]-4-carboxamide (Compound 123)

[0496] Step 1: Intermediate 51 (45 mg, 0.18 mmol), intermediate 5 (70.7 mg, 0.24 mmol), and PyBOP (281.0 mg, 0.54 mmol) were weighed into a 25 mL single-necked flask. DMF (2 mL) and DIEA (0.09 mL, 0.54 mmol) were added and the mixture was allowed to react overnight at room temperature. LCMS analysis revealed the presence of product. The reaction mixture was purified by prep-HPLC to afford the target compound 123 (22 mg, 0.04 mmol, 21.7% yield). MS Calcd: 519.03; MS Found: 519.90 ([M+H] + ).

[0497] 1 H NMR (400MHz, DMSO-d6) δ13.03(s,1H),8.84(s,1H),8.71(s,1H),8.02(d,J=1 6.0Hz,2H),7.48(s,1H),6.76(s,1H),5.64(s,2H),3.57(s,3H),3.51(s,3H).

[0498] Example 49: Preparation of 2'-chloro-5'-methoxy-N-(5-((6-methoxypyridin-3-yl)methoxy)-1,3,4-thiadiazol-2-yl)-1-methyl-6-oxo-1,6-dihydro-[3,4'-bipyridine]-4-carboxamide (Compound 124)

[0499] Step 1: Intermediate 52 (77 mg, 0.33 mmol), HATU (154 mg, 0.41 mmol), and intermediate 5 (80 mg, 0.27 mmol) were weighed into a 25 mL single-necked vial. DMF (2 mL) and DIEA (105 mg, 0.81 mmol) were then added and allowed to react at room temperature overnight. LCMS monitored the reaction for completion. The reaction solution was purified by prep-HPLC to afford the title compound 124 (15 mg, 0.03 mmol, 10.1% yield). MS Calcd: 514.08; MS Found: 515.08 ([M+H] + ).

[0500] 1 H NMR (400MHz, DMSO-d6) δ12.99(s,1H),8.32(d,J=3.2Hz,1H),8.06(s,1H),8.02(s,1H),7.55(d,J=8.4Hz, 1H),7.50(s,1H),7.47(d,J=3.2Hz,1H),6.77(s,1H),5.48(s,2H),3.87(s,3H),3.59(s,3H),3.53(s,3H).

[0501] Example 50: Preparation of 5-(2-methoxy-5-methylphenyl)-1-methyl-N-(5-((6-methylpyridin-3-yl)methoxy)-1,3,4-thiadiazol-2-yl)-2-oxo-1,2-dihydropyridine-4-carboxamide (Compound 125)

[0502] Step 1: Intermediate 5 (50 mg, 0.17 mmol) was weighed into a 25 mL single-necked flask. HATU (96.7 mg, 0.25 mmol) and DMF (1 mL) were added, followed by DIEA (0.08 mL, 0.51 mmol) and stirring for 5 minutes. Finally, Intermediate 53 (43.7 mg, 0.17 mmol) was added and allowed to react at room temperature for 1 hour. LCMS monitored the reaction for completion. 5 mL of aqueous ammonium chloride was added to the reaction solution, and the mixture was extracted with DCM (10 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, and the residue was purified by prep-HPLC to yield the target compound 125 (15 mg, 0.03 mmol, 16.3% yield). MS Calcd: 533.07; MS Found: 534.06 ([M+H] + ).

[0503] 1H NMR(400MHz,DMSO-d6)δ12.98(s,1H),8.01(d,J=16.9Hz,2H),7.67–7.57(m,4H),7.4 7(s,1H),7.05(t,J=55.8Hz,1H),6.75(s,1H),5.55(s,2H),3.56(s,3H),3.51(s,3H).

[0504] Example 51: Preparation of N-(5-((5-cyanopyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-yl)-5-(2-methoxy-5-(trifluoromethyl)phenyl)-1-methyl-2-oxo-1,2-dihydropyridine-4-carboxamide (Compound 126)

[0505] Step 1: Intermediate 50 (40.8 mg, 0.17 mmol), intermediate 8 (66.8 mg, 0.20 mmol), and PyBOP (176.9 mg, 0.34 mmol) were weighed into a 25 mL single-necked flask. DMF (1.5 mL) and DIEA (0.09 mL, 0.51 mmol) were added and the mixture was allowed to react overnight at room temperature. LCMS analysis indicated the presence of product. The reaction mixture was purified by prep-HPLC to afford the target compound 126 (42 mg, 0.08 mmol, 44.2% yield). MS Calcd: 542.10; MS Found: 543.10 ([M+H] + ).

[0506] 1 H NMR (400 MHz, DMSO-d6) δ 9.03 (d, J = 2.1 Hz, 1H), 8.36 (dd, J = 8.2, 2.2 Hz, 1H), 7.82 (s, 1H), 7.72 (d, J = 8.2 Hz, 1H), 7.67–7.58 (m, 2H), 7.08 (d, J = 8.5 Hz, 1H), 6.70 (s, 1H), 5.61 (s, 2H), 3.54 (s, 3H), 3.54 (s, 3H) (amide NH not shown).

[0507] Example 52: Preparation of 5-(2-(difluoromethoxy)-5-methylphenyl)-N-(5-((5-fluoropyridin-2-yl)methoxy]-1,3,4-thiadiazol-2-yl)-1-methyl-2-oxo-1,2-dihydropyridine-4-carboxamide (Compound 127)

[0508] Step 1: Intermediate 41 (21.9 mg, 0.10 mmol), intermediate 44 (30 mg, 0.09 mmol), and PyBOP (151.4 mg, 0.29 mmol) were weighed into a 25 mL single-necked flask. DMF (1 mL) and DIEA (0.05 mL, 0.29 mmol) were added and reacted at room temperature for 2 hours. LCMS analysis indicated the presence of product. The reaction mixture was purified by prep-HPLC to afford the target compound 127 (5 mg, 0.01 mmol, 9.8% yield). MS Calcd: 517.10; MS Found: 517.91 ([M+H] + ).

[0509] 1 H NMR (400MHz, DMSO-d6) δ12.94(s,1H),8.59(d,J=2.9Hz,1H),7.83-7.76(m,2H),7.65(dd,J=8.7,4.5Hz,1H),7.2 1–7.15(m,2H),6.98(d,J=8.2Hz,1H),6.90(t,J=72Hz,1H),6.75(s,1H),5.53(s,2H),3.51(s,3H),2.31(s,3H).

[0510] Example 53: Preparation of 5-(2-methoxy-5-(trifluoromethyl)phenyl)-1-methyl-2-oxo-N-(5-((4-(trifluoromethyl)benzyl)oxy)-1,3,4-thiadiazol-2-yl)-1,2-dihydropyridine-4-carboxamide (Compound 128)

[0511] Step 1: Intermediate 37 (50 mg, 0.18 mmol), intermediate 8 (71.4 mg, 0.22 mmol), and PyBOP (283.6 mg, 0.55 mmol) were weighed into a 25 mL single-necked flask. DMF (1.5 mL) and DIEA (0.09 mL, 0.55 mmol) were added and the mixture was allowed to react overnight at room temperature. LCMS monitoring indicated product formation. The reaction mixture was purified by prep-HPLC to afford the target compound 128 (23 mg, 0.04 mmol, 21.2% yield). MS Calcd: 584.09; MS Found: 585.10 ([M+H] + ).

[0512] 1H NMR (400MHz, DMSO-d6) δ12.92(s,1H),7.87(s,1H),7.78(d,J=8.1Hz,2H),7.71(d,J=8.0Hz,2H) ,7.68–7.62(m,2H),7.08(d,J=8.5Hz,1H),6.71(s,1H),5.59(s,2H),3.54(s,3H),3.52(s,3H).

[0513] Example 54: Preparation of N-(5-((5-chloropyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-yl)-5-(2-(difluoromethoxy-4-fluoro-5-methylphenyl)-1-methyl-2-oxo-1,2-dihydropyridine-4-carboxamide (Compound 129)

[0514] Step 1: Intermediate 54 (35 mg, 0.11 mmol) was weighed into a 25 mL single-necked flask. HATU (63.1 mg, 0.17 mmol) and DMF (1 mL) were added, followed by DIEA (0.05 mL, 0.33 mmol) and stirring for 5 minutes. Finally, Intermediate 1 (32.5 mg, 0.13 mmol) was added and allowed to react at room temperature for 1 hour. LCMS monitored the reaction for completion. 5 mL of aqueous ammonium chloride was added to the reaction solution, and the mixture was extracted with DCM (10 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, and the residue was purified by prep-HPLC to obtain the target compound 129 (7 mg, 0.01 mmol, 11.7% yield). MS Calcd: 551.06; MS Found: 552.12 ([M+H] + ).

[0515] 1 H NMR (400MHz, DMSO-d6) δ12.99(s,1H),8.66(d,J=2.1Hz,1H),8.01(dd,J=8.4,2.3Hz,1H),7.82(s,1H),7.61(d,J=8.4H z,1H),7.34(d,J=8.6Hz,1H),7.02(s,1H),7.00(t,J=82.8Hz,1H),6.78(s,1H),5.55(s,2H),3.52(s,3H),2.25(s,3H).

[0516] Example 55: Preparation of 5-(5-(difluoromethyl)-2-methoxyphenyl)-1-methyl-2-oxo-N-(5-((4-(trifluoromethyl)benzyl)oxy)-1,3,4-thiadiazol-2-yl)-1,2-dihydropyridine-4-carboxamide (Compound 130)

[0517] Step 1: Intermediate 34 (49.5 mg, 0.16 mmol) was weighed into a 25 mL single-necked flask. HATU (90.8 mg, 0.24 mmol) and DMF (1 mL) were added, followed by DIEA (0.08 mL, 0.48 mmol) and stirring for 5 minutes. Finally, intermediate 37 (58.2 mg, 0.21 mmol) was added and allowed to react at room temperature for 1 hour. LCMS monitored the reaction for completion. 5 mL of aqueous ammonium chloride was added to the reaction solution, and the mixture was extracted with DCM (10 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, and the residue was purified by prep-HPLC to obtain the target compound 130 (25 mg, 0.04 mmol, 27.2% yield). MS Calcd: 566.10; MS Found: 567.10 ([M+H] + ).

[0518] 1 H NMR (400MHz, DMSO-d6) δ12.89(s,1H),7.82(s,1H),7.78(d,J=8.0Hz,2H),7.71(d,J=7.8Hz,2H),7.50(d,J=7. 7Hz,2H),7.13(s,1H),7.01(d,J=8.4Hz,1H),6.99(s,1H),6.85(s,1H),6.69(s,1H),5.59(s,2H),3.51(s,6H).

[0519] Example 56: Preparation of N-(5-((5-chloropyrimidin-2-yl)methoxy)-1,3,4-thiadiazol-2-yl)-5-(2-methoxy-5-(trifluoromethyl)phenyl)-1-methyl-2-oxo-1,2-dihydropyridine-4-carboxamide (Compound 131)

[0520] Step 1: Intermediate 55 (100 mg, 0.31 mmol), HATU (174.2 mg, 0.46 mmol), and intermediate 8 (89.3 mg, 0.37 mmol) were weighed into a 25 mL single-necked flask. DMF (2 mL) and DIEA (118.4 mg, 0.92 mmol) were then added and the mixture was allowed to react at room temperature overnight. LCMS monitored the reaction for completion. A large amount of solid precipitated from the reaction solution, which was filtered and the filter cake was washed with EA (5 mL x 2) to obtain the target compound. 5 mL of methanol was then added, the mixture was stirred for 10 minutes, filtered, and the filter cake was dried to obtain the target compound 131 (5 mg, 0.15 mmol, 49.6% yield). MS Calcd: 552.06; MS Found: 553.20 ([M+H] + ).

[0521] 1 H NMR(400MHz,DMSO-d6)δ12.92(s,1H),8.98(s,2H),7.89(s,1H),7.78–7.52(m, 2H),7.12(d,J=8.4Hz,1H),6.73(s,1H),5.67(s,2H),3.57(s,3H),3.53(s,3H).

[0522] Example 57: Preparation of N-(5-((4-(difluoromethyl)benzyl)oxy)-1,3,4-thiadiazol-2-yl)-5-(2-methoxy-5-methylphenyl)-1-methyl-2-oxo-1,2-dihydropyridine-4-carboxamide (Compound 132)

[0523] Step 1: Intermediate 11 (70 mg, 0.16 mmol) was weighed into a 25 mL single-necked flask. HATU (146.0 mg, 0.38 mmol) and DMF (1 mL) were added, followed by DIEA (0.14 mL, 0.77 mmol) and stirred for 5 minutes. Finally, Intermediate 53 (65.9 mg, 0.26 mmol) was added and allowed to react at room temperature for 1 hour. LCMS monitored the reaction for completion. 5 mL of aqueous ammonium chloride was added to the reaction solution, and the mixture was extracted with DCM (10 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, and the residue was purified by prep-HPLC to obtain the target compound 132 (20 mg, 0.04 mmol, 15.2% yield). MS Calcd: 512.13; MS Found: 513.23 ([M+H] + ).

[0524] 1 H NMR (400MHz, DMSO-d6) δ12.81(s,1H),7.74(s,1H),7.65–7.57(m,4H),7.08(d,J=9.9Hz,2H),7.05(t,J =55.8Hz,1H),6.76(d,J=8.2Hz,1H),6.64(s,1H),5.54(s,2H),3.50(s,3H),3.41(s,3H),2.27(s,3H).

[0525] Example 58: Preparation of N-(5-((5-(hydroxymethyl)pyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-yl)-5-(2-methoxy-5-(trifluoromethyl)phenyl)-1-methyl-2-oxo-1,2-dihydropyridine-4-carboxamide (Compound 133)

[0526] Step 1: In a 10 mL single-necked vial, intermediate 56 (100 mg, 0.17 mmol) and THF (4 mL) were added. Lithium aluminum hydride (9.9 mg, 0.26 mmol) was slowly added under ice-cooling and stirred for 2 hours. LCMS monitoring confirmed the completion of the reaction. The reaction mixture was quenched by adding 2 drops of water, filtered through celite, and washed with THF (5 mL x 2). The filtrate was then dried under reduced pressure. The residue was purified by prep-HPLC to obtain the target compound 133 (12 mg, 0.02 mmol, 12.5%). MS Calcd: 547.11; MS Found: 548.25 ([M+H] + ).

[0527] 1 H NMR (400MHz, DMSO-d6) δ12.93(s,1H),8.54(d,J=2.0Hz,1H),7.88(s,1H),7.79(dd,J=8.0,2.0Hz,1H),7.70–7.62(m,2H),7.52(d,J= 8.0Hz,1H),7.10(d,J=8.4Hz,1H),6.72(s,1H),5.52(s,2H),5.36(t,J=5.6Hz,1H),4.56(d,J=5.6Hz,2H),3.56(s,3H),3.53(s,3H).

[0528] Example 59: Preparation of N-(5-((4-(difluoromethyl)benzyl)oxy)-1,3,4-thiadiazol-2-yl)-5-(2-methoxy-5-(trifluoromethyl)phenyl)-1-methyl-2-oxo-1,2-dihydropyridine-4-carboxamide (Compound 134)

[0529] Step 1: Intermediate 53 (60 mg, 0.23 mmol), intermediate 8 (84.0 mg, 0.26 mmol), and PyBOP (364.1 mg, 0.70 mmol) were weighed into a 25 mL single-necked flask. DMF (1.5 mL) and DIEA (0.12 mL, 0.70 mmol) were added and the mixture was allowed to react overnight at room temperature. LCMS monitoring indicated product formation. The reaction mixture was purified by prep-HPLC to afford the target compound 134 (27 mg, 0.05 mmol, 19.4% yield). MS Calcd: 566.10; MS Found: 567.10 ([M+H] + ).

[0530] 1H NMR (400 MHz, DMSO-d6) δ 7.84 (s, 1H), 7.68–7.58 (m, 6H), 7.08 (d, J = 8.5 Hz, 1H), 7.05 (t, J = 56 Hz, 1H), 6.70 (s, 1H), 5.52 (s, 2H), 3.53 (s, 3H), 3.51 (s, 3H) (amide NH not shown).

[0531] Example 60: Preparation of 5-(5-chloro-2-methoxyphenyl)-N-(5-(((4-(difluoromethyl)benzyl)oxy)-1,3,4-thiadiazol-2-yl)-1-methyl-2-oxo-1,2-dihydropyridine-4-carboxamide (Compound 135)

[0532] Step 1: Intermediate 53 (60 mg, 0.23 mmol), intermediate 9 (67.6 mg, 0.23 mmol), and PyBOP (364.1 mg, 0.70 mmol) were weighed into a 25 mL single-necked flask. DMF (1.5 mL) and DIEA (0.12 mL, 0.70 mmol) were added and the mixture was allowed to react overnight at room temperature. LCMS analysis indicated the presence of product. The reaction mixture was purified by prep-HPLC to afford the target compound 135 (25 mg, 0.05 mmol, 19.7% yield). MS Calcd: 532.08; MS Found: 532.90 ([M+H] + ).

[0533] 1 H NMR(400MHz,DMSO-d6)δ12.85(s,1H),7.84(s,1H),7.65–7.58(m,4H),7.37–7.30(m,2H),7. 05(t,J=56Hz,1H),6.90(d,J=12Hz,1H),6.67(s,1H),5.54(s,2H),3.50(s,3H),3.45(s,3H).

[0534] Example 61: Preparation of N-(5-((6-chloropyridin-3-yl)methoxy)-1,3,4-thiadiazol-2-yl)-5-(2-methoxy-5-(trifluoromethyl)phenyl)-1-methyl-2-oxo-1,2-dihydropyridine-4-carboxamide (Compound 136)

[0535] Step 1: Intermediate 8 (50 mg, 0.15 mmol) was weighed into a 25 mL single-necked flask. HATU (87.1 mg, 0.23 mmol) and DMF (1 mL) were added, followed by DIEA (0.08 mL, 0.46 mmol) and stirring for 5 minutes. Finally, Intermediate 57 (37.1 mg, 0.15 mmol) was added and allowed to react at room temperature for 1 hour. LCMS monitored the reaction for completion. 5 mL of aqueous ammonium chloride was added to the reaction solution, and the mixture was extracted with DCM (10 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, and the residue was purified by prep-HPLC to obtain the target compound 136 (30 mg, 0.05 mmol, 35.2% yield). MS Calcd: 551.06; MS Found: 552.15 ([M+H] + ).

[0536] 1 H NMR (400MHz, DMSO-d6) δ12.91(s,1H),8.55(s,1H),8.00(d,J=6.3Hz,1H),7.83(s,1H),7.69–7.60(m, 2H),7.58(d,J=8.2Hz,1H),7.07(d,J=8.5Hz,1H),6.70(s,1H),5.51(s,2H),3.53(s,3H),3.51(s,3H).

[0537] Example 62: Preparation of 5-(2-(difluoromethoxy)-5-methylphenyl)-N-(5-((4-(difluoromethyl)benzyl)oxy)-1,3,4-thiadiazol-2-yl)-1-methyl-2-oxo-1,2-dihydropyridine-4-carboxamide (Compound 137)

[0538] Step 1: Intermediate 44 (50 mg, 0.16 mmol), HATU (92 mg, 0.24 mmol), and intermediate 53 (49 mg, 0.19 mmol) were weighed into a 25 mL single-necked vial. DMF (2 mL) and DIEA (62 mg, 0.48 mmol) were then added and allowed to react at room temperature overnight. LCMS monitored the reaction for completion. The reaction solution was purified by prep-HPLC to afford the title compound 137 (12 mg, 0.02 mmol, 13.4% yield). MS Calcd: 548.11; MS Found: 549.29 ([M+H] + ).

[0539] 1H NMR(400MHz,DMSO-d6)δ12.95(s,1H),7.82(s,1H),7.64(s,4H),7.23–7.17(m,2H),7.00( d,J=8.0Hz,1H),6.93(t,J=74Hz,1H),6.77(s,1H),5.55(s,2H),3.53(s,3H),2.33(s,3H).

[0540] Example 63: Preparation of N-(5-((5-(difluoromethyl)pyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-yl)-5-(2-methoxy-5-(trifluoromethyl)phenyl)-1-methyl-2-oxo-1,2-dihydropyridine-4-carboxamide (Compound 138)

[0541] Step 1: Intermediate 8 (50 mg, 0.15 mmol), HATU (87.1 mg, 0.23 mmol), and intermediate 58 (38.7 mg, 0.15 mmol) were weighed into a 10 mL single-necked flask. DMF (1 mL) and DIEA (59.1 mg, 0.46 mmol) were then added and allowed to react at room temperature for 3 hours. LCMS monitored the reaction for completion. 10 mL of aqueous ammonium chloride was added to the reaction solution, and EA was extracted (10 mL x 2). The organic phases were combined, dried over anhydrous sodium sulfate, and the residue was purified by prep-HPLC to obtain the target compound 138 (21 mg, 0.04 mmol, 23.4% yield). MS Calcd: 567.10; MS Found: 568.16 ([M+H] + ).

[0542] 1 H NMR (400MHz, DMSO-d6) δ12.93(s,1H),8.79(s,1H),8.07(d,J=7.5Hz,1H),7.87(s,1H),7.74–7.61(m,3 H),7.17(t,J=55.2Hz,1H),7.09(d,J=8.4Hz,1H),6.71(s,1H),5.61(s,2H),3.55(s,3H),3.51(s,3H).

[0543] Example 64: Preparation of N-(5-((6-(difluoromethyl)pyridin-3-yl)methoxy)-1,3,4-thiadiazol-2-yl)-5-(2-methoxy-5-(trifluoromethyl)phenyl)-1-methyl-2-oxo-1,2-dihydropyridine-4-carboxamide (Compound 140)

[0544] Step 1: Intermediate 8 (92 mg, 0.28 mmol), intermediate 59 (60 mg, 0.23 mmol), and PyBOP (362.8 mg, 0.70 mmol) were weighed into a 25 mL single-necked flask. DMF (1 mL) and DIEA (0.12 mL, 0.70 mmol) were added and stirred at room temperature for 2 hours. The reaction was monitored for completion by LCMS. The reaction mixture was purified by prep-HPLC to obtain the target compound 140 (44 mg, 0.08 mmol, 32.7% yield). MS Calcd: 567.10; MS Found: 568.10 ([M+H] + ).

[0545] 1 H NMR (400MHz, DMSO-d6) δ12.93(brs,1H),8.81(d,J=2.0Hz,1H),8.13(dd,J=8.0,2.1Hz,1H),7.86(s,1H),7.75(d,J=8.1H z,1H),7.69-7.61(m,2H),,7.08(d,J=8Hz,1H),6.98(t,J=56Hz,1H),6.70(s,1H),5.60(s,2H),3.54(s,3H),3.51(s,3H).

[0546] Example 65: Preparation of 5-(2-methoxy-5-methylphenyl)-1-methyl-2-sulfoxy-N-(5-((4-(trifluoromethyl)benzyl)oxy)-1,3,4-thiadiazol-2-yl)-1,2-dihydropyridine-4-carboxamide (Compound 142)

[0547] Step 1: Intermediate 60 (75 mg, 0.26 mmol), HATU (157.6 mg, 0.41 mmol), and intermediate 37 (83.7 mg, 0.30 mmol) were weighed into a 10 mL single-necked flask. DMF (1 mL) and DIEA (107 mg, 0.83 mmol) were then added and allowed to react at room temperature for 3 hours. LCMS monitored the reaction for completion. 10 mL of aqueous ammonium chloride was added to the reaction solution, and EA was extracted (10 mL x 2). The organic phases were combined, dried over anhydrous sodium sulfate, and the residue was purified by prep-HPLC to obtain the target compound 142 (40 mg, 0.02 mmol, 25.5% yield). MS Calcd: 546.10; MS Found: 547.08 ([M+H] + ).

[0548] 1H NMR (400MHz, DMSO-d6) δ12.92 (s, 1H), 7.77 (d, J = 8.2Hz, 2H), 7.74–7.66 (m, 3H), 7.21–7. 11(m,2H),7.03(s,1H),6.73(s,1H),5.57(s,2H),3.49(s,3H),2.26(s,3H),2.22(s,3H).

[0549] Example 66: Preparation of 5-(2-methoxy-5-(trifluoromethyl)phenyl)-1-methyl-N-(5-((4-(methylsulfonyl)benzyl)oxy)-1,3,4-thiadiazol-2-yl)-2-oxo-1,2-dihydropyridine-4-carboxamide (Compound 149)

[0550] Step 1: Intermediate 8 (60 mg, 0.18 mmol), HATU (104.5 mg, 0.27 mmol), and intermediate 61 (62.8 mg, 0.22 mmol) were weighed into a 10 mL single-necked flask. DMF (1 mL) and DIEA (70.9 mg, 0.55 mmol) were then added and allowed to react at room temperature for 3 hours. LCMS monitored the reaction for completion. 10 mL of aqueous ammonium chloride was added to the reaction solution, and EA was extracted (10 mL x 2). The organic phases were combined, dried over anhydrous sodium sulfate, and the residue was purified by prep-HPLC to obtain the target compound 149 (14 mg, 0.02 mmol, 12.5% ​​yield). MS Calcd: 595.08; MS Found: 594.65 ([M+H] + ).

[0551] 1 H NMR (400MHz, DMSO-d6) δ12.91(s,1H),7.95(t,J=8.0Hz,3H),7.74(d,J=8.4Hz,2H),7.68–7.60(m,2H),7.08(d,J=8.5Hz,1H),6.70(s,1H),5.60(s, 2H),3.54(s,3H),3.51(s,3H),3.22(s,3H).

[0552] Example 67: Preparation of 1-methyl-5-(5-methyl-2-(methylthio)phenyl)-2-oxo-N-(5-((4-(trifluoromethyl)benzyl)oxy)-1,3,4-thiadiazol-2-yl)-1,2-dihydropyridine-4-carboxamide (Compound 153)

[0553] Step 1: Intermediate 62 (80 mg, 0.28 mmol), HATU (157.6 mg, 0.41 mmol), and intermediate 37 (83.7 mg, 0.30 mmol) were weighed into a 10 mL single-necked flask. DMF (1 mL) and DIEA (107 mg, 0.83 mmol) were then added and allowed to react at room temperature for 3 hours. LCMS monitored the reaction for completion. 10 mL of aqueous ammonium chloride was added to the reaction solution, and EA was extracted (10 mL x 2). The organic phases were combined, dried over anhydrous sodium sulfate, and the residue was purified by prep-HPLC to obtain the target compound 153 (40 mg, 0.02 mmol, 25.5% yield). MS Calcd: 546.10; MS Found: 547.1 ([M+H] + ).

[0554] 1 H NMR (400MHz, DMSO-d6) δ12.92 (s, 1H), 7.77 (d, J = 8.2Hz, 2H), 7.74–7.66 (m, 3H), 7.21–7. 11(m,2H),7.03(s,1H),6.73(s,1H),5.57(s,2H),3.49(s,3H),2.26(s,3H),2.22(s,3H).

[0555] Compound A

[0556] Compound A was prepared with reference to the synthesis method of Example 8 in WO2022118210A1.

[0557] Compound B

[0558] Compound B was prepared with reference to the synthesis method of Example 138 in WO2020243459A1.

[0559] Example 68: In vitro enzymatic activity evaluation

[0560] By measuring IC 50 The inhibitory activity of the compounds on human DNA polymerase theta (Polθ) was evaluated by

[0561] Compounds were serially diluted 4x in DMSO (Sigma, D5879) (starting at 1.0 μM, 4x dilutions for a total of 8 concentration points). 2 μL was added to each well of a 384-well assay plate (Coring, 3824) using a 12-channel pipette (Rainin: Pipet-Lite XLS+). 4 μL of recombinant human Polθ (AiSyP, S2201T-B02H) with a final concentration of 2 nM was added to the 384-well plate. After centrifugation at 1000 rpm (Eppendorf, 5840R) for 1 minute, the plate was pre-incubated at room temperature for 15 minutes. 4 μL of substrate (150 nM ssDNA (Sangon, 2313977514), 100 μM ATP (Thermo Fisher, R0441)) was added to the 384-well plate. The plate was centrifuged at 1000 rpm for 1 minute and incubated at room temperature for 120 minutes. Add 5 μL ADP-Glo ​​reagent (Promega, V9102) to a 384-well plate, centrifuge at 1000 rpm for 1 min, and incubate at room temperature for 40 min. Add 10 μL detection solution (Promega, V9102) to a 384-well plate, centrifuge at 1000 rpm for 1 min, and incubate at room temperature for 40 min. Subsequently, the luminescence signal of the reaction system in luminescence mode was read using a high-throughput drug screening multifunctional microplate reader (TECAN Spark). The inhibition percentage (%) of each concentration of the compound was calculated based on the signals of the minimum luminescence signal group and the maximum luminescence signal group contained in each detection plate. The minimum luminescence signal group had no enzyme and compound added, and the others were consistent with the compound group, with the minimum luminescence signal and set to 100% inhibition. The maximum luminescence signal group had no compound added, and the others were consistent with the compound group, with the maximum luminescence signal and set to 0% inhibition.

[0562] The inhibition rate of each compound concentration was calculated as follows: inhibition rate % = {1-[(maximum luminescence signal group - luminescence signal of compound group) / (maximum luminescence signal group - minimum luminescence signal group)]}*100%. Finally, the four-parameter logistic dose-response equation was used to determine the compound concentration required for 50% inhibition, i.e., IC 50 The results are shown in Table 1.

[0563] Table 1 Polθ inhibitory activity of the compounds of the present invention

[0564] As shown in Table 1, the compounds of the present invention have excellent Pol θ inhibitory activity and can be used as drugs for the prevention and / or improvement and / or treatment of diseases associated with this activity.

[0565] Example 69: Cell assay evaluation

[0566] 1. Construction of BRCA2- / -DLD1 cell line

[0567] The colon cancer cell line DLD1 (Nanjing Kebai) was co-transfected with the gene-editing tool CRISPR / Cas9 and sgRNA. Western blotting, Sanger sequencing, and other assays were used to generate the BRCA2- / -DLD1 cell line, which exhibits biallelic inactivation of the BRCA2 gene. This BRCA2- / -DLD1 cell line was used to screen and evaluate compounds that selectively target the synergistic mechanism of BRCA2 loss and POLQ inhibition, primarily through colony formation assays.

[0568] 2. Cell clone formation test

[0569] BRCA2- / -DLD1 and wild-type DLD1 cell lines were cultured in complete culture medium (RPIM1640 (Gibco, 22400089) / 10% FBS (Gibco, 10099141C) / 1% p / S (Sigma, A5955) to evaluate the selective inhibition and enhancement of BRCA2- / -DLD1 cell colony formation. On Day 0, 100 DLD1 wild-type cells and 1000 DLD1BRCA2- / - cells were plated per well in a 24-well cell culture plate (Corning 3524) and cultured in a 37°C, 5% CO2 incubator. On Day 1, the compound was diluted to multiple concentration points and treated with cells (wild-type cells: 30 μM starting point, 3X dilution, 6 doses; deletion cells: 10 μM / 1 μM starting point, 3X dilution, 6 doses), and continued to be cultured in a 37°C, 5% CO2 incubator; on Day 7, the cell medium was changed and the compound was treated (the conditions were the same as the first compound treatment), and continued to be cultured in a 37°C, 5% CO2 incubator; on Day 10, the wild-type cells were collected, 600 μL of PBS was added to each well for washing, and then 300 μL of 95% ethanol (Aladdin, E130059) was added to each well and fixed at room temperature for 30 minutes in an oscillator (300 rpm). After the ethanol was aspirated, 300 μL of 0.04% crystal violet staining solution (Bickman, 110703008) was stained in an oscillator (300 rpm) at room temperature for 20 minutes, then the staining solution was recovered, 600 μL of pure water was added to each well to wash 6 times, and then dried at room temperature. Then 250 μL of 20% glacial acetic acid (Cologne, CAS64-19-7) was added to each well and destained in an oscillator (300 rpm) at room temperature for 20 minutes. 100 μL of cell destaining solution was aspirated into a 96-well plate (corning, 3599) per well. Subsequently, the reaction system was read using a high-throughput drug screening multifunctional microplate reader (TECAN Spark) in the light absorption mode to detect the light absorption signal at a wavelength of 595 nm. Day 13, the deletion cells were sampled and the operation was consistent with the wild-type cells.

[0570] The inhibition percentage (%) of each concentration of compound is calculated based on the signals of the minimum light absorption signal group and the maximum light absorption signal group contained in each test plate. Among them, the minimum light absorption signal group does not have cell decolorization solution, but only has 20% acetic acid solution, and the light absorption signal is the smallest, which is set to 100% inhibition. The maximum light absorption signal group is the 0.03% DMSO control group. The others are consistent with the compound group, with the maximum light absorption signal, which is set to 0% inhibition. The inhibition rate of each compound concentration is calculated as follows: Inhibition rate % = {1-[(maximum light absorption signal group-compound group light absorption signal) / (maximum light absorption signal group-minimum light absorption signal group)]}*100%. Finally, the four-parameter logistic dose-response equation is used to determine the compound concentration required for 50% inhibition, that is, IC 50 The results are shown in Table 2.

[0571] Table 2 Selective inhibitory and enhancing effects of the compounds of the present invention on BRCA2- / -DLD1 cell colony formation

[0572] As shown in Table 2, the compounds of the present invention can selectively inhibit and enhance the colony formation of BRCA2- / -DLD1 cells, and can be used as drugs for the prevention and / or improvement and / or treatment of diseases related to this effect.

[0573] Example 70: Human liver microsome stability experiment

[0574] 1. Experimental materials:

[0575] The experiments used human liver microsomes (supplier: Read Liver Disease Research (Shanghai) Co., Ltd., brand: BIOIVT, catalog number: X008070); NADPH (reduced nicotinamide adenine dinucleotide phosphate, catalog number: 481973-500mg, Sigma).

[0576] 2. Reagent preparation:

[0577] PBS: 0.1 M KH2PO4 and K2HPO4 buffer, pH 7.4.

[0578] MgCl2: Weigh a certain amount of MgCl2 and prepare a 16mM MgCl2 solution with PBS.

[0579] NADPH: Weigh a certain amount of NADPH and prepare NADPH to 4 mM with 16 mM MgCl2 solution, and the final incubation concentration is 1 mM.

[0580] Compounds: Test compounds were prepared at 4 μM in PBS, with a final incubation concentration of 1 μM.

[0581] Liver microsomes: Dilute liver microsomes to 1 mg / mL with PBS, and the final incubation concentration is 0.5 mg / mL.

[0582] 3. Experimental steps:

[0583] Add the prepared test compound to the test tube, followed by the prepared NADPH, and mix well. Place in a 37°C, 220rpm constant temperature incubator for preincubation. After preincubation for 5 minutes, add the prepared liver microsomes to initiate the reaction, and perform the duplicate operation. At 0min, 5min, 15min, 30min, and 60min, add a certain volume of ice acetonitrile solution containing internal standard to the corresponding tube to precipitate the protein, vortex for 5 minutes, then centrifuge at 4000rpm for 10 minutes, and take the supernatant into a 96-well plate. Place in LC-MS / MS (Shimadzu LC-30A, AB API 4500) for analysis. The concentration (peak area ratio) of the example compound is determined by LC-MS / MS, and the rate constant is obtained by plotting "Ln (compound residual amount %)" against "incubation time" in Excel, thereby calculating the half-life and intrinsic clearance of the drug, providing a basis for predicting the clearance rate in vivo.

[0584] 4. Data Analysis

[0585] CL int =(0.693 / t 1 / 2 , microsomes) × [incubation medium volume (mL) / microsomal protein mass (mg)] × [microsomal protein mass (mg) / liver mass (g)] × [liver mass (g) / body weight (kg)] [1]

[0586] CL H =CL int ×f u ×Q h / (CL int ×f u +Q h )

[0587] In the formula

[0588] CL int --Intrinsic clearance (ml / min / kg)

[0589] CL H --Hepatic clearance (ml / min / kg)

[0590] f u --Plasma protein binding rate is 1

[0591] Q h --Hepatic blood flow

[0592] Table 3 Experimental results

[0593] References:

[0594] [1]Davies B, Morris T.Physiological parameters in laboratory animals and humans.Pharm Res.1993;10:1093-5.

[0595] As can be seen from Table 3, the compounds of the present invention have a longer half-life and a longer duration of action in the body, which is beneficial to improving the efficacy.

[0596] Example 71: Pharmacokinetics in mice

[0597] 1. Experimental Materials and Methods

[0598] The experimental animals were healthy adult BALB / c female mice (provided by Beijing Huafukang Biotechnology Co., Ltd.).

[0599] BALB / c female mice were given a single oral gavage (10 mg / kg). 60 μL of whole blood was collected from the fundus venous plexus of the mice at different time points at 0.25, 0.5, 1, 2, 4, 6, 8, and 24 h after administration, and the blood was centrifuged at 4000 rpm for 10 min to obtain plasma.

[0600] 2. Sample analysis:

[0601] 10 μL of mouse plasma samples were collected and protein was precipitated with 190 μL of acetonitrile solution containing an internal standard. The samples were vortexed for 10 minutes and then centrifuged at 4000 rpm for 10 minutes. The supernatant was then transferred to a 96-well plate and analyzed by LC-MS / MS (Shimadzu LC-30A, AB API 4500). LC-MS / MS was used to determine plasma drug concentrations at different times after oral administration of the example compounds to mice. The relevant pharmacokinetic parameters were calculated to investigate the pharmacokinetic behavior of the compounds in mice and to evaluate their pharmacokinetic profiles.

[0602] Table 4 Experimental results

[0603] Note: 1. The solvent is 5% DMSO + 5% solutol + 90% saline; 2. The solvent is 0.5% CMC-Na / 0.2% Tween 80

[0604] As shown in Table 4, the compound of the present invention has a significant advantage in drug exposure compared to the control compound.

[0605] Example 72: Pharmacokinetics in rats

[0606] 1. Experimental Materials and Methods

[0607] The experimental animals were healthy adult SD male rats (provided by Beijing Huafukang Biotechnology Co., Ltd. or Sichuan Weitonglihua Experimental Animal Technology Co., Ltd.).

[0608] SD male rats were given a single oral gavage (2 mg / kg or 5 mg / kg), and 200 μL of whole blood was collected from the retinal venous plexus of the rats at different time points at 0.25, 0.5, 1, 2, 4, 6, 8, and 24 hours after administration, and the plasma was obtained by centrifugation at 4000 rpm for 6 minutes.

[0609] 2. Sample analysis:

[0610] 10 μL of rat plasma samples were collected and protein was precipitated with 190 μL of acetonitrile solution containing an internal standard. The samples were vortexed for 10 minutes and then centrifuged at 4000 rpm for 10 minutes. The supernatant was then transferred to a 96-well plate and analyzed by LC-MS / MS (Shimadzu LC-30A, AB API 4500). LC-MS / MS was used to determine plasma concentrations of the example compounds at different times after oral administration to rats. The relevant pharmacokinetic parameters were calculated to investigate the pharmacokinetic behavior of the compounds in rats and to evaluate their pharmacokinetic profiles.

[0611] Table 5 Experimental results

[0612] Note: 1. The solvent is 5% DMSO + 5% solutol + 90% saline; 2. The solvent is 0.5% CMC-Na / 0.2% Tween 80

[0613] As can be seen from Table 5, the compounds of the present invention have very high drug exposure.

[0614] Experimental Example 73: CYP450 enzyme inhibition study

[0615] 73.1 CYP3A4 Enzyme Inhibition Studies

[0616] Using PROMEGA P450-Glo TMCYP3A4 inhibition assays were performed using the CYP3A4 Assay and Screening Systems (V9920). 4X CYP3A4 Membrane Reaction Mixture, 4X Control Membrane Reaction Mixture, and 2X NADPH Regeneration System were pre-configured. In a 384-well plate, 6.25 μL of DMSO solution was added to each negative control and background control wells, 6.25 μL of ketoconazole solution was added to the positive control wells, and 6.25 μL of test compound solution was added to the compound reaction wells. All wells were set up in duplicate. 6.25 μL of CYP3A4 Membrane Reaction Mixture was added to each negative control, positive control, and compound reaction wells, respectively, and 6.25 μL of Control Membrane Reaction Mixture was added to the background control wells. The wells were pre-incubated at 37°C for 30 minutes. After the pre-incubation, 12.5 μL of NADPH Regeneration System was added to each well to initiate the reaction. The reaction was incubated at 37°C for 10 minutes. After the reaction, 25 μL of Reconstituted Luciferin Detection Reagent was added to each well and the cells were placed in the dark at room temperature for 20 min. Relative Light Units (RLU) were measured using a microplate reader with an integration time of 1 second.

[0617] The inhibition rate of the compound or positive control was calculated using the following formula.

[0618] Inhibition rate % = (1-(compound or positive control RLU-background control RLU) / (negative control RLU-background control RLU))*100%

[0619] Using the above experimental method, the CYP450CYP3A4 inhibition test results of some compounds of the present invention are shown in Table 6 below.

[0620] Table 6 CYP450 CYP3A4 inhibition test results

[0621] 73.2 CYP1A2 Enzyme Inhibition Studies

[0622] Using PROMEGA P450-Glo TMCYP1A2 inhibition assays were performed using the CYP1A2 Assay and Screening Systems (V9770). 4X CYP1A2 Membrane Reaction Mixture, 4X Control Membrane Reaction Mixture, and 2X NADPH Regeneration System were pre-configured. In a 384-well plate, 6.25 μL of DMSO solution was added to each negative control and background control wells, 6.25 μL of furafylline solution was added to the positive control wells, and 6.25 μL of test compound solution was added to the compound reaction wells. All wells were assayed in duplicate. 6.25 μL of CYP1A2 Membrane Reaction Mixture was added to each negative control, positive control, and compound reaction wells, respectively, while 6.25 μL of Control Membrane Reaction Mixture was added to the background control wells. The assays were pre-incubated at 37°C for 30 minutes. After the pre-incubation, 12.5 μL of NADPH Regeneration System was added to each well to initiate the reaction. The reaction was incubated at 37°C for 10 minutes. After the reaction, 25 μL of Reconstituted Luciferin Detection Reagent was added to each well and the cells were placed in the dark at room temperature for 20 min. Relative Light Units (RLU) were measured using a microplate reader with an integration time of 1 second.

[0623] The inhibition rate of the compound or positive control was calculated using the following formula.

[0624] Inhibition rate % = (1-(compound or positive control RLU-background control RLU) / (negative control RLU-background control RLU))*100%

[0625] Using the above experimental method, the CYP450CYP1A2 inhibition test results of some compounds of the present invention are shown in Table 7 below.

[0626] Table 7 CYP450 CYP1A2 inhibition test results

[0627] 73.3 CYP2D6 Enzyme Inhibition Studies

[0628] Using PROMEGA P450-Glo TMCYP2D6 inhibition assays were performed using the CYP2D6 Assay and Screening System (V9890). 4X CYP2D6 Membrane Reaction Mixture, 4X Control Membrane Reaction Mixture, and 2X NADPH Regeneration System were pre-assembled. In a 384-well plate, 6.25 μL of 0.1% DMSO solution was added to each of the negative control and background wells, 6.25 μL of quinidine solution (final reaction concentration 1 μM) was added to the positive control wells, and 6.25 μL of the test compound solution was added to the compound reaction wells. All wells were set up in duplicate. 6.25 μL of CYP2D6 Membrane Reaction Mixture was added to each of the negative control, positive control, and compound reaction wells, and 6.25 μL of Control Membrane Reaction Mixture was added to the background wells. The plates were pre-incubated at 37°C for 30 minutes. After pre-incubation, 12.5 μL of NADPH Regeneration System was added to each well to initiate the reaction. The reaction was incubated at 37°C for 30 minutes. After the reaction, 25 μL of Reconstituted Luciferin Detection Reagent was added to each well and the cells were placed in the dark at room temperature for 20 min. Relative Light Units (RLU) were measured using a microplate reader with an integration time of 1 second.

[0629] The inhibition rate of the compound or positive control was calculated using the following formula.

[0630] Inhibition rate % = (1-(compound or positive control RLU-background control RLU) / (negative control RLU-background control RLU))*100%

[0631] Using the above experimental method, the results of the CYP450 CYP2D6 inhibition test of some compounds of the present invention are shown in Table 8 below.

[0632] Table 8 CYP450 CYP2D6 inhibition test results

[0633] Experimental Example 74: hERG inhibition study

[0634] Using Predictor TMhERG Fluorescence Polarization Assay Kit (ThermoFisher Scientific PV5365) was used for hERG inhibition assay. TM hERG Tracer Red and 4×E-4031 positive controls. In a 384-well plate, add 5 μL of Predictor TM hERG FP Assay Buffer and 5μL Predictor TM hERG Membrane. Add 2.5 μL Predictor to each of the negative control, positive control, and test compound wells. TM hERG FP Assay Buffer, 2.5 μL 4×E-4031 Positive Control, 2.5 μL 4× test compound, and then 5 μL Predictor TM hERG Membrane and 2.5 μL 4×Predictor TM hERG Tracer Red. Incubate at room temperature (25°C) in the dark for 3.5 hours. After the reaction, measure fluorescence polarization using a microplate reader; the G factor is 2.14.

[0635] The inhibition rate of the compound or positive control was calculated using the following formula.

[0636] Inhibition rate % = (mP negative control - mP compound) / (mP negative control - mP positive control) * 100% Using the above experimental method, the hERG inhibition test results of some compounds of the present invention are shown in Table 9 below.

[0637] Table 9 hERG inhibition test results

[0638] Experimental Example 75: In DLD1 BRCA2 - / - Evaluation of the anti-tumor activity of compound 108 in combination with the PARP inhibitor Olaparib in the mouse CDX model

[0639] Balb / c nude mice (Zhejiang Weitong Lihua Experimental Animal Technology Co., Ltd.) were subcutaneously inoculated with BRCA2 knockout human colorectal cancer epithelial cells DLD1BRCA2 in the left axilla. - / - (Nanjing Kebai Biotechnology Co., Ltd.), 0.1 mL was inoculated per mouse, and the inoculum volume was 5 × 10 6 The average tumor volume in the group was 89.86 mm 3Animals were randomly divided into three groups of six animals each based on tumor volume, body weight, and tumor growth. Dosing began on the day of grouping: the vehicle group was gavage-administered with the vehicle, the olaparib (MedChemExpress LLC) group was gavage-administered with an olaparib solution (30 mg / kg, once daily), and the 108+olaparib group was gavage-administered with a compound 108 solution (30 mg / kg, twice daily) and an olaparib solution (30 mg / kg, once daily) for 28 consecutive days. Animals were euthanized after the final dose. The experimental vehicle was 10% DMSO + 20% Solutol + 70% PBS.

[0640] During the administration period, the tumor volume and body weight of each group of animals were measured 3 times a week. The tumor volume was measured by measuring the long axis (L) and short axis (W) of the tumor of each group of mice with a vernier caliper, and the tumor volume V and TGI were calculated according to the following formula TV .

[0641] V(mm 3 )=0.5×L×W 2

[0642] TGI TV =1-((V Tt -V T0 ) / (V Ct -V C0 ))*100%. V Tt is the tumor volume of the treatment group at each measurement, V T0 The tumor volume was measured when the treatment groups were divided into groups and given medication; V Ct is the tumor volume of the Vehicle group at each measurement, V C0 The tumor volumes were measured at the time of vehicle group administration.

[0643] Tumor volume and body weight were statistically analyzed using GraphPad Prism 9.0 software. One-way analysis of variance (ANOVA) was used to compare the differences between the drug-treated groups and the vehicle group. When there were statistically significant differences, pairwise comparisons were performed using the Brown-Forsythe method (homogeneity of variance) or Dunnett's T3 method (uneven variance).

[0644] The data in Figures 1 and 2 show that the combination of compound 108 and Olaparib can significantly enhance the anti-tumor effect of Olaparib. The combination of compound 108 and Olaparib can alleviate the weight loss of tumor-bearing mice, and the combination is well tolerated.

[0645] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principles of the present invention. These improvements and modifications should also be regarded as within the scope of protection of the present invention.

Claims

1. A compound of general formula (I), or a pharmaceutically acceptable salt, stereoisomer, tautomer, polymorph, cocrystal, hydrate, solvate, metabolite, prodrug, or deuterated compound thereof: in, X is selected from -C(O)- or -C(S)-, and Y is selected from -NR 1 -; or X is selected from -NR 1 -, Y is selected from -C(O)- or -C(S)-; Ring A is selected from phenyl, 5-10 membered heteroaryl; wherein the 5-10 membered heteroaryl contains 1 to 3 heteroatoms selected from N, O and S; the phenyl and 5-10 membered heteroaryl are each independently unsubstituted or substituted by one or more identical or different R a replace; R 1 Selected from C 1-8 Alkyl, C 3-8 Cycloalkyl, C 1-8 Haloalkyl, C 1-8 Hydroxyalkyl; wherein the C 1-8 Alkyl, C 3-8 Cycloalkyl, C 1-8 Haloalkyl, C 1-8 The hydroxyalkyl groups are each independently unsubstituted or substituted with one or more identical or different R b replace; R 2 Selected from C 1-8 Alkyl, 5-10 membered heteroaryl, C 6-10 Aryl, C 3-10 Cycloalkyl, 4-10 membered heterocycloalkyl, unsaturated 4-10 membered heterocyclic group; wherein the C 3-10 The -CH2- on the cycloalkyl ring is optionally replaced by -C(=O)-, -C(=S)- and -S(=O)2-; the 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, unsaturated 4-10 membered heterocyclic group each independently contains 1 to 3 heteroatoms selected from N, O and S; wherein the C 1-8 Alkyl, 5-10 membered heteroaryl, C 6-10 Aryl, C 3-10 The cycloalkyl, 4-10 membered heterocycloalkyl, and unsaturated 4-10 membered heterocyclic group are each independently unsubstituted or substituted with one or more identical or different R c replace; L does not exist or C 1-3 Alkylene; Each R a , R b , R c Each independently selected from halogen, -CN, -OH, -SR i 、-SF5、-SCF3、-S(O)2R i 、-S(O)(=NR i )R j 、-N=S(O)R i R j , C 1-8 Alkyl, C 1-8 Alkoxy, C 1-8 Haloalkyl, C 1-8 Halogenated alkoxy, C 1-8 Hydroxyalkyl, C 3-8 Cycloalkyl, unsubstituted or substituted with one or more identical or different R aa Substituted 5-6 membered heteroaryl, -NR i R j 、-C(O)NR i R j ; or two adjacent R a Combined with the atoms on ring A to form an unsubstituted or substituted with one or more identical or different R bb substituted 4-7 membered heterocycloalkyl; wherein the 5-6 membered heteroaryl and the 4-7 membered heterocycloalkyl each independently contain 1 to 3 heteroatoms selected from N, O and S; each R aa , R bb are each independently selected from halogen, C 1-4 alkyl; Each R i , R j Each independently selected from the same or different -H, C 1-4 Alkyl; or R i , R j The N to which it is attached is unsubstituted or is replaced by one or more identical or different R cc substituted 4-7 membered heterocycloalkyl; wherein the 4-7 membered heterocycloalkyl contains 1 to 3 heteroatoms selected from N, O and S, and the -CH2- on the 4-7 membered heterocycloalkyl ring is optionally replaced by -C(=O)-, -C(=S)- and -S(=O)2-; each R cc Each independently selected from C 1-4 Alkyl, halogen.

2. A compound of formula (I), or a pharmaceutically acceptable salt, stereoisomer, tautomer, polymorph, cocrystal, hydrate, solvate, metabolite, prodrug, or deuterated compound thereof: in, X and Y are each independently selected from -C(O)- or -NR 1 -, and X and Y are not the same; Ring A is selected from phenyl, 5-10 membered heteroaryl; wherein the 5-10 membered heteroaryl contains 1 to 3 heteroatoms selected from N, O and S; the phenyl and 5-10 membered heteroaryl are each independently unsubstituted or substituted by one or more identical or different R a replace; R 1 Selected from C 1-8 Alkyl, C 3-8 Cycloalkyl, C 1-8 Haloalkyl, C 1-8 Hydroxyalkyl; wherein the C 1-8 Alkyl, C 3-8 Cycloalkyl, C 1-8 Haloalkyl, C 1-8 The hydroxyalkyl groups are each independently unsubstituted or substituted with one or more identical or different R b replace; R 2 Selected from C 1-8 Alkyl, 5-10 membered heteroaryl, C 6-10 Aryl, C 3-10 Cycloalkyl, 4-10 membered heterocycloalkyl, unsaturated 4-10 membered heterocyclic group; wherein the C 3-10 The -CH2- on the cycloalkyl ring is optionally replaced by -C(=O)-, -C(=S)- and -S(=O)2-; the 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, unsaturated 4-10 membered heterocyclic group each independently contains 1 to 3 heteroatoms selected from N, O and S; wherein the C 1-8 Alkyl, 5-10 membered heteroaryl, C 6-10 Aryl, C 3-10 The cycloalkyl, 4-10 membered heterocycloalkyl, and unsaturated 4-10 membered heterocyclic group are each independently unsubstituted or substituted with one or more identical or different R c replace; L does not exist or C 1-3 Alkylene; Each R a , R b , R c are independently selected from halogen, -CN, -OH, C 1-8 Alkyl, C 1-8 Alkoxy, C 1-8 Haloalkyl, C 1-8 Haloalkoxy, C 1-8 Hydroxyalkyl, C 3-8 Cycloalkyl, unsubstituted or substituted with one or more identical or different R aa Substituted 5-6 membered heteroaryl, -NR i R j 、-C(O)NR i R j ; or two adjacent R a Combined with the atoms on ring A to form an unsubstituted or substituted with one or more identical or different R bb substituted 4-7 membered heterocycloalkyl; wherein the 5-6 membered heteroaryl and the 4-7 membered heterocycloalkyl each independently contain 1 to 3 heteroatoms selected from N, O and S; each R aa , R bb are each independently selected from halogen, C 1-4 alkyl; Each R i , R j Each independently selected from -H, C 1-4 Alkyl; or R i , R j The N to which it is attached is unsubstituted or is replaced by one or more identical or different R cc substituted 4-7 membered heterocycloalkyl; wherein the 4-7 membered heterocycloalkyl contains 1 to 3 heteroatoms selected from N, O and S, and the -CH2- on the 4-7 membered heterocycloalkyl ring is optionally replaced by -C(=O)-, -C(=S)- and -S(=O)2-; each R cc Each independently selected from C 1-4 Alkyl, halogen.

3. A compound of formula (I), or a pharmaceutically acceptable salt, stereoisomer, tautomer, polymorph, cocrystal, hydrate, solvate, metabolite, prodrug, or deuterated compound thereof: in, X and Y are each independently selected from -C(O)- or -NR 1 -, and X and Y are not the same; Ring A is selected from phenyl, 5-10 membered heteroaryl; wherein the 5-10 membered heteroaryl contains 1 to 3 heteroatoms selected from N, O and S; the phenyl and 5-10 membered heteroaryl are each independently unsubstituted or substituted by one or more identical or different R a replace; R 1 Selected from C 1-8 Alkyl, C 3-8 Cycloalkyl, C 1-8 Haloalkyl, C 1-8 Hydroxyalkyl; wherein the C 1-8 Alkyl, C 3-8 Cycloalkyl, C 1-8 Haloalkyl, C 1-8 The hydroxyalkyl groups are each independently unsubstituted or substituted with one or more identical or different R b replace; R 2 Selected from C 1-8 Alkyl, 5-10 membered heteroaryl, C 6-10 Aryl, C 3-10 Cycloalkyl, 4-10 membered heterocycloalkyl, unsaturated 4-10 membered heterocyclic group; wherein the C 3-10 The -CH2- on the cycloalkyl ring is optionally replaced by -C(=O)-, -C(=S)- and -S(=O)2-; the 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, and unsaturated 4-10 membered heterocyclic group each independently contain 1 to 3 heteroatoms selected from N, O and S; wherein the 5-10 membered heteroaryl, C 6-10 Aryl, C 3-10 The cycloalkyl, 4-10 membered heterocycloalkyl, and unsaturated 4-10 membered heterocyclic group are each independently unsubstituted or substituted with one or more identical or different R c replace; L does not exist or C 1-3 Alkylene; Each R a , R b , R c are independently selected from halogen, -CN, -OH, C 1-8 Alkyl, C 1-8 Alkoxy, C 1-8 Haloalkyl, C 1-8 Halogenated alkoxy, C 1-8 Hydroxyalkyl, C 3-8 Cycloalkyl, unsubstituted or substituted with one or more identical or different R aa Substituted 5-6 membered heteroaryl, -NR i R j 、-C(O)NR i R j ; or two adjacent R a Combined with the atoms on ring A to form an unsubstituted or substituted with one or more identical or different R bb substituted 4-7 membered heterocycloalkyl; wherein the 5-6 membered heteroaryl and the 4-7 membered heterocycloalkyl each independently contain 1 to 3 heteroatoms selected from N, O and S; each R aa , R bb are each independently selected from halogen, C 1-4 alkyl; Each R i , R j Each independently selected from -H, C 1-4 Alkyl; or R i , R j The N to which it is attached is unsubstituted or is replaced by one or more identical or different R cc substituted 4-7 membered heterocycloalkyl; wherein the 4-7 membered heterocycloalkyl contains 1 to 3 heteroatoms selected from N, O and S, and the -CH2- on the 4-7 membered heterocycloalkyl ring is optionally replaced by -C(=O)-, -C(=S)- and -S(=O)2-; each R cc Each independently selected from C 1-4 alkyl.

4. The compound according to any one of claims 1 to 3, or a pharmaceutically acceptable salt, stereoisomer, tautomer, polymorph, cocrystal, hydrate, solvate, metabolite, prodrug, or deuterated compound thereof, characterized in that: Ring A is selected from phenyl and 5-6 membered heteroaryl; wherein the 5-6 membered heteroaryl contains 1 to 3 heteroatoms selected from N, O and S; the phenyl and 5-6 membered heteroaryl are each independently unsubstituted or substituted by one or more identical or different R a replace; Preferably, ring A is selected from phenyl and 6-membered heteroaryl; wherein the 6-membered heteroaryl contains 1 to 2 heteroatoms selected from N; the phenyl and 6-membered heteroaryl are each independently unsubstituted or substituted by one or more identical or different R a replace; Preferably, ring A is selected from phenyl and pyridyl; wherein the phenyl and pyridyl are each independently unsubstituted or substituted with one or more identical or different R a replace; Preferably, ring A is selected from phenyl and pyridyl; wherein the phenyl and pyridyl are each independently unsubstituted or substituted by 1, 2 or 3 identical or different R a replace; Preferably, ring A is selected from Each R a Each independently selected from halogen, -CN, -OH, -SR i 、-SF5、-SCF3、-S(O)2R i 、-S(O)(=NR i )R j 、-N=S(O)R i R j , C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, C 1-6 Halogenated alkoxy, C 1-6 Hydroxyalkyl, C 3-6 Cycloalkyl, unsubstituted or substituted with one or more identical or different R aa Substituted 5-6 membered heteroaryl, -NR i R j 、-C(O)NR i R j ; or two adjacent R a Combined with the atoms on ring A to form an unsubstituted or substituted with one or more identical or different R bb substituted 4-7 membered heterocycloalkyl; wherein the 5-6 membered heteroaryl and the 4-7 membered heterocycloalkyl each independently contain 1 to 3 heteroatoms selected from N, O and S; each R aa , R bb are each independently selected from halogen, C 1-4 alkyl; Each R i , R j Each independently selected from the same or different -H, C 1-4 Alkyl; or R i , R j The N to which it is attached is unsubstituted or is replaced by one or more identical or different R cc substituted 4-7 membered heterocycloalkyl; wherein the 4-7 membered heterocycloalkyl contains 1 to 3 heteroatoms selected from N, O and S, and the -CH2- on the 4-7 membered heterocycloalkyl ring is optionally replaced by -C(=O)-, -C(=S)- and -S(=O)2-; each R cc Each independently selected from C 1-4 alkyl; Preferably, each R a Each independently selected from halogen, -CN, -SR i 、-SF5、-SCF3、-S(O)2R i 、-S(O)(=NR i )R j 、-N=S(O)R i R j , C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, C 1-6 Haloalkoxy; or two adjacent R a Combined with the atoms on ring A to form an unsubstituted or substituted with one or more identical or different R bb Substituted 4-7 membered heterocycloalkyl; wherein the 4-7 membered heterocycloalkyl contains 1 to 3 heteroatoms selected from N, O and S; each R bb are each independently selected from halogen, C 1-4 Alkyl; each R i , R j Each independently selected from the same or different -H, C 1-4 alkyl; Preferably, each R a Each independently selected from halogen, -CN, -SR i 、-SF5、-SCF3、-S(O)2R i 、-S(O)(=NR i )R j 、-N=S(O)R i R j , C 1-4 Alkyl, C 1-4 Alkoxy, C 1-4 Halogenated alkyl, C 1-4 Haloalkoxy; or two adjacent R a Combined with the atoms on ring A to form an unsubstituted or substituted with one or more identical or different R bb Substituted 5-6 membered heterocycloalkyl; wherein the 5-6 membered heterocycloalkyl contains 1 to 2 heteroatoms selected from N and O; each R bb are each independently selected from halogen, C 1-4 Alkyl; each R i , R j Each independently selected from the same or different -H, C 1-4 alkyl; Preferably, each R a Each independently selected from -F, -Cl, -Br, -CN, -SR i 、-SF5、-SCF3、-S(O)2R i 、-S(O)(=NR i )R j 、-N=S(O)R i R j , methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, sec-butoxy, isobutoxy, tert-butoxy, fluoromethyl, fluoroethyl, fluoro-n-propyl, fluoroisopropyl, fluoro-n-butyl, fluoro-sec-butyl, fluoroisobutyl, fluoro-tert-butyl, fluoromethoxy, fluoroethoxy, fluoro-n-propoxy, fluoroisopropoxy, fluoro-n-butoxy, fluoro-sec-butoxy, fluoroisobutoxy, fluoro-tert-butoxy; or two adjacent R a Combined with the atoms on ring A to form an unsubstituted or substituted with one or more identical or different R bb Substituted 1,3-dioxolane or morpholinyl; each R bb Each R is independently selected from -F, -Cl, -Br, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl; i , R j Each is independently selected from the same or different -H, methyl, ethyl; Preferably, each R a Each is independently selected from -F, -Cl, -Br, -CN, methyl, ethyl, methoxy, ethoxy, fluoromethyl, fluoroethyl, fluoromethoxy, fluoroethoxy, -SR i 、-SF5、-SCF3、-S(O)2R i 、-S(O)(=NR i )R j 、-N=S(O)R i R j ; or two adjacent R a Combined with the atoms on ring A to form an unsubstituted or substituted with one or more identical or different R bb Substituted 1,3-dioxolane or morpholinyl; each R bb Each R is independently selected from -F, methyl; i , R j Each is independently selected from the same or different -H, methyl; Preferably, each R a Each independently selected from -F, -Cl, -Br, -CN, methyl, methoxy, -CF3, -OCF3, -CHF2, -OCHF2, -CH2CHF2, -SF5, -SCF3, -SCH3, Or two adjacent R a Combined with the atoms on ring A to form an unsubstituted or substituted with one or more identical or different R bb Substituted 1,3-dioxolane or morpholinyl; each R bb Each independently selected from -F, methyl; Each R a are independently selected from halogen, -CN, -OH, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, C 1-6 Halogenated alkoxy, C 1-6 Hydroxyalkyl, C 3-6 Cycloalkyl, unsubstituted or substituted with one or more identical or different R aa Substituted 5-6 membered heteroaryl, -NR i R j 、-C(O)NR i R j ; or two adjacent R a Combined with the atoms on ring A to form an unsubstituted or substituted with one or more identical or different R bb substituted 4-7 membered heterocycloalkyl; wherein the 5-6 membered heteroaryl and the 4-7 membered heterocycloalkyl each independently contain 1 to 3 heteroatoms selected from N, O and S; each R aa , R bb are each independently selected from halogen, C 1-4 alkyl; R i , R j Each independently selected from -H, C 1-4 Alkyl; or R i , R j Unsubstituted with attached N or one or more identical or different R cc substituted 4-7 membered heterocycloalkyl; wherein the 4-7 membered heterocycloalkyl contains 1 to 3 heteroatoms selected from N, O and S, and the -CH2- on the 4-7 membered heterocycloalkyl ring is optionally replaced by -C(=O)-, -C(=S)- and -S(=O)2-; each R cc Each independently selected from C 1-4 alkyl; Preferably, each R a are independently selected from halogen, -CN, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, C 1-6 Haloalkoxy; or two adjacent R a Combined with the atoms on ring A to form an unsubstituted or substituted with one or more identical or different R bb substituted 4-7 membered heterocycloalkyl; wherein the 4-7 membered heterocycloalkyl each independently contains 1 to 3 heteroatoms selected from N, O and S; each R bb are each independently selected from halogen, C 1-4 alkyl; Preferably, each R a are independently selected from halogen, -CN, C 1-4 Alkyl, C 1-4 Alkoxy, C 1-4 Haloalkyl, C 1-4 Haloalkoxy; or two adjacent R a Combined with the atoms on ring A to form an unsubstituted or substituted with one or more identical or different R bb Substituted 5-6 membered heterocycloalkyl; wherein the 5-6 membered heterocycloalkyl contains 1 to 2 heteroatoms selected from N and O; each R bb are each independently selected from halogen, C 1-4 alkyl; Preferably, each R a R is independently selected from -F, -Cl, -Br, -CN, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, sec-butoxy, isobutoxy, tert-butoxy, fluoromethyl, fluoroethyl, fluoro-n-propyl, fluoroisopropyl, fluoro-n-butyl, fluoro-sec-butyl, fluoroisobutyl, fluoro-tert-butyl, fluoromethoxy, fluoroethoxy, fluoro-n-propoxy, fluoroisopropoxy, fluoro-n-butoxy, fluoro-sec-butoxy, fluoroisobutoxy, fluoro-tert-butoxy; or two adjacent R a Combined with the atoms on ring A to form an unsubstituted or substituted with one or more identical or different R bb Substituted 1,3-dioxolane or morpholinyl; each R bb Each is independently selected from -F, -Cl, -Br, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl; Preferably, each R a Each independently selected from -F, -Cl, -Br, -CN, methyl, methoxy, fluoromethyl, fluoroethyl, fluoromethoxy; or two adjacent R a Combined with the atoms on ring A to form an unsubstituted or substituted with one or more identical or different R bb Substituted 1,3-dioxolane or morpholinyl; each R bb Each independently selected from -F, methyl; Preferably, each R a Each independently selected from -F, -Cl, -Br, -CN, methyl, methoxy, -CF3, -OCF3, -CHF2, -OCHF2, -CH2CHF2; or two adjacent R a Combined with the atoms on ring A to form an unsubstituted or substituted with one or more identical or different R bb Substituted 1,3-dioxolane or morpholinyl; each R bb Each independently selected from -F, methyl; Preferably, each R a Each independently selected from -F, -Cl, -Br, -CN, methyl, methoxy, fluoromethyl, fluoromethoxy; or two adjacent R a Combined with the atoms on ring A to form an unsubstituted or substituted with one or more identical or different R bb Substituted 1,3-dioxolane or morpholinyl; each R bb Each independently selected from -F, methyl; Preferably, each R a Each independently selected from -F, -Cl, -Br, -CN, methyl, methoxy, -CF3, -OCF3, -CHF2, -OCHF2; or two adjacent R a Combined with the atoms on ring A to form an unsubstituted or substituted with 1 or 2 identical or different R bb Substituted 1,3-dioxolane or morpholinyl; each R bb Each independently selected from -F, methyl; Preferably, ring A is selected from Preferably, ring A is selected from Most preferably, Ring A is selected from 5. The compound according to any one of claims 1 to 4, or a pharmaceutically acceptable salt, stereoisomer, tautomer, polymorph, cocrystal, hydrate, solvate, metabolite, prodrug, or deuterated compound thereof, characterized in that: R 1 Selected from C 1-6 Alkyl, C 3-6 Cycloalkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl; wherein the C 1-6 Alkyl, C 3-6 Cycloalkyl, C 1-6 Haloalkyl, C 1-6 The hydroxyalkyl groups are each independently unsubstituted or substituted with one or more identical or different R b replace; Preferably, R 1 Selected from C 1-6 Alkyl; wherein the C 1-6 The alkyl group is unsubstituted or substituted with one or more identical or different R b replace; Preferably, R 1 Selected from C 1-4 Alkyl; wherein the C 1-4 The alkyl group is unsubstituted or substituted with one or more identical or different R b replace; Preferably, R 1 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl and tert-butyl; wherein the methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl and tert-butyl are each independently unsubstituted or substituted with one or more R b replace; Preferably, R 1 is selected from methyl, ethyl, isopropyl; wherein the methyl, ethyl, isopropyl are each independently unsubstituted or substituted by one or more R b replace; Preferably, R 1 is selected from methyl, ethyl, isopropyl; wherein the methyl and ethyl are each independently unsubstituted or substituted by one or more R b replace; Preferably, R 1 is selected from methyl, ethyl, isopropyl; wherein the methyl and ethyl are each independently unsubstituted or substituted with one R b replace; Preferably, R 1 Selected from C 1-2 Alkyl; wherein the C 1-2 The alkyl group is unsubstituted or substituted with one or more identical or different R b replace; Preferably, R 1 is selected from methyl and ethyl; wherein the methyl and ethyl are each independently unsubstituted or substituted by one or more identical or different R b replace; Preferably, R 1 is selected from methyl and ethyl; wherein the methyl and ethyl are each independently unsubstituted or substituted with one R b replace; Each R b are independently selected from halogen, -CN, -OH, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, C 1-6 Halogenated alkoxy, C 1-6 Hydroxyalkyl, C 3-6 Cycloalkyl, unsubstituted or substituted with one or more identical or different R aa Substituted 5-6 membered heteroaryl, -NR i R j 、-C(O)NR i R j ; wherein the 5-6 membered heteroaryl group contains 1 to 3 heteroatoms selected from N, O and S; Preferably, each R b Each independently selected from C 1-6 Alkoxy, C 3-6 Cycloalkyl, unsubstituted or substituted with one or more identical or different R aa Substituted 5-6 membered heteroaryl, -NR i R j 、-C(O)NR i R j ; wherein the 5-6 membered heteroaryl group contains 1 to 3 heteroatoms selected from N, O and S; Preferably, each R b Each independently selected from C 1-4 Alkoxy, C 3-6 Cycloalkyl, unsubstituted or substituted with one or more identical or different R aa Substituted 5-membered heteroaryl, -NR i R j 、-C(O)NR i R j ; wherein the 5-membered heteroaryl group contains 2 to 3 heteroatoms selected from N, O and S; Preferably, each R b Each is independently selected from methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, sec-butoxy, isobutoxy, tert-butoxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, -NR i R j 、-C(O)NR i R j , unsubstituted or substituted with one or more identical or different R aa Substituted 5-membered heteroaryl; the 5-membered heteroaryl is selected from pyrazolyl, thiazolyl, oxazolyl, oxadiazolyl; Preferably, each R b Each independently selected from methoxy, cyclopropyl, -NR i R j 、-C(O)NR i R j , 1 or more identical or different R aa Substituted 5-membered heteroaryl; the 5-membered heteroaryl is selected from pyrazolyl, thiazolyl, oxazolyl, oxadiazolyl; Preferably, each R b Each independently selected from methoxy, cyclopropyl, -NR i R j 、-C(O)NR i R j , 1 R aa Substituted 5-membered heteroaryl; the 5-membered heteroaryl is selected from pyrazolyl, thiazolyl, oxazolyl, oxadiazolyl; Each R aa are each independently selected from halogen, C 1-4 alkyl; Preferably, each R aa Each independently selected from C 1-4 alkyl; Preferably, each R aa Each is independently selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl; Preferably, each R aa are each independently selected from methyl; Each R i , R j Each independently selected from -H, C 1-4 Alkyl; or R i , R j The N to which it is attached is unsubstituted or is replaced by one or more identical or different R cc substituted 4-6 membered heterocycloalkyl; wherein the 4-6 membered heterocycloalkyl contains 1 to 3 heteroatoms selected from N, O and S, and the -CH2- on the 4-6 membered heterocycloalkyl ring is optionally replaced by -C(=O)-, -C(=S)- and -S(=O)2-; each R cc Each independently selected from C 1-4 Alkyl, halogen; Preferably, each R i , R j Each independently selected from -H, C 1-4 Alkyl; or R i , R j The N to which it is attached is unsubstituted or is replaced by one or more identical or different R cc Substituted 4-6 membered heterocycloalkyl; wherein the 4-6 membered heterocycloalkyl contains 1 to 2 heteroatoms selected from N and O, and the 4-6 membered heterocyclic -CH2- on the alkyl ring is optionally replaced by -C(=O)-; each R cc Each independently selected from C 1-4 Alkyl, halogen; Preferably, each R i , R j Each is independently selected from -H, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl; or R i , R j The N to which it is attached is unsubstituted or is replaced by one or more identical or different R cc substituted azetidinyl, piperidinyl, piperazinyl, morpholinyl or piperazinonyl; wherein each R cc Each is independently selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, F, Cl, Br; Preferably, each R i , R j are each independently selected from -H, methyl; or R i , R j The N to which it is attached is unsubstituted or is replaced by one or more identical or different R cc substituted azetidinyl, piperidinyl, piperazinyl, morpholinyl or piperazinonyl; wherein each R cc Each is independently selected from methyl, F; Preferably, each R i , R j are each independently selected from -H, methyl; or R i , R j Forming a fluoroazetidinyl, morpholinyl, piperidinyl, N-methylpiperazinyl or N-methylpiperazinone group with the attached N; Each R i , R j Each independently selected from -H, C 1-4 Alkyl; or R i , R j The N to which it is attached is unsubstituted or is replaced by one or more identical or different R cc substituted 5-6 membered heterocycloalkyl; wherein the 5-6 membered heterocycloalkyl contains 1 to 3 heteroatoms selected from N, O and S, and the -CH2- on the 5-6 membered heterocycloalkyl ring is optionally replaced by -C(=O)-, -C(=S)- and -S(=O)2-; each R cc Each independently selected from C 1-4 alkyl; Preferably, each R i , R j Each independently selected from -H, C 1-4 Alkyl; or R i , R j The N to which it is attached is unsubstituted or is replaced by one or more identical or different R cc Substituted 5-6 membered heterocycloalkyl; wherein the 5-6 membered heterocycloalkyl contains 1 to 2 heteroatoms selected from N and O, and the -CH2- on the 5-6 membered heterocycloalkyl ring is optionally replaced by -C(=O)-; each R cc Each independently selected from C 1-4 alkyl; Preferably, each R i , R j Each is independently selected from -H, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl; or R i , R j The N to which it is attached is unsubstituted or is replaced by one or more identical or different R cc substituted piperidinyl, piperazinyl, morpholinyl or piperazinonyl; wherein each R cc Each is independently selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl; Preferably, each R i , R j are each independently selected from -H, methyl; or R i , R j The N to which it is attached is unsubstituted or is replaced by one or more identical or different R cc substituted piperidinyl, piperazinyl, morpholinyl or piperazinonyl; wherein each R cc are each independently selected from methyl; Preferably, each R i , R j are each independently selected from -H, methyl; or R i , R j Forming a morpholinyl, piperidinyl, N-methylpiperazinyl or N-methylpiperazinone group with the attached N; Most preferably, R 1 Selected from methyl, ethyl, isopropyl, Most preferably, R 1 Selected from methyl, 6. The compound according to any one of claims 1 to 5, or a pharmaceutically acceptable salt, stereoisomer, tautomer, polymorph, cocrystal, hydrate, solvate, metabolite, prodrug, or deuterated compound thereof, characterized in that: R 2 Selected from C 1-6 Alkyl, 5-6 membered heteroaryl, phenyl, C 3-8 Cycloalkyl, 4-7 membered heterocycloalkyl, unsaturated 4-7 membered heterocyclic group; wherein the C 3-8 The -CH2- on the cycloalkyl ring is optionally replaced by -C(=O)-, -C(=S)- and -S(=O)2-; the 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, unsaturated 4-7 membered heterocyclic group each independently contains 1 to 3 heteroatoms selected from N, O and S; the C 1-6 Alkyl, 5-6 membered heteroaryl, phenyl, C 3-8 The cycloalkyl, 4-7 membered heterocycloalkyl, and unsaturated 4-7 membered heterocyclic group are each independently unsubstituted or substituted with one or more identical or different R c replace; Preferably, R 2 Selected from C 1-6 Alkyl, 5-6 membered heteroaryl, phenyl, C 3-8 Cycloalkyl, 4-7 membered heterocycloalkyl; wherein the C 3-8 The -CH2- on the cycloalkyl ring is optionally replaced by -C(=O)-, -C(=S)- and -S(=O)2-; the 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl each independently contain 1 to 3 heteroatoms selected from N, O and S; the C 1-6 Alkyl, 5-6 membered heteroaryl, phenyl, C 3-8 The cycloalkyl and 4-7 membered heterocycloalkyl groups are each independently unsubstituted or substituted with one or more identical or different R c replace; Preferably, R 2 Selected from C 1-4 Alkyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, furanyl, thienyl, pyrrolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, pyrazolyl, imidazolyl, phenyl, C 3-7 Cycloalkyl, 4-6 membered heterocycloalkyl; wherein the C 3-7 -CH2- on the cycloalkyl ring is optionally replaced by -S(=O)2-; the 4-6 membered heterocycloalkyl contains 1 to 2 heteroatoms selected from N and O; the C 1-4 Alkyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, furanyl, thienyl, pyrrolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, pyrazolyl, imidazolyl, phenyl, C 3-7 The cycloalkyl and 4-6 membered heterocycloalkyl groups are each independently unsubstituted or substituted with one or more identical or different R c replace; Preferably, R 2 Selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, furanyl, thienyl, pyrrolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, pyrazolyl, imidazolyl, phenyl, C 3-7 Cycloalkyl, 4-6 membered heterocycloalkyl; wherein the 4-6 membered heterocycloalkyl contains 1 to 2 heteroatoms selected from N and O; the methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, furanyl, thienyl, pyrrolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, pyrazolyl, imidazolyl, phenyl, C 3-7 The cycloalkyl and 4-6 membered heterocycloalkyl groups are each independently unsubstituted or substituted with one or more identical or different R c replace; Preferably, R 2 Selected from Methyl, ethyl, pyridyl, pyrimidyl, pyrazinyl, phenyl, C 3-7 Cycloalkyl, 4-6 membered heterocycloalkyl; wherein the C 3-7 The cycloalkyl group is selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, C5 bridged cycloalkyl, C7 spirocycloalkyl, the 4-6 membered heterocycloalkyl group is selected from tetrahydrofuranyl, oxetanyl, piperidinyl, 1,4-dioxocyclohexyl; the methyl, ethyl, pyridinyl, pyrimidinyl, pyrazinyl, phenyl, C 3-7 The cycloalkyl and 4-6 membered heterocycloalkyl groups are each independently unsubstituted or substituted with one or more identical or different R c replace; Preferably, R 2 Selected from Methyl, ethyl, pyridyl, pyrimidyl, pyrazinyl, phenyl, C 3-7 Cycloalkyl, 4-6 membered heterocycloalkyl; wherein the C 3-7 The cycloalkyl group is selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, C5 bridged cycloalkyl, C7 spirocycloalkyl, the 4-6 membered heterocycloalkyl group is selected from tetrahydrofuranyl, oxetanyl, piperidinyl, 1,4-dioxocyclohexyl; the methyl, ethyl, pyridinyl, pyrimidinyl, pyrazinyl, phenyl, C 3-7 The cycloalkyl and 4-6 membered heterocycloalkyl groups are each independently unsubstituted or substituted with 1, 2 or 3 R c replace; Preferably, R 2 Selected from C 1-4 Alkyl, pyridyl, phenyl, C 3-7 Cycloalkyl, 4-6 membered heterocycloalkyl; wherein the C 3-7 -CH2- on the cycloalkyl ring is optionally replaced by -S(=O)2-; the 4-6 membered heterocycloalkyl contains 1 to 2 heteroatoms selected from N and O; the C 1-4 Alkyl, pyridyl, phenyl, C 3-7 The cycloalkyl and 4-6 membered heterocycloalkyl groups are each independently unsubstituted or substituted with one or more identical or different R c replace; Preferably, R 2 Selected from Methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, pyridyl, phenyl, C 3-7 Cycloalkyl, 4-6 membered heterocycloalkyl; wherein the 4-6 membered heterocycloalkyl contains 1 to 2 heteroatoms selected from N and O; the methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, pyridyl, phenyl, C 3-7 The cycloalkyl and 4-6 membered heterocycloalkyl groups are each independently unsubstituted or substituted with one or more identical or different R c replace; Preferably, R 2 Selected from Methyl, ethyl, pyridyl, phenyl, C 3-7 Cycloalkyl, 4-6 membered heterocycloalkyl; wherein the C 3-7 The cycloalkyl group is selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, C5 bridged cycloalkyl, C7 spirocycloalkyl, the 4-6 membered heterocycloalkyl group is selected from tetrahydrofuranyl, oxetanyl, piperidinyl, 1,4-dioxocyclohexyl; the methyl, ethyl, pyridinyl, phenyl, C 3-7 The cycloalkyl and 4-6 membered heterocycloalkyl groups are each independently unsubstituted or substituted with one or more identical or different R c replace; Preferably, R 2 Selected from Methyl, ethyl, pyridyl, phenyl, C 3-7 Cycloalkyl, 4-6 membered heterocycloalkyl; wherein the C 3-7 The cycloalkyl group is selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, C5 bridged cycloalkyl, C7 spirocycloalkyl, the 4-6 membered heterocycloalkyl group is selected from tetrahydrofuranyl, oxetanyl, piperidinyl, 1,4-dioxocyclohexyl; the methyl, ethyl, pyridinyl, phenyl, C 3-7 The cycloalkyl and 4-6 membered heterocycloalkyl groups are each independently unsubstituted or substituted with 1, 2 or 3 R c replace; R 2 Selected from C 1-6 Alkyl, 5-6 membered heteroaryl, phenyl, C 3-8 Cycloalkyl, 4-7 membered heterocycloalkyl, unsaturated 4-7 membered heterocyclic group; wherein the C 3-8 The -CH2- on the cycloalkyl ring is optionally replaced by -C(=O)-, -C(=S)- and -S(=O)2-; the 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, unsaturated 4-7 membered heterocyclic group each independently contains 1 to 3 heteroatoms selected from N, O and S; the 5-6 membered heteroaryl, phenyl, C 3-8 The cycloalkyl, 4-7 membered heterocycloalkyl, and unsaturated 4-7 membered heterocyclic group are each independently unsubstituted or substituted with one or more identical or different R c replace; Preferably, R 2 Selected from C 1-6 Alkyl, 5-6 membered heteroaryl, phenyl, C 3-8 Cycloalkyl, 4-7 membered heterocycloalkyl; wherein the C 3-8 The -CH2- on the cycloalkyl ring is optionally replaced by -C(=O)-, -C(=S)- and -S(=O)2-; the 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl each independently contain 1 to 3 heteroatoms selected from N, O and S; the 5-6 membered heteroaryl, phenyl, C 3-8 The cycloalkyl and 4-7 membered heterocycloalkyl groups are each independently unsubstituted or substituted with one or more identical or different R c replace; Preferably, R 2 Selected from C 1-4 Alkyl, pyridyl, phenyl, C 3-7 Cycloalkyl, 4-6 membered heterocycloalkyl; wherein the C 3-7 -CH2- on the cycloalkyl ring is optionally replaced by -S(=O)2-; the 4-6 membered heterocycloalkyl contains 1 to 2 heteroatoms selected from N and O; the pyridyl, phenyl, C 3-7 The cycloalkyl and 4-6 membered heterocycloalkyl groups are each independently unsubstituted or substituted with one or more identical or different R c replace; Preferably, R 2 Selected from Methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, pyridyl, phenyl, C 3-7 Cycloalkyl, 4-6 membered heterocycloalkyl; wherein the 4-6 membered heterocycloalkyl contains 1 to 2 heteroatoms selected from N and O; the pyridyl, phenyl, C 3-7 The cycloalkyl and 4-6 membered heterocycloalkyl groups are each independently unsubstituted or substituted with one or more identical or different R c replace; Preferably, R 2 Selected from Methyl, ethyl, pyridyl, phenyl, C 3-7 Cycloalkyl, 4-6 membered heterocycloalkyl; wherein the C 3-7 Cycloalkyl is selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, C5 The 4-6 membered heterocycloalkyl is selected from tetrahydrofuranyl, oxetanyl, piperidinyl, 1,4-dioxocyclohexyl; the pyridinyl, phenyl, C 3-7 The cycloalkyl and 4-6 membered heterocycloalkyl groups are each independently unsubstituted or substituted with one or more identical or different R c replace; Preferably, R 2 Selected from Methyl, ethyl, pyridyl, phenyl, C 3-7 Cycloalkyl, 4-6 membered heterocycloalkyl; wherein the C 3-7 The cycloalkyl group is selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, C5 bridged cycloalkyl, C7 spirocycloalkyl, the 4-6 membered heterocycloalkyl group is selected from tetrahydrofuranyl, oxetanyl, piperidinyl, 1,4-dioxocyclohexyl; the pyridinyl, phenyl, C 3-7 The cycloalkyl and 4-6 membered heterocycloalkyl groups are each independently unsubstituted or substituted with 1, 2 or 3 R c replace; Each R c Each independently selected from halogen, -CN, -OH, -SR i 、-SF5、-SCF3、-S(O)2R i 、-S(O)(=NR i )R j 、-N=S(O)R i R j , C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, C 1-6 Halogenated alkoxy, C 1-6 Hydroxyalkyl, C 3-6 Cycloalkyl, unsubstituted or substituted with one or more identical or different R aa Substituted 5-6 membered heteroaryl, -NR i R j 、-C(O)NR i R j ; wherein the 5-6 membered heteroaryl group contains 1 to 3 heteroatoms selected from N, O and S; each R aa are each independently selected from halogen, C 1-4 Alkyl; each R i , R j Each independently selected from -H, C 1-4 Alkyl; or R i , R j The N to which it is attached is unsubstituted or is replaced by one or more identical or different R cc substituted 4-7 membered heterocycloalkyl; wherein the 4-7 membered heterocycloalkyl contains 1 to 3 heteroatoms selected from N, O and S, and the -CH2- on the 4-7 membered heterocycloalkyl ring is optionally replaced by -C(=O)-, -C(=S)- and -S(=O)2-; each R cc Each independently selected from C 1-4 alkyl; Preferably, each R c Each independently selected from halogen, -CN, -OH, -SF5, -SCF3, -S(O)2R i , C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 3-6 Cycloalkyl; R i Selected from -H, C 1-4 alkyl; Preferably, each R c Each independently selected from halogen, -CN, -OH, -SF5, -SCF3, -S(O)2R i , C 1-4 Alkyl, C 1-4 Alkoxy, C 1-4 Haloalkyl, C 1-4 Hydroxyalkyl, C 3-6 Cycloalkyl; R i Selected from -H, C 1-4 alkyl; Preferably, each R c Each independently selected from -F, -Cl, -Br, -CN, -OH, -SF5, -SCF3, -S(O)2R i R, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, sec-butoxy, isobutoxy, tert-butoxy, fluoromethyl, fluoroethyl, fluoro-n-propyl, fluoroisopropyl, fluoro-n-butyl, fluorosec-butyl, fluoroisobutyl, fluorotert-butyl, hydroxymethyl, hydroxyethyl, hydroxy-n-propyl, hydroxyisopropyl, hydroxy-n-butyl, hydroxysec-butyl, hydroxyisobutyl, hydroxytert-butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl; R i Selected from -H, methyl, ethyl; Preferably, each R c Each independently selected from -F, -Cl, -Br, -CN, -OH, -SF5, -SCF3, Methyl, ethyl, methoxy, ethoxy, fluoromethyl, fluoroethyl, hydroxymethyl, hydroxy Ethyl, hydroxyisopropyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl; Preferably, each R c Each independently selected from -F, -Cl, -CN, -OH, -SF5, -SCF3, Methyl, methoxy, -CF3, -CHF2, -CH2F, hydroxymethyl, hydroxyisopropyl, cyclopropyl; Each R c are independently selected from halogen, -CN, -OH, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, C 3-6 Cycloalkyl, unsubstituted or substituted with one or more identical or different R aa Substituted 5-6 membered heteroaryl, -NR i R j 、-C(O)NR i R j ; wherein the 5-6 membered heteroaryl group contains 1 to 3 heteroatoms selected from N, O and S; each R aa are each independently selected from halogen, C 1-4 Alkyl; each R i , R j Each independently selected from -H, C 1-4 Alkyl; or R i , R j The N to which it is attached is unsubstituted or is replaced by one or more identical or different R cc substituted 4-7 membered heterocycloalkyl; wherein the 4-7 membered heterocycloalkyl contains 1 to 3 heteroatoms selected from N, O and S, and the -CH2- on the 4-7 membered heterocycloalkyl ring is optionally replaced by -C(=O)-, -C(=S)- and -S(=O)2-; each R cc Each independently selected from C 1-4 alkyl; Preferably, each R c are independently selected from halogen, -CN, -OH, C 1-6 Alkoxy, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 3-6 Cycloalkyl; Preferably, each R c are independently selected from halogen, -CN, -OH, C 1-4 Alkoxy, C 1-4 Haloalkyl, C 1-4 Hydroxyalkyl, C 3-6 Cycloalkyl; Preferably, each R c each independently selected from -F, -Cl, -Br, -CN, -OH, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, sec-butoxy, isobutoxy, tert-butoxy, fluoromethyl, fluoroethyl, fluoro-n-propyl, fluoroisopropyl, fluoro-n-butyl, fluoro-sec-butyl, fluoroisobutyl, fluoro-tert-butyl, hydroxymethyl, hydroxyethyl, hydroxy-n-propyl, hydroxyisopropyl, hydroxy-n-butyl, hydroxy-sec-butyl, hydroxyisobutyl, hydroxy-tert-butyl, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl; Preferably, each R c Each is independently selected from -F, -Cl, -Br, -CN, -OH, methoxy, ethoxy, fluoromethyl, fluoroethyl, hydroxymethyl, hydroxyethyl, hydroxyisopropyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl; Preferably, each R c Each is independently selected from -F, -Cl, -CN, -OH, methoxy, -CF3, -CHF2, -CH2F, hydroxyisopropyl, cyclopropyl; Preferably, each R c are independently selected from halogen, -OH, C 1-6 Alkoxy, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl; Preferably, each R c are independently selected from halogen, -OH, C 1-4 Alkoxy, C 1-4 Haloalkyl, C 1-4 Hydroxyalkyl; Preferably, each R c Each independently selected from -F, -Cl, -Br, -OH, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, sec-butoxy, isobutoxy, tert-butoxy, fluoromethyl, fluoroethyl, fluoro-n-propyl, fluoro-isopropyl, fluoro-n-butyl, fluoro-sec-butyl, fluoro-isobutyl, fluoro-tert-butyl, hydroxymethyl, hydroxyethyl, hydroxy-n-propyl, hydroxy-isopropyl, hydroxy-n-butyl, hydroxy-sec-butyl, hydroxy-isobutyl, hydroxy-tert-butyl; Preferably, each R c Each is independently selected from -F, -Cl, -OH, methoxy, -CF3, -CH2CF3, hydroxyisopropyl; Preferably, R 2 Selected from Fluoromethyl, fluoroethyl, pyridyl, phenyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, C5 bridged cycloalkyl, C7 spirocycloalkyl, tetrahydrofuranyl, oxetanyl, piperidinyl, 1,4-dioxocyclohexyl; wherein the cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, C5 bridged cycloalkyl, C7 spirocycloalkyl are each independently unsubstituted or substituted by hydroxy, hydroxyisopropyl or methoxy; the pyridyl and phenyl are each independently unsubstituted or substituted by F, Cl, -CN, -CF3 or cyclopropyl; Preferably, R 2 Selected from Fluoromethyl, fluoroethyl, pyridyl, pyrimidinyl, pyrazinyl, phenyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, C5 bridged cycloalkyl, C7 spirocycloalkyl, tetrahydrofuranyl, oxetanyl, piperidinyl, 1,4-dioxocyclohexyl; wherein the cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, C5 bridged cycloalkyl, C7 spirocycloalkyl are each independently unsubstituted or substituted by hydroxy, hydroxyisopropyl or methoxy; the pyridyl, pyrimidinyl, pyrazinyl, phenyl are each independently unsubstituted or substituted by -SF5, -SCF3, Substituted with hydroxymethyl, methoxy, methyl, F, Cl, -CN, -CHF2, -CH2F, -CF3 or cyclopropyl; Preferably, R 2 Selected from Cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, -CF3, -CH2CF3, Preferably, R 2 Selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, -CF3, -CH2CF3, Most preferably, R 2 Selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, -CF3, -CH2CF3, 7. The compound according to any one of claims 1 to 6, or a pharmaceutically acceptable salt, stereoisomer, tautomer, polymorph, cocrystal, hydrate, solvate, metabolite, prodrug, or deuterated compound thereof, characterized in that: L does not exist or C 1-2 Alkylene; Preferably, L is absent or -CH2-; Preferably, L is -CH2-.

8. The compound according to any one of claims 1 to 7, or a pharmaceutically acceptable salt, stereoisomer, tautomer, polymorph, cocrystal, hydrate, solvate, metabolite, prodrug, or deuterated compound thereof, selected from the following structures: Further, Formula III is selected from the following structures: in, m is 1 or 2; R b is hydrogen or as defined in claim 1, 2, 3 or 5; L is as defined in claim 1, 2, 3 or 7; R 2 As defined in claim 1, 2, 3 or 6; Ring A is as defined in claim 1, 2, 3 or 4; R a As defined in claim 1, 2, 3 or 4; n is 0, 1, 2 or 3.

9. The compound according to claim 1, or a pharmaceutically acceptable salt, stereoisomer, tautomer, polymorph, cocrystal, hydrate, solvate, metabolite, prodrug, or deuterated compound thereof, having a structure shown in Formula III-4: in, Z1 is selected from N or CH; Z2 is selected from N or CH; R a Selected from halogen, -CN, C 1-8 Alkyl, C 1-8 Haloalkyl; R c Selected from halogen, -CN, C 1-8 Alkyl, C 1-8 Halogenated alkyl.

10. The compound according to claim 1, or a pharmaceutically acceptable salt, stereoisomer, tautomer, polymorph, cocrystal, hydrate, solvate, metabolite, prodrug, or deuterated compound thereof, having a structure shown in Formula III-5: in, R a Selected from halogen, -CN, C 1-8 Alkyl, C 1-8 Haloalkyl; R c Selected from halogen, -CN, C 1-8 Alkyl, C 1-8 Halogenated alkyl.

11. The compound according to claim 9 or 10, or a pharmaceutically acceptable salt, stereoisomer, tautomer, polymorph, cocrystal, hydrate, solvate, metabolite, prodrug, or deuterated compound thereof, characterized in that: R a Selected from halogen, -CN, C 1-6 Alkyl, C 1-6 Haloalkyl; Preferably, R a Selected from halogen, -CN, C 1-4 Alkyl, C 1-4 Haloalkyl; Preferably, R a Selected from halogen, -CN, C 1-2 Alkyl, C 3-4 Alkyl, C 1-2 Fluorinated alkyl, C 3-4 Fluorinated alkyl; Preferably, R a Selected from halogen, C 1-2 Alkyl, C 3-4 Alkyl, C 1-2 Fluorinated alkyl, C 3-4 Fluorinated alkyl; Preferably, R a Selected from F, Cl, Br, -CN, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, fluoromethyl, fluoroethyl; Preferably, R a is selected from F, Cl, Br, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, fluoromethyl, fluoroethyl; Preferably, R a Selected from F, Cl, -CN, methyl, -CF3, -CHF2; Preferably, R a Selected from Cl, methyl, -CF3, -CHF2.

12. The compound according to any one of claims 9 to 11, or a pharmaceutically acceptable salt, stereoisomer, tautomer, polymorph, cocrystal, hydrate, solvate, metabolite, prodrug, or deuterated compound thereof, characterized in that: R c Selected from halogen, -CN, C 1-6 Alkyl, C 1-6 Haloalkyl; Preferably, R c Selected from halogen, -CN, C 1-4 Alkyl, C 1-4 Haloalkyl; Preferably, R c Selected from halogen, -CN, C 1-2 Fluorinated alkyl, C 3-4 Fluorinated alkyl; Preferably, R c Selected from -CN, C 1-2 Fluorinated alkyl, C 3-4 Fluorinated alkyl; Preferably, R c Selected from F, Cl, Br, -CN, fluoromethyl, fluoroethyl; Preferably, R c Selected from -CN, fluoromethyl, fluoroethyl; Preferably, R c Selected from Cl, -CN, -CHF2, -CF3; Preferably, R c Selected from -CN, -CHF2, -CF3.

13. The compound according to claim 1, or a pharmaceutically acceptable salt, stereoisomer, tautomer, polymorph, cocrystal, hydrate, solvate, metabolite, prodrug, deuterated compound thereof, wherein the compound is selected from the following structures:

14. A pharmaceutical composition, characterized in that: Comprising the compound according to any one of claims 1 to 13 or a pharmaceutically acceptable salt, stereoisomer, tautomer, polymorph, cocrystal, hydrate, solvate, metabolite, prodrug, deuterated compound thereof, and optionally a pharmaceutically acceptable carrier and / or adjuvant and / or diluent.

15. Use of the compound according to any one of claims 1 to 13 or its pharmaceutically acceptable salt, stereoisomer, tautomer, polymorph, cocrystal, hydrate, solvate, metabolite, prodrug, deuterated compound, or the pharmaceutical composition according to claim 14 in the preparation of a Polθ inhibitor or in the preparation of a drug for treating a related disease mediated by Polθ; Preferably, the Polθ-mediated related diseases include cancer or tumor; Preferably, the Polθ-mediated related diseases refer to Polθ-mediated related diseases with HR deficiency; Preferably, the Polθ-mediated disease refers to cancer or tumor with HR deficiency.

16. A compound according to any one of claims 1 to 13 or a pharmaceutically acceptable salt, stereoisomer, tautomer, polymorph, cocrystal, hydrate, solvate, metabolite, prodrug, deuterated compound thereof, or a pharmaceutical composition according to claim 14, for use in treating and / or preventing diseases mediated by Polθ; Preferably, the Polθ-mediated related diseases include cancer or tumor; Preferably, the Polθ-mediated related diseases refer to Polθ-mediated related diseases with HR deficiency; Preferably, the Polθ-mediated disease refers to cancer or tumor with HR deficiency.

17. A method for treating and / or preventing a disease mediated by Polθ, comprising: Administering a therapeutically and / or prophylactically effective amount of the compound according to any one of claims 1 to 13 or a pharmaceutically acceptable salt, stereoisomer, tautomer, polymorph, cocrystal, hydrate, solvate, metabolite, prodrug, deuterated compound thereof, or the pharmaceutical composition according to claim 14 to a subject / individual in need thereof; Preferably, the Polθ-mediated related diseases include cancer or tumor; Preferably, the Polθ-mediated related diseases refer to Polθ-mediated related diseases with HR deficiency; Preferably, the Polθ-mediated disease refers to cancer or tumor with HR deficiency.

Citation Information

Patent Citations

  • Thiadiazolyl derivatives as DNA polymerase Theta inhibitors

    CN114127062A

  • Substituted thiadiazolyl derivatives as DNA polymerase theta inhibitors

    WO2022118210A1

  • O-linked thiadiazolyl compounds as DNA polymerase theta inhibitors

    WO2022259204A1

  • N-(5-substituted-[(1,3,4-thiadiazolyl) or (thiazolyl)])(substituted)carboxamide compounds and use thereof for inhibiting human polymerase theta

    WO2023050007A1

  • Thiadiazolyl compounds as DNA polymerase theta inhibitors

    WO2023067515A1